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ABSTRACT 
 
 
 
Penile squamous cell carcinoma is a rare disease, but can have a profound 
physical and psychological effect on those afflicted.  Although rare in 
developed countries, it presents a significant problem in developing countries. 
The relatively recent developments in molecular genetics have given us the 
opportunity to explore various cancers using a variety of different techniques, 
but in comparison to other squamous cell carcinomas, relatively little is known 
about the molecular genetics of penile cancer. 
The aim was to determine the spectrum of gene copy number aberrations in 
a large series of PSCCs, define the correlation of any genetic aberrations with 
human papillomavirus, histopathological subtype, and tumour grade, stage 
and lymph node status, identify potential candidate driver genes and to 
validate them using fluorescence in situ hybridization and analyse validated 
potential driver genes, assessing clinicopathological correlation.  
Several potential candidate driver genes have been identified in this study and 
the high frequency of PI3CKA gain/amplifications validated with fluorescence 
in situ hybridisation suggests that patients with basaloid, high grade, high 
stage PSCCs would benefit from chemotherapeutic agents that manipulate 
the PI3CK/AKT/mTOR pathway. 
There remains a general paucity of studies in PSCC compared to other 
squamous cell carcinomas. However, the library of PSCC genetic data is 
expanding and our current study lays the foundation for clinical trials involving 
PI3K/AKT/mTOR chemotherapeutic agents in high-risk PSCC patients. 
 
 
	 6	
TABLE OF CONTENTS 
 
1. CHAPTER 1:  INTRODUCTION  
1.1. Epidemiology, Anatomy and Pathology      12 
1.1.1. Epidemiology       12 
1.1.2. Anatomy        13 
1.1.3. Pathology        15 
1.1.3.1. Usual type SCCs      16 
1.1.3.2. Verrucous SCCs      17 
1.1.3.3. Basaloid SCCs      19 
1.1.3.4. Warty (condylomatous) SCCs     20 
1.1.3.5. Guidelines for Pathology Reporting    22 
1.1.3.6. Premalignant Penile Lesions     23 
1.2. Risk Factors for PSCC       24 
1.2.1. Lichen Sclerosis et Atrophicus     24 
1.2.2. Circumcision       25 
1.2.3. Smoking        27 
1.2.4. Ultraviolet Radiation       27 
1.2.5. HPV and Sexually transmitted Infections    28 
1.3. Staging, Diagnosis, Management and Prognosis    34 
1.3.1. Classification       34 
1.3.2. Clinical Diagnosis, Staging and Management    36 
1.3.2.1. Primary Tumour      36 
1.3.2.2. Assessment of Lymph Nodes     36 
1.3.2.2.1. Impalpable lymph nodes                  36 
1.3.2.2.2. Palpable Lymph nodes                  38 
1.3.3. Prognostic Factors       40 
1.4. PSCC Molecular Genetics      42 
1.4.1. Molecular markers Correlated with HPV    42 
1.4.2. Molecular Markers Not Correlated with HPV    43 
1.4.3. Other Molecular Markers and Clinical Association   51 
1.5. Molecular Genetics in Other Squamous Cell Carcinomas   53 
1.5.1. Cervical Squamous Cell Carcinomas      53 
1.5.2. Vulvar Squamous Cell Carcinoma     55 
	 7	
1.5.3. Oesophageal Squamous Cell Carcinoma    56 
1.5.4. Head and Neck Squamous Cell Carcinoma    57 
1.6. Pilot Study: P16 as Surrogate Marker for HPV Infection in Penile Cancer 59 
1.6.1. Introduction       59 
1.6.2. Methods and Materials      59 
1.6.2.1. DNA Extraction and PCR     59 
1.6.2.2. P16 Immunostaining      60 
1.6.3. Results        63 
1.6.4. Conclusion        64 
1.7. Critical appraisal of methods      65 
1.7.1. Polymerase chain reaction (PCR)     65 
1.7.1.1. Advantages and disadvantages of PCR    66 
1.7.2. Comparative genomic hybridisation (CGH) and array comparative  66 
genomic hybridisation (aCGH) 
1.7.2.1. Advantages of aCGH      67 
1.7.2.2. Disadvantages of aCGH     68 
1.7.3. High Density Oligonucleotide Arrays     68 
1.7.4. Next Generation Sequencing      70 
1.7.4.1. Advantages and disadvantages of Next generation sequencing 71 
1.7.5. Conclusion        71 
1.8. Aims and Objectives       72 
2. CHAPTER 2: METHODS 
2.1. Methodology for Part 1 including comparative Genomic Hybridisation  73 
2.1.1. Cases        73 
2.1.2. Dissection and DNA Extraction     76 
2.1.3. HPV analysis       78 
2.1.4. Microarray Comparative Genomic Hybridisation (aCGH)   80 
2.1.5. Data Analysis and statistical methodology    81 
2.2. Methodology for Part 2 including Fluorescence in situ Hybridisation  83 
2.2.1. TMA Slide Preparation      83 
2.2.2. Bacterial Culture Preparation and BAC DNA extraction   84 
2.2.3. BAC DNA Amplification and Cleaning     86 
2.2.4. BAC DNA Labelling (Indirect)      88 
2.2.5. Tissue Microarray Slide Preparation and Probe Hybridisation  89 
2.2.6. Microscope Procedure      90 
	 8	
3. CHAPTER 3: RESULTS 
3.1. Array CGH Results       91 
3.1.1. Patients and study samples      91 
3.1.2. Array CGH and Candidate Driver Genes    94 
3.1.3. HPV Subgroup Analysis      97 
3.1.4. Further Clinico Pathological Subgroup Analysis    100 
3.1.5. aCGH Cohort: Contingency Analysis     109 
3.2. FISH DATA Overall       110 
4. CHAPTER 4: DISCUSSION  
4.1. Interpretation of HPV Status      126 
4.2. Comparison of Array CGH in PSCC     127 
4.2.1. Genome Wide Copy Number Aberrations    127 
4.2.2. Copy Number Aberrations and HPV Status    129 
4.2.3. Copy Number Aberrations and Clinicopathological Status  131 
4.2.4. Potential Candidate Driver Genes and Genes of Interest   133 
4.2.5. Genetic Aberrations in other Squamous Cell Carcinomas and                               
Clinical Correlation       137  
4.2.5.1. Cervical Squamous Cell Carcinoma    137 
4.2.5.2. Vulvar Squamous Cell Carcinoma    137 
4.2.5.3. Oesophageal Squamous Cell Carcinoma    139 
4.3. PI3CKA FISH, Clinicopathological Correlation and Clinical Significance  141 
4.4. Experimental Limitations       143 
4.5. CONCLUSION        145 
5. CHAPTER 5: FUTURE WORK: Possible future Design of Experiments and Targeted      
Therapies         146 
6. REFERENCES        147 
7. SUPPLEMENTARY FILES: CGH DATA       158 
8. APPENDIX: PUBLISHED PAPER      188 
 
 
 
 
 
	 9	
List of Figures 
 
Figure 1.1.  Anatomy of the penis        13  
Figure 1.2. Microscopic and Macroscopic appearances of Usual type PSCC   17 
Figure 1.3. Microscopic and Macroscopic appearances of Verrucous type PSCC   18 
Figure 1.4. Microscopic and Macroscopic appearances of Basaloid type PSCC  20 
Figure 1.5. Microscopic and Macroscopic appearances of Warty type PSCC   21 
Figure 1.6. The HPV genome       29 
Figure 1,7   HPV related and HPV unrelated molecular pathways in PSCC  33 
Figure 1.8. PI3K Pathway        45-6 
Figure 1.9. Comparison of an uninfected cell and an HPV infected cell, demonstrating  
                   interactions of the HPV E7 oncoprotein with cellular processes  48  
Figure 1.10. Interactions of the HPV E6 oncoprotein with cellular processes  49 
Figure.1.11. P16 expression in penile cancer tissue     62 
Figure 2.1. Histological subtypes of penile Squamous cell carcinoma  
                  demonstrating distinct morphological features    74 
Figure 2.2. Examples of the PCR machines used in these experiments   79  
Figure 2.3. Example of a PSCC TMA slide (with H&E staining)    84 
Figure 2.4. BAC culture preparation       85 
Figure 3.1. Microarray-based comparative genomic hybridisation analysis  
                   invasive penile squamous cell carcinoma components   93 
Figure 3.2. Samples of invasive penile squamous cell carcinoma   95 
Figure 3.3. HPV status of PSCCs       99 
Figure 3.4. Histological subtype of PSCCs      102 
Figure 3.5. Histological grade of PSCCs      104 
Figure 3.6. Clinical Stage of PSCCs       106 
Figure 3.7. Lymph node status of PSCCs      108 
Figure 3.8. FISH capture images showing PI3K (red) and RP11348P10 (green)  110 
Figure 3.9. FISH capture images showing PI3K (red) and RP11348P10 (green)  111 
Figure 3.10.FISH capture images showing PI3K (red) and RP11348P10 (green)  112 
Figure 3.11.FISH on PSCC samples. A graph comparing histopathological  
                   subtypes: PI3CKA gain and amplification vs no gain   116 
Figure 3.12.FISH on PSCC samples. A graph comparing basaloid with  
     other histopathological subtypes: PI3CKA gain and amplification vs no gain 117 
	 10	
Figure 3.13.FISH on PSCC samples. A graph comparing verrucous with  
                     other histopathological subtypes: PI3CKA gain and amplification vs no gain 118  
Figure 3.14.  FISH on PSCC samples. A graph comparing usual with other  
                     histopathological subtypes: PI3CKA gain vs amplification vs no gain  119 
Figure 3.15.  FISH on PSCC samples. A graph comparing histological grades:  
       PI3CKA gain vs amplification vs no gain     121 
Figure 3.16.  FISH on PSCC samples. A graph comparing clinical stages:  
       PI3CKA gain and amplification vs no gain    122  
Figure 3.17.  FISH on PSCC samples. A graph comparing clinical stage 1 with  
       stages 2,3 and 4: PI3CKA gain vs amplification vs no gain   123 
Figure 3.18.  FISH on PSCC samples. A graph comparing clinical stage 3 with  
       stages 1,2 and 4: PI3CKA gain vs amplification vs no gain   124 
Figure 3.19.  FISH on PSCC samples. A graph comparing low clinical stage 1 and 2    
       with high clinical stage 3 and 4: PI3CKA gain vs amplification vs no gain 125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 11	
 
List of tables 
 
Table 1.1. Invasive  Penile SCC Classification and Subtypes    15 
Table 1.2. WHO 2016 Classification of HPV related and Non HPV related PSCCs  16 
Table 1.3. TNM classification of PSCCs      35 
Table 1.4. Survival Data from St George’s Hospital     39 
Table 1.5. DNA Aberrations in Cervical squamous cell carcinoma   54 
Table 1.6. Molecular alterations in OSCC      56 
Table 1.7. P16 expression sensitivity, specificity and Kappa value (interobserver  
   variability) for HPV positive and negative penile cancer tissue samples  64 
Table 2.1.  Number of cases according to cancer type, HPV status, stage, grade and  
   nodal status        75 
Table 3.1.  Demographics of PSCC cases      92 
Table 3.2. Penile Cancer Overall Recurrent Copy Number Gains and Losses  96 
Table 3.3. Clinico-pathological Subgroup Analysis of Differential Copy Number Changes 100 
Table 3.4. Number of Cases Demonstrating Gain, Amplification or No Gain using  
   FISH Analysis, According to Histopathological Subtype   113 
Table 3.5. Number of Cases Demonstrating Gain, Amplification or No Gain using  
   FISH Analysis, According to Histological Grade    113 
Table 3.6. Number of Cases Demonstrating Gain, Amplification or No Gain using  
   FISH Analysis, According to Clinical Stage     114 
Table 3.7. Number of Cases Demonstrating Gain, Amplification or No Gain using  
   FISH Analysis, According to available HPV status    114 
Table S1. Gains in 3 or more cases. Gain threshold =0.08    158 
Table S2. Losses in 3 or more cases. Loss threshold = -0.08    168 
Table S3. Amplifications in 1 or more cases. Amplification threshold =0.4  181 
 
 
 
 
	 12	
CHAPTER 1: INTRODUCTION 
1.1. EPIDEMIOLOGY, ANATOMY AND 
PATHOLOGY 
 
Penile squamous cell carcinoma is a rare disease, but can have a profound 
physical and psychological effect on those afflicted.   
 
1.1.1. Epidemiology 
Although rare in developed countries, it presents a significant problem in 
developing countries. In the UK and USA there are approximately 0.6 cases 
per 100,000 population per year, with disease usually originating in the 
epithelium of the glans or prepuce. This equates to 360 new cases recorded 
in the UK each year [6-9]. However, in Brazil the incidence of penile cancer 
ranges from 2.9-6.8/100,000 inhabitants [10] and in Trinidad 1.3/100, 000, 
accounting for up to 3% of male cancers [11]. In the USA and Europe penile 
cancer accounts for 0.4-0.6% of all malignant diseases in men [12]. 
Race and ethnicity impact upon incidence as seen in North America with 
highest rates in white Hispanics (1.01/100,000), followed by Alaska 
Native/American Indians (0.77/100,000) and Blacks (0.62/100,000) [9, 13]. 
Incidences are higher in many sub-saharan countries, including Uganda 
(2.7/100,000), Swaziland (3.2/100,000) and Zimbabwe (1.6/100,000).  [12] 
The Puerto-Rico cancer registry has demonstrated that Puerto Rican men 
have higher rates of penile cancer than other groups [14]. US population 
based registries showed that Hispanic and African men had highest rates of 
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penile cancer, and African American men were diagnosed at an advanced 
stage with more node positive disease [15]. 
 
1.1.2. Anatomy 
Penile SCCs are most commonly found on the glans and less frequently occur 
on the inner mucosa of the prepuce or coronal sulcus. Identification of the 
anatomical sites and layers is of paramount importance in correlating depth of 
invasion to prognosis or other clinical parameters. Details of these anatomical 
landmarks are shown in fig.1.1 below[2] 
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Figure 1.1.  Gross and cross sectional anatomy of the penis 
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Details of the lymphatic drainage and anatomy, as relates to clinical staging, 
will be discussed in later chapters 
 
 
 
 
 
 
 
 
 
(A) Distal penis: glans (G), meatus urethralis (M), glans corona (GC), coronal 
sulcus (COS), and retracted foreskin (F). Frenulum (FR), median raphe (R), 
and distal penile shaft (S) also shown. Dashed arrowed lines represent 
parallel sections that should be taken for gross examination of penile 
carcinoma.  
(B) Parasagittal section of distal penis showing penile anatomic levels. E, 
squamous epithelium; LP, lamina propria; CS, corpus spongiosum; F, 
foreskin; COS, coronal sulcus; CC, corpus cavernosum; TA, tunica albuginea; 
D, dartos layers; PF penile fascia.  
(C) Sagittal section of distal penis showing superficial spreading carcinoma 
(CA, green) extending through glans (G), coronal sulcus and inner foreskin (F) 
and invading most distal portion of distal urethra (U). Tunica albuginea (TA) 
and corpus cavernosum (CC) not affected.  
(D) Transverse section through penile shaft showing 2 dorsally located 
corpora cavernosa (CC) and ventral corpus spongiosum (CS), with distal 
urethra (U) running across. Tunica albuginea (TA) surrounds these erectile 
tissues. Diagram also depicts skin of shaft (S), dartos layer (D), penile fascia 
(PF), and superficial (SDV) and deep (DDV) dorsal veins.  
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1.1.3. Pathology 
More than 95% of malignant penile lesions are squamous cell carcinomas. 
The remaining 5% comprise malignant melanomas, lymphomas, 
mesenchymal tumours, metastases and, rarely, sarcomas. Many 
histopathological subtypes of penile SCC have been identified, with 
characteristic morphological features and associated clinical outcomes. This 
section provides an overview of these subtypes and those occurring most 
frequently are discussed in more detail. 
 
Subtype Frequency (%) 
Usual SCC 48-65	
Basaloid carcinoma 4-10	
Warty carcinoma 7-10	
Verrucous carcinoma 3-8	
Papillary carcinoma 5-15	
Sarcomatoid carcinoma 1-3	
Mixed carcinomas 9-10	
Adenosquamous carcinoma 1-2	
Pseudohyperplastic carcinoma <1	
Carcinoma cuniculatum <1	
Pseudoglandular carcinoma <1	
Warty-basaloid carcinoma 9-14	
 
Table 1.1. The frequency of Invasive Penile SCC Classification and 
Subtypes[1-3] 
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The new WHO classification of tumours of the penis has subclassified PSCC 
in to HPV related and Non-HPV related[16] 
 
Non-	HPV	Related	PSCC	 HPV	Related	PSCC	SCC	usual	type	 Basaloid	SCC	Pseudohyperplastic	carcinoma	 Papillary-	basaloid	carcinoma	Pseudoglandular	carcinoma	 Warty	carcinoma	Verrucous	carcinoma	 Warty-basaloid	carcinoma	Carcinoma	cuniculatum	 Clear	cell	squamous	cell	carcinoma	Papillary	SCC,	NOS	 Lymphoepithelioma-like	carcinoma	Adenosquamous	SCC	 Other	rare	carcinomas	Mixed	SCC	 	
 
 
1.1.3.1. Usual Type SCCs 
This tumour subtype arises from the epithelium in the form of atypical 
squamous epithelial cells. Macroscopic appearance ranges from white/grey, 
irregular exophytic to reddish flat and ulcerated endophytic lesions (figure 1.2). 
Central keratinisation with horn pearls is a key feature and dyskeratotic cells 
are commonplace. Most tumours are moderately differentiated and may be 
highly keratinised. 
This type of penile SCC is more likely to be recognised in biopsy specimens 
than other SCC subtypes. [17] Lymph node metastases have been associated 
with grade and lymphovascular invasion, as prognostic indicators. Lymph 
node metastases occur in 28-39% of patient with usual type PSCC [16, 18]. 
Table 1.2. WHO 2016 Classification of HPV related and Non HPV related 
PSCCs. 
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1.1.3.2. Verrucous SCCs 
These are exophytic, endophytic, verrucoid and extremely well differentiated. 
Macroscopically, the cut surface is white, superficial, and with a broad base 
separating the tumour from the stroma (figure 1.3). Microscopically, there is 
significant papillomatosis, acanthosis and hyperkeratosis. Atypia and 
Figure 1.2. Microscopic and Macroscopic appearances of Usual type 
PSCC. Medium power view and macroscopic appearance. 
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koilocytosis are absent (differentiating from giant condylomas/ Buschke-
Lowenstein tumours). The nuclei are round and featureless.  
Although these tumours can be locally aggressive invading the underlying 
stroma with a ‘pushing edge’, they rarely invade beyond the lamina propria, 
superficial dartos or corpus spongiosum. In the majority of correctly diagnosed 
pure verrucous cases, where tumours are non invasive and well differentiated, 
lymph node metastases do not tend to occur[16]. However, mixed or hybrid 
tumours may have a metastatic rate of ≤25% [2] 
 
 
 
 
Figure 1.3. Microscopic and Macroscopic appearances of Verrucous 
type PSCC. Medium power view and macroscopic appearance 
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1.1.3.3. Basaloid SCCs 
This tumour subtype is usually shows less keratinisation and is very infiltrative.   
Macroscopically, they are ulcerative with a non-specific aspect. They 
demonstrate a solid, tan, firm cut surface, with a moderate to deep invasion 
(in to the corpus spongiosum or cavernosum) and harbour small foci of yellow 
necrosis. There is evidence of a solid nest of small, uniform cells usually 
accompanying central necrosis (comedonecrosis) or central abrupt 
keratinisation. Pallisading at the periphery of the nests may be a feature, but 
is rarely present and therefore not required for diagnosis. The cells are small 
or intermediate, basophilic, basoloid, spindle or pleomorphic, with scant 
cytoplasm and many apoptotic and mitotic figures (figure 1.4). 
This is an aggressive, HPV-related tumour, which preferentially affects the 
glans. Vascular and perineural invasion are common findings. Lymph node 
metastases may occur in 50-100% of cases[18-20]. Variation may be 
attributable to studies utilising different samples sizes. 
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1.1.3.4. Warty (condylomatous) SCCs 
Grossly, this is a verruciform tumour with cobblestone appearance and its cut 
surface shows exoendophytic tumour. The tumour-stromal interface ranges 
from broad-based to jagged and irregular. Typical features include 
condylomatous, “cauliflower-like” hyperpapillomatosis, a central fibrovascular 
Figure 1.4. Microscopic and Macroscopic appearances of Basaloid 
type PSCC.  Medium power view and macroscopic appearance. 
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core, and atypical, keratinised cells with superficial and deep pleomorphic 
koilocytosis (figure 1.5). Nuclear atypia and koilocytosis differentiates warty 
from verrucous SCC. 
Low risk HPV detection by PCR or negative p16INK4a IHC favours diagnosis 
of condyloma. Biological behaviour lies between that of usual type and 
verrucous/papillary. Growth usually penetrates the corpus cavernosa or 
corpus spongiosum. Nodal metastases are rare, mainly occurring with deeply 
invasive, high-grade lesions; so prognosis is often favourable. 
 
 
 
Figure 1.5. Microscopic and Macroscopic appearances of Warty type 
PSCC.  Medium power view and macroscopic appearance. 
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1.1.3.5. Guidelines for Pathology Reporting 
Later in this thesis, molecular and genetic data is correlated to 
clinicopathological features commonly present in standard, current pathology 
reporting. 
This usually includes the number of tumours and any surface abnormalities or 
discrepancies. National guidelines for reporting are available from the Royal 
College of Pathologists and have recently been revised [21] and there are also 
guidelines produced by the International Collaboration on Cancer 
Reporting(ICCR) due for publication [22]. Important factors incorporated are 
the anatomical site of the primary tumour, the histological subtype, grade (1-
3), depth of invasion, perineural invasion, vascular invasion 
(venous/lymphatic), irregular growth and front of invasion, urethral invasion, 
invasion of corpus spongiosum/cavernosum and surgical margin status, with 
the extent of any positive margins measured in millimetres. [2, 13] The 
presence or absence of carcinoma in situ (PeiN) is also noted This is referred 
to as stage Tis according to the TNM classification (see chapter 3: Staging, 
Diagnosis, Management and Prognosis). 
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1.1.3.6. Pre-Malignant Penile Lesions 
Pre-malignant lesions of the penis have a variable association with invasive 
SCC. These include penile intraepithelial neoplasia (PeIN) and 
extramammary Paget’s disease. PeIN constitutes dysplastic changes in the 
epithelium with an intact basement membrane and, similar to invasive PSCC, 
may be HPV related or non-HPV related. Non-HPV related PeIN includes 
differentiated (simplex) PeIN, which is mostly associated with usual and low 
grade subtypes of PSCC. It is associated with lichen sclerosis and other 
chronic inflammatory disorders. HPV related PeIN includes basaloid, warty 
and warty basaloid PeIN (most commonly associated with HPV16). Other rare 
forms of PeIN include pleomorphic, spindle, clear cell and pagetoid. [16]  
 
Differetiated PeIN mainly affects the foreskin and presents as a solitary white 
or pink macule or plaque, which can be a raised lesion, with either an irregular 
or sharp edge. There is thickened epithelium, often with anastomosing and 
elongated rete edges, prominent intercellular bridges, whirling and keratin 
pearl formation and atypical basal layer cells. Parakeratosis is a frequent 
finding[16]. 
Warty-basaloid PeIN affects the glans and is characterised by dark brown or 
black macules, papules or plaques. They are flat to slightly elevated, velvety, 
moist, erythematous. Granular, warty, smooth or villous with variable contours 
and mostly solitary. These lesions are characterised by a spiking surface with 
koilocytic changes and small basaloid cells constitute the lower half of the 
epithelium. Most of the warty and basaloid PeINs are high grade lesions[16]. 
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1.2. RISK FACTORS FOR PSCC 
 
1.2.1 Lichen Sclerosis et Atrophicus 
Lichen Sclerosis et atrophicus (LS) is synonymous with Balanitis Xerotica 
Obliterans (BXO). It is a chronic inflammatory condition affecting the prepuce 
and glans. 
Nasca et al. retrospectively reviewed cases of 86 uncircumcised men with 
genital LS and a mean age of 53 at diagnosis. 5 men (5.8%) demonstrated 
premalignant or malignant histopathological lesions, including 3 squamous 
cell carcinoma (SCC), 1 erythroplasia of Queyrat and 1 verrucous carcinoma. 
The average lag time for these cases was 17 years. [23] The proportion of 
SCC cases found was updated to 9.3% in later analysis. Barbagli et al. also 
conducted a multi-centre survey of men with genital LS. [24] The histology 
was re-examined for evidence of LS and all cases of histologically proven 
malignancy were again reviewed. They reported that 11 of 130 patients (8.4%) 
with genital LS showed premalignant or malignant changes. However, much 
higher rates ranging from 32-50% have also been demonstrated. [25, 26] The 
rates of malignant transformation are therefore comparable, if not in excess 
of those found on vulval cancer 4-8%. [27] 
The association between LS and PSCC is further supported by Velazquez 
who found LS in tissues adjacent to invasive penile cancers in 33% of cases 
and a study of 20 patients with penile SCC in whom 40% had evidence of LS, 
which lead the investigators to advocate that all circumcision samples should 
be sent for histological analysis. [25] In a much larger series reviewing 
histology and clinical notes of 155 patients with penile SCC, 28% were found 
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to have LS. Of these, 34 men had SCC and 10 had carcinoma in situ. This 
highlighted that the most common mode of presentation of LS and SCC was 
synchronous. [28] 
Medical treatment is utilised in selected patients and involves the regular use 
of topical corticosteroids for up to 12-16 weeks [29] This group of patients with 
LS should be followed up closely [30]. Although there is no overall consensus 
on the appropriate follow-up policy in this cohort of patients, regular self- 
examination is encouraged. In patients for whom medical treatment has failed 
or with phimosis, surgical management with circumcision is performed and 
often curative. Glans penis resurfacing techniques with or without skin grafts 
may be performed in severe cases. Long term prospective studies are 
required to determine the real risk of malignant transformation of penile LS. 
[29]  
 
1.2.2. Circumcision 
The worldwide prevalence of male circumcision in males older than 15 years 
is approximately 30%, with 69% of these being Muslim and 0.8% Jewish. 
However, this is likely to be an underestimation, as it does not include some 
who are circumcised for cultural or social reasons. [31-33]  
The effect of circumcision on invasive penile SCC has been investigated 
extensively. A strong protective effect of circumcision was shown in 3 of 4 
analyses in children/adolescents, using uncircumcised males as a control. 
However, an inverse relationship was shown in men mostly circumcised as 
adults. In addition, in childhood/adolescents, a stronger association has been 
demonstrated with invasive disease compared to in situ disease. [12]  
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A population based case controlled study by Daling et al. evaluating 
aetiological factors in penile cancer included 62 men with invasive penile 
cancer and 75 with carcinoma in situ.  Males not circumcised in childhood 
(<10yrs) but those circumcised in later life were included. They found that lack 
of circumcision during childhood, as well as phimosis and cigarette smoking, 
were significant risk factors. [34] They advocated early childhood circumcision 
in order to eliminate the development of phimosis and hence prevent penile 
cancer, as did Tseng et al. in an earlier case controlled study. [35] In 
communities where neonatal circumcision is routine, the prevalence of penile 
cancer is almost zero. [36, 37]  
Phimosis leads invariably to the retention of the normally desquamated 
epidermal cells and urinary products (smegma) resulting in chronic irritation 
with or without bacterial infection of the prepuce and glans. [5] Chronic 
inflammation of the prepuce is often referred to as Lichen sclerosis (LS) or 
Balanitis Xerotica obliterans (BXO). Circumcision is a potentially curative 
treatment for LS, even when extending on to the glans [38]   and may even be 
protective against HPV prevalence. [12, 39] However only borderline evidence 
of a protective effect of circumcision on HPV incidence was found in cross-
sectional analysis by Canadas et al. [40] 
So, timely surgical intervention could prevent the incidence of complications 
such as penile cancer in later life. 
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1.2.3. Smoking 
Smoking is a known causative factor for several types of cancer, including 
penile SCC.  
A population-based, case-control study of 110 men demonstrated the risk of 
penile cancer (including in-situ disease) to be 2.8 times greater than in men 
who have never smoked cigarettes.[41] 
A larger study of 503 individuals was assessed for their use of tobacco in the 
form of snuff, chewing tobacco and cigarettes. In this multivariate analysis, 
tobacco was shown to be a significant risk factor for penile carcinoma, and the 
use of more than one form of tobacco increased this risk. [42]  
Furthermore, the odds ratios associated with former smoking were 
substantially less than those associated with current smoking and diminished 
with increasing time since cessation of smoking. Risks increased in proportion 
with the number of cigarettes smoked. [43]  
 
1.2.4. UltraViolet Radiation 
UV radiation has been associated with many malignancies, including penile 
SCC and melanoma [5] 
A prospective study of 892 men with psoriasis treated with oral methoxsalen 
and ultraviolet A photochemotherapy (PUVA), identified 14 patients with 30 
genital malignancies. They showed that patients exposed to high levels and 
low levels of PUVA, had incidences of invasive penile SCC of 162 and 7 times 
that of the general population, respectively. [44] This and other studies have 
led to the conclusion that PUVA therapy should be used conservatively, in 
very selected patients, with close monitoring for several months. Furthermore, 
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whatever the mode of ultraviolet light exposure, men should use genital 
protection. [44, 45]  
 
1.2.5. Human Papillomavirus (HPV) and Sexually Transmitted Infections 
(STIs) 
Oncogenic viruses pose a significant burden to cancer aetiology, accounting 
for 10-15 % of all cancers. [46, 47] 
HPV refers to a family of small double-stranded DNA viruses (8000 base 
pairs) with specific pathogenic subtypes. High-risk HPV types include 16, 18, 
31, 33, 35, 39, 45, 51, 52, 54, 56, 58, 59, 66, 68, and 69 and low-risk types 
are 6, 11, 26, 30, 34, 40, 42–44, 53, 55, 57, 61, 62, 64, 67, 70, 71, 73, 74, 79, 
and 81–84. [48] 
In clinical practice, the high risk HPV subtypes 16 and 18 are associated with 
penile cancer, cervical cancer and head and neck cancer, amongst others. 
Data suggests that HPV types 16, 18 and 6 are the most prevalent types in 
PSCC. [49] A recent study has further confirmed HPV16 as the main HPV 
type aetiologically involved in development of PSCC. [50]  
 
The genome can be divided in to 3 domains (Figure 1.6): a non coding 
upstream regulatory region (URR) of approximately 1kb; an early region with 
6 genes E6, E7, E1, E2, E4 and E5; and a late region encoding 2 genes, L1 
(major capsid protein) and L2 (minor capsid protein). [51] 
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URR – upstream regulatory region; ORI – origin of replication; pRB – 
retinoblastoma protein 
 
 
High risk HPV genotypes produce viral proteins which disrupt the cell cycle. 
Viral proteins E6 and E7 have been proven to induce cell proliferation and 
have oncogenic potential. E6 mediates p53 degradation and E7 inactivates 
some members of the pRB family of tumour suppressor proteins. [52] The 
interaction of HPV with cellular pathways will be discussed later. 
Figure 1.6. The HPV genome. HPV structure and viral protein function. 
Human papillomavirus encodes nine viral proteins, seven early proteins 
(E1-E7) and two late proteins (L1, L2), performing various viral functions, 
including viral DNA replication, gene expression regulation, particle 
assembly and release, and membrane signaling. 
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HPV is the most common sexually transmitted infection responsible for 
approximately 500,000 new cases per year, including cancers of the 
oropharynx, head and neck, anus, uterine cervix, vulva and penis. [46] 
Rates of HPV detection are considerably lower in penile cancer than in 
cervical cancer, where it is 100%. HPV DNA has been detected in 14% -100% 
of invasive penile carcinoma. [53] 
In a meta-analysis of 30 studies encompassing 1266 men with invasive penile 
cancer, overall HPV prevalence was 47.9%. When adjusted for primer, 
histology subtype, study year and region the HPV prevalence was slightly 
reduced at 45.4%, which is comparable to prevalence found in vulval cancer. 
[54] These results also demonstrated geographical variation in prevalence, 
ranging from 39.7% in South America to 59.3% in Asia. Interestingly, HPV 
prevalence was found to be lowest in verrucous carcinoma (22.4%) and 
highest in basaloid/warty subtypes (66.3%). [49] 
Similarly, a global HPV prevalence in invasive penile cancer of 46.9% was 
shown by Miralles-Guri et al. in a review of 1466 patients with PSCC from 31 
studies. In this series the lowest prevalence was demonstrated in South 
America (40.7%) and the highest in North America (57%). However, the 
observed specific HPV contribution by histological type mirrored that of 
Backes et al. [55] 
A prospective study from Rio de Janeiro by Scheiner et al studied 80 cases of 
invasive penile cancer over a 5 year period. HPV DNA was detected in 75% 
of patients with invasive squamous cell carcinoma and in 50% of those with 
verrucous carcinomas. Although no statistically significant correlation could 
be demonstrated between HPV status and histological subtype or stage of 
disease. [56] 
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Variations in detection rates could be caused by the use of different 
techniques (PCR vs Southern blot). PCR relies on the isolation and 
amplification of small segments of DNA, whereas Southern blot utilises 
electrophoresis to separate DNA and probe hybridisation for detection. Also, 
the type of primers used for polymerase chain reaction (PCR, degenerate vs 
conventional) or perhaps the type of tissue storage (paraffin embedded vs 
fresh frozen tissue) and thus DNA quality, could affect results.  
Much of this data is based on cross-sectional studies. Longitudinal studies 
although logistically difficult would perhaps provide better information about 
disease progression. 
Circumcision rates, rates of concomitant STIs and availability or utilisation of 
the HPV vaccination could contribute to the worldwide variation in prevalence. 
The prevalence of HPV was 90.7% in HIV positive men and 60.9% in HIV 
negative men. [57] 
In some countries, females who are not yet sexually active are being 
vaccinated against strains of HPV, to protect against cervical cancer. There 
are currently 2 types of vaccines available: Bivalent HPV16/18 and 
Quadrivalent HPV 16/18/6/11. In the UK, the HPV vaccine has been offered 
to school girls (not boys) aged 12 and 13 since 2008, relying on the premise 
of herd immunity. The efficacy of a single dose of vaccine in preventing HPV 
infection has been investigated in a clinical trial [58, 59] and the potential 
benefit of ‘therapeutic HPV vaccines’ to prevent cancer in women previously 
infected with HPV [60]. The impact of female vaccination on prevalence of 
HPV and HPV related cancers in the male population has not yet been 
thoroughly investigated. However, HPV vaccines have been shown to be 
clinically effective in men. In a recent randomized, multicentre, placebo-
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controlled, double-blind trial of 4065 men aged 16–26 years, vaccination using 
the quadrivalent vaccine effectively reduced the incidence of genital warts in 
90% of patients with no HPV at enrolment. [61]  In the future, it is likely that 
the combination of preventative and therapeutic vaccines may play a greater 
role in reducing the overall burden of HPV related squamous cell carcinomas.  
Given the global burden of HPV associated cancers, there is an argument for 
more widely available vaccination schemes for men.  
Evidence pertaining to the cost effectiveness of implementing the HPV 
vaccine in male populations is contentious. In Denmark extending the current 
HPV vaccination programme to include boys and girls was deemed a cost 
effective strategy that would lead to a faster prevention of cancers, cancer 
precursors and genital warts in men and women. [62] However, data from the 
US suggests that increasing the vaccine coverage in females would be a more 
efficient approach for reducing the overall health burden of HPV in the 
population.[63] 
 
As there is a proportion of penile cancers that do not exhibit HPV, it is 
postulated that two separate pathways are responsible for its pathogenesis: 
HPV dependent and HPV independent. 
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Figure 1.7. Visual representation of the HPV related and HPV unrelated 
pathways in penile squamous cell carcinoma.with a combined common 
final pathway. Modes of intervention in yellow. Cellular pathways are 
shown with text in white [5] 
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1.3. STAGING, DIAGNOSIS, MANAGEMENT AND 
PROGNOSIS 
 
1.3.1. Classification 
The Jackson classification, introduced in 1966, was the first classification 
system used. It divided penile tumours in to 4 categories, according to 
operability of the primary tumour and nodal metastases.[64] The TNM 
classification is the most widely used, comprehensive system for staging 
malignancies [65]. 
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Clinical classification 
T - Primary Tumour 
TX Primary tumour  cannot  be assessed  
No evidence of primary tumour Carcinoma in situ 
Non-invasive carcinoma 
Tumour invades subepithelial connective tissue 
T1a Tumour invades subepithelial connective tissue without lymphovascular invasion and is not poorly 
differentiated or undifferentiated (T1G1-2) 
T1b Tumour invades subepithelial connective tissue with lymphovascular invasion or is poorly 
differentiated or undifferentiated (T1G3-4) 
Tumour invades corpus spongiosum and/or corpora cavernosa 
Tumour invades urethra 
Tumour invades other adjacent structures 
T0 
Tis 
Ta 
T1 
	
T2 
T3 
T4 
N - Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No palpable or visibly enlarged inguinal lymph node 
N1 Palpable mobile unilateral inguinal lymph node 
N2 Palpable mobile multiple unilateral or bilateral inguinal lymph nodes 
N3 Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral 
M - Distant Metastasis 
M0 
M1 
No distant mets 
metastasis 
Distant metastasis 
Pathological classification 
The cT categories correspond to the clinical T categories. The pN categories are based upon biopsy or 
surgical excision 
pN - Regional Lymph Nodes 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Intranodal metastasis in a single inguinal lymph node 
pN2 Metastasis in multiple or bilateral inguinal lymph nodes 
pN3 Metastasis in pelvic lymph node(s), unilateral or bilateral or extranodal extension of any regional lymph 	 node metastasis 
pM - Distant Metastasis 
pM0 
pM1 
No distant mets 
metastasis 
Distant  
G - Histopathological Grading 
GX Grade of differentiation cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3-4 Poorly differentiated/undifferentiated 
Table 1.3. TNM classification of PSCCs. Formatted: Font: 12 pt
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1.3.2. Clinical Diagnosis, Staging and Management   
 
1.3.2.1. Primary Tumour 
Diagnosis of the primary tumour is principally clinical. PSCC most commonly 
manifests itself as a visible and/or palpable lesion on the glans, followed by 
the prepuce, coronal sulcus and shaft.[66, 67] Ultrasonography is unreliable 
and inconsistent in diagnosis, but MRI combined with artificial erection has 
proven useful in determining cavernosal involvement.[68]  
 
For CIS, topical chemotherapy is recommended as first line treatment (5FU or 
imiquimod). The mainstay of management for invasive PSCC remains 
surgical, focusing on excision of the primary tumour (glans resurfacing, 
glansectomy, partial penectomy, total penectomy) with satisfactory resection 
margins. Local recurrence rates range between 4-13%. Laser therapy, 
micrographic surgery (microscopic sequential tissue excision used primarily 
in dermatological conditions) and radiotherapy have also been utilised for 
treatment of local disease dependent on stage.[69] 
 
1.3.2.2. Assessment of Lymph Nodes 
1.3.2.2.1 Impalpable lymph nodes: CN0 
Approximately 20%-25% of patients with impalpable lymph nodes at 
presentation harbour occult metastases. [69, 70] 
The sensitivity of 18F-Fluorodeoxyglucose Positron Emission Tomography- 
Computed Tomography (PET-CT) in detecting metastases in the inguinal 
basins of CN0 patients ranges from 75%-89% and 100% in deep inguinal and 
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obturator nodes. Specificity ranges from 87.5%-100%.[71-73] However, there 
are limitations including the inability to detect metastases ≤10mm. [74]  
 
Various imaging modalities have been utilised to assess the presence or 
absence of lymph node metastases in PSCC, including CT, PET/CT, USS and 
MRI; each with specific advantages and disadvantages. It is appreciated that 
conventional CT or MRI alone cannot accurately diagnose micrometastases. 
[69]  However, Combined PET/computed tomography and sentinel lymph 
node biopsy may help to detect both inguinal micrometastasis and pelvic and 
abdominal metastasis.[75]  Inguinal USS can detect abnormal nodes with the 
highest specificity (97%) combining features of L/T ratio <2 and an absent 
lymph node hilum. [76] When combined with fine needle aspiration cytology 
(FNAC) in CN0 patients USS has a sensitivity and specificity of 39% and 
100%, respectively.[77]  In MRI assessment of lymph nodes, spatial resolution 
with lymphotrophic nanoparticles in a study by Tabatabaei is reported as 1-
2mm, although the smallest nodes isolated were 3mm in size, so it is unclear 
as to whether micrometastases could have been missed.[78] 
 
 
Lymph node dissection has been shown to increase the accuracy of lymph 
node staging in PSCC patients, but prophylactic modified elective Inguinal 
Lymph node dissection in CN0 patients has potential risks of morbidity and 
would be unnecessary in up to 80% of patients. The EAU guidelines suggest 
that invasive lymph node staging may be required for those at intermediate or 
high risk of lymphatic spread.[69] In our centre (St. George’s Hospital) those 
with SCCp with a histology of ≥T1 or ≥G2 and CN0, USS undergo FNAC is 
	 38	
performed on any abnormal lymph nodes. Dynamic sentinel lymph node 
biopsy is then performed by injection of Tecnetium 99 (Tc99m) nanocolloid 
around the base of the penis 4 hours prior to surgery, dynamic 
lymphoscintogram intraoperatively and injection of patent blue dye.[79] This 
technique has a proven false negative rate of approximately 5% and a 
complication rate of 5.7%-7.6%.[79, 80] Those with positive sentinel lymph 
nodes require ipsilateral inguinal lymph node dissection within 4 weeks of 
DSNB. 
 
1.3.2.2.2. Palpable Lymph Nodes: CN+ (CN1/CN2) 
Inguinal lymph nodes are clinically palpable in 28-64% of patients at 
presentation. Metastases accounts for 47%-85% of these and the remainder 
can be attributed to inflammation. [66] There has been some controversy 
surrounding administration of antibiotics, but this has been proven to have 
adverse oncological outcomes.[81, 82] 
In a study of 30 patients In the 8 cN+ cases (total of 16 inguinal lymph node 
basins analyzed) PET-CT had 100% sensitivity, specificity and positive 
predictive value.[73] FNAC has also been evaluated in a small series of 16 
patients with palpable inguinal lymph nodes, demonstrating a sensitivity of 
93% and specificity of 91%.[83] It has been advocated for use in clinically 
doubtful cases.[69] 
Radical inguinal lymphadenectomy is advocated for those with clinically 
palpable lymph nodes. Complications have been reported as ranging from 
10.3-58%. A modified approach to iLND has been proven to reduce morbidity 
whilst preserving oncological outcomes.[84-86] 
A study of 188 node positive inguinal basins from 142 patients demonstrated 
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a 5 year cancer specific survival of 71% in those with inguinal lymph node 
metastases and 33.2% in those with pelvic lymph node metastases.[87] In our 
centre survival rates vary considerably, depending on lymph node positivity 
(Table 1.4).  Data from over 200 patients in another UK supraregional centre 
have shown five-year CSS, with pN0 tumors (92%), N1 (73%), N2 (61%), N3 
(33%), and M1 (0%; P <.0001). 
 
 
 
 
 
 
 
 
 
Parameters of inguinal lymph node metastases that predict pelvic lymph node 
involvement include the number of positive inguinal nodes and the extent of 
extracapsular spread.[88, 89] The diameter of inguinal lymph nodes has also 
been associated with pelvic lymph node metastases.[87] If more than 2 
inguinal lymph nodes are involved, the rate of positive pelvic lymph nodes is 
23% and this rises to 56% when more than 3 nodes are involved.[88] The EAU 
guidelines advocate ipsilateral pelvic lymphadenectomy if 2 or more positive 
lymph nodes or one node with extracapsular spread (pN3) are found 
unilaterally.[69] 
From a study of 73 penile cancer patients (33 inguinal lymph node basins), it 
has also been suggested that pelvic lymph node dissection should be 
	 5	year	disease	specific	survival	
Overall	 84.9%	
Node	Negative	 97.1%	
Node	Positive	 50.1%	
Table 1.4. Survival Data from St George’s Hospital. 
Figures calculated from a cohort of 1100 invasive PSCCs. 
(p=<0.001) 
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considered in the case of aggressive histological PSCC subtypes and strong 
expression of p53.[90] 
 
Chemotherapy rather than radiotherapy is recommended in patients with 
pN2/pN3 disease.[69] However, a BAUS National, multi-centre, retrospective 
review examined 120 patients with PSCC. This cohort underwent either 
surveillance only, PLND only, PLND plus chemo and/or radiotherapy and 
chemotherapy and/or radiotherapy alone. Data from this study suggested that 
there is no survival benefit from treatment of pelvic lymph nodes with any 
modality.[91] 
 
1.3.3. Prognostic Factors 
Prognostic factors include tumour type, histological grade, perineural invasion 
and lymphovascular invasion.[92] 
Lymph node status is one of the most important independent prognostic 
factors in patients with squamous cell carcinoma of the penis and has been 
shown to correlate with stage of tumour, depth of invasion, histological type, 
and grade.[19] Although, nodal stage has been refuted as a predictive factor 
in lymph node metastases by other studies. [93] 
 
Verrucous, papillary, warty, pseudohyperplastic and carcinoma cuniculatum 
PSCC subtypes confer an excellent prognosis. However, high-risk subtypes 
with a propensity for early metastases and high mortality include basaloid, 
sarcomatoid, adenosquamous and poorly differentiated tumours.  
Although T2 tumours encompass spongiosal (pT2a) and tunical/cavernosal 
invasion (pT2b), the latter have been associated with worse outcomes. pT2b 
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had a higher local recurrence rate (35% vs 17%) and mortality rate (30% vs 
21%).[94] This difference has also been highlighted by other studies.[95] 
 
Stage pT3 PSCCs include those of the distal urethra in 25% of cases, and of 
the proximal urethra. Urethral involvement with PSCC has been demonstrated 
as having poor outcomes.[92] Anterior urethral PSCCs do not necessarily 
confer poor prognosis.[96] Tumours that invade the proximal urethra are 
highly aggressive with a poor prognosis.[69]  
Molecular markers as potential prognostic indicators will be discussed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 42	
1.4. PSCC Molecular Genetics 
The relatively recent developments in molecular genetics have given us the 
opportunity to explore various cancers using a variety of different techniques, 
but in comparison to other squamous cell carcinomas, relatively little is known 
about the molecular genetics of penile cancer. 
 
 
1.4.1. Molecular Markers Correlated with HPV 
There is one early study that has investigated chromosomal changes in order 
to elicit information regarding DNA sequence copy number alterations 
(CNAs). 
26 patients with penile SCC were identified in a Brazilian centre and tissue 
samples were fresh frozen. Comparative genomic hybridisation was 
performed and identified various copy number gains and deletions. However, 
no chromosomal changes were identified in 3 patients. 
One tumour sample showed amplification in 12q13–14, and in four other 
cases this region was part of a larger overrepresented region. 12q13–14 
harbors the MDM2 gene and overexpression leads to excessive inactivation 
of tumour protein p53, diminishing its tumour suppressor function. Thus the 
potential of MDM2 as an important molecular marker was emphasised and 
follow up studies suggested. In addition, the overall number of CNAs showed 
a possible correlation with clinical outcome. The number of cases analysed 
was small and thus, any conclusions drawn are of limited strength and 
validity.[97] 
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A more recent study has utilised next generation sequencing on 20 patients 
with PSCC, highlighting clinically relevant genomic alterations. These 
included CDKN2A point mutations and homozygous deletion (40%), NOTCH1 
point mutations and rearrangements (25%), CCND1 amplification (20%), 
BRCA2 insertions/deletions (10%), RICTOR amplifications (10%), and 
FBXW7 point mutations (10%). PIK3CA point mutations and amplification 
(25%), and EGFR amplification (20%) were found in those with advanced 
PSCC [98]. 
 
Although some correlation of MIB1/Ki-67 immunohistochemical expression 
with lymph node status has been proven. [99] the highest expression of Ki-67 
has been noted in basaloid tumours and the lowest in verrucous PSCCs. 
Proliferation cell nuclear antigen (PCNA) is a nuclear protein and cofactor of 
DNA polymerase delta, vital for repair and synthesis of DNA. There has been 
no correlation found between PCNA immune expression and lymph node 
metastases or prognosis. [100]  
 
1.4.2. Molecular Markers Not Correlated with HPV 
Further studies have focussed on other methodologies with regard to factors 
involved in cell cycle regulation and their association with HPV status and 
survival/prognosis. Using immunohistochemistry on TMAs of varying 
histopathological subtypes, Stankiewicz et al. demonstrated that Ki-67 (a 
nuclear protein encoded by the MK167 gene and a cellular marker for 
proliferation) is only a moderate surrogate marker for HPV infection in PSCC 
and does not show prognostic value for cancer-specific survival and overall 
survival in PSCC.[101] This is in keeping with other studies that have found 
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no significant association of Ki-67 with pathological features, HPV status or 
survival.[102, 103] 
The human epidermal growth factor (HER) family comprises EGFR, HER 2, 
HER3 and HER4 transmembrane tyrosine kinase receptors. Activation of 
EGFR by EGF or TGFα ultimately induces several proliferative pathways. In 
a study exploring HER/PTEN/Akt pathway activation (using IHC, FISH and 
PCR) EGFR, HER3 and HER4 (not HER2) had proven association with 
PSCC. HER3 expression was also found more commonly in HPV+ve cases 
and positively correlated with cytoplasmic Akt1 expression.[104, 105] pEGFR 
has been expressed more in HPV-ve than HPV+ve PSCCs [104]  and its 
expression has also strongly related to increase risk of recurrence and shorter 
overall survival.[106] 
Active HER receptors also stimulate the PI3K/Akt intracellular signalling 
pathway, which is responsible for regulation of cell differentiation, migration, 
proliferation and survival (Figure 1.7). A study by Andersson et al. focused on 
mutational analysis rather than protein expression and showed mutations in 
PIK3CA in 29% of PSCC samples. [107] Phosphatase and tension homolog 
(PTEN) negatively regulates the Akt pathway and losses of alleles in PTEN 
have been noted in the literature.[105] 
 
This tyrosine kinase/HER family pathway has been manipulated in trials 
assessing the efficacy of the irreversible, pan-epidermal growth factor inhibitor 
(HER inhibitor), Dacomitinib. It was active and well tolerated in patients with 
advanced PSCC. Mutations in downstream effectors of EGFR signalling in 
relation to dacomitinib activity require more extensive investigation. [108] 
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Figure 1.8. PI3K Pathway: Autophosphorylation of ligand-activated 
receptor tyrosine kinases (RTKs) causes recruitment of inactive 
heterodimeric class IA phosphatidylinositol 3-kinases (PI3Ks) through 
the interaction of phosphotyrosine residues on the receptor and SRC-
homology 2 (SH2) domains on the PI3K p85 regulatory subunit, or the 
adaptor proteins IRS1 and IRS2. IRS1 and IRS2 are phosphorylated by 
the activated receptor, generating docking sites for the SH2 domains 
of p85 and inducing proper assembly of the signalling complex. These 
SH2–phosphotyrosine interactions bring PI3K in close proximity to its 
substrate at the plasma membrane and relieve the inhibitory action of 
p85 on the p110 catalytic subunit, which is then free to convert 
PtdIns(4,5)P2 (PIP2) into PtdIns(3,4,5)P3 (PIP3). Alternatively, binding 
of PI3K to activated RAS can also stabilize its membrane localization 
and activate the catalytic domain. This occurs by recruitment of the 
adaptor proteins SHC, GRB2 and GAB2 to activated RTKs. C2, C2 
domain; CD, catalytic domain; p85 BD, p85-binding domain; RBD, 
RAS-binding domain. 
 
RTK = Receptor tyrosine kinase 
PI3K = phosphatidylinositol 3-kinases 
SH2 = SRC-homology 2 
PtdIns = phosphatidylinositols  
PIP2 = PtdIns(4,5)P2 
PIP3 = PtdIns(3,4,5)P3 
GRB2 = Growth factor receptor-bound protein 2 
GAB2 = GRB2 Associated binding protein 2  
IRS1/2 = insulin receptor substrates 
P = Phosphoryl group 
CD = Catalytic domain 
P85 BD = p85 binding domain 
RBD = RAS-binding domain 
C2 = C2 domain 
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Human papillomavirus (HPV) E6 and E7 oncoproteins are essential to HPV 
oncogenesis, as demonstrated by high risk subtypes in cervical cancer.  
 
The E6 and E7 oncoproteins interfere with cell cycle checkpoints and 
apoptosis by reacting with tumour suppressor gene products retinoblastoma 
(RB) protein and p53 (Figures 1.8 and 1.9).  
The E6 oncoprotein is composed of 150 amino acids with a molecular weight 
of 16-18kD [109]. It encompases two CX2C-X29-CX2C zinc- like fingers 
coupled by a 36 amino acid interdomain linker. The E6 protein is not 
enzymatically active, but protein-protein interactions are responsible for 
initiating its activity. The most frequent protein to interface with E6 is a 
ubiquitin ligase, E6-associated protein (E6AP). Ubiquitin monomers are 
attached to the protein targeted for destruction as part of the ubiquitin 
cascade. A complex is formed of E6, E6AP and target proteins. Ubiquitination 
of the target protein then ensues, followed by proteasome –mediated 
breakdown [110]. 
The E7 oncogene encodes a 100 amino acid protein and comprises 3 
conserved regions, which include the NH2 terminal CR1 domain, the CR2 
region and the COOH terminal CR3 domain [110] . In high risk HPVs the E7 
oncoprotein is required for viral pathogenesis and cellular  
transformation[109]. 
 
 
 
 
 
	 48	
 
  
FADD = Fas-associated protein with death domain; HDAC = histone deacetylase; CDK = Cyclin dependent kinase; RB = Retinoblastoma; IRF1 = Interferon regulatory factor 1; ATM = ataxia- telangiectasiamutated; RAD = related DNA damage response 
Figure 1.9. Comparison of an uninfected cell and an HPV infected cell, demonstrating interactions of the HPV E7 
oncoprotein with cellular processes. E7 oncoprotein expressing cells are usually predisposed to undergo apoptosis, in part due 
to the degradation of the antiapoptotic protein pRb and E2F-1 binding.  
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TERT = Telemorase reverse transcriptase; FADD = Fas-associated protein with death domain; CDK = Cyclin dependent kinase; IRF3 = Interferon regulatory factor 3; Ac = acetylation; NFX123 = nuclear transcription factor, X box-binding protein-123; FAK = focal 
Figure 1.10. Interactions of the HPV E6 oncoprotein with cellular processes. E6 protein inhibits apoptosis by targeting proapoptotic proteins, including 
p53 and Bax, for proteolytic degradation. It protects cells from death receptor induced apoptosis by blocking apoptotic signal transduction and inducing the 
expression of ‘inhibitors of apoptosis’. 
Formatted: Left
	 50	
adhesion kinase; Ub = ubiquiti Deleted: ¶
	 51	
Strong expression of p53 leads to an inhibition of the cell cycle by the 
p21/Retinoblastoma (Rb) cascade. RB protein regulates cell-cycle 
progression (preventing uncontrolled proliferation) and is regulated by cyclin-
dependent kinase phosphorylation. The p16INK4a protein inhibits cyclin 
dependent kinase phosphorylation of RB protein, thereby ceasing cell-cycle 
progression. [103, 105, 111, 112]  
 
HPV has been found to disrupt the RB/p16INK4A pathway by down-regulating 
RB, which ultimately results in overexpression of p16INK4A.[111, 112] Other 
studies have demonstrated that HPV-associated alterations of tumour 
suppressor genes p53/pRb/p16 are only evident in a limited number of penile 
cancer cases particularly basaloid and warty subtypes of penile cancer.[105, 
113] 
TP53 mutations, as well as HPV negative status, tumourigenicity and 
cisplatin/epirubicin sensitivity, have also been demonstrated in a study to 
establish new penile cancer cell lines from 21 fresh tissue samples. [114] 
 
Copy number gains and overexpression of Myc has been demonstrated in 
PSCCs and the integration of HPV-16 DNA has been localised to sites 
containing the proto-oncogene c-myc (8q24.1) using the penile cancer 
specific cell line, ISC2. Insertion of HPV DNA sequences, resulting in Myc 
activation may be a key occurrence in the development of HPV associated 
tumours.[100, 115, 116] 
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1.4.3. Other Molecular Markers and Clinical Association 
The ras pathway is activated by receptor tyrosine kinases and consists of 3 
members: HRAS, KRAS and NRAS. The KRAS gene encodes a protein that 
is an important component of the EGFR signalling pathway.[117] A study of 
28 PSCCs found somatic missense mutations: one mutation in KRAS and 2 
in HRAS. Both KRAS and HRAS mutations were discovered in larger, more 
advanced tumours.[100, 107] 
 
Research investigating other molecular markers remains sparse, but has 
included the following: 
Telemorase adds DNA sequence repeats to the 3’ end of the DNA strands in 
the telomere region. Telomerases are very important for cells to overcome the 
regulated process of senescense and are therefore an important factor in 
tumour progression[105]. 
 
E cadherins are cell adhesion molecules and their expression has been 
significantly correlated with lymph node metastases in penile cancer. [102] 
Low ecadherin immunoreactivity has also been associated with a greater risk 
of lymph node metastases.[118] 
Matrix metalloproteases are enzymes that degrade type 4 collagen in the 
basal membrane. High MMP-9 immunoreactivity was an independent risk 
factor for disease. Recurrence and both MMP-2 and MMP-9 were found to be 
highly expressed in PSCCs.[100, 118] 
 
Epigenetic events include changes in DNA methylation of CpG rich islands 
have been associated with tumour suppressor gene inactivation and 
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oncogene activation/overexpression. Methylation in 26 PSCCs demonstrated 
frequencies of DAPK, 26.9% (7/26); FHIT, 88.4% (23/26); MGMT, 
19.2%(5/26); p14, 3.8% (1/26); p16, 23.1% (6/26); RAR-b, 23.1%(6/26); 
RASSF1A, 11.5% (3/26); and RUNX3, 42.3% (11/26). Methylation was more 
frequently found in HPV-negative than in HPV-positive patients.[119] FHIT is 
located in the chromosomal region 3p14.2 and is thought to be a tumour 
suppressor gene, thus it is postulated to play a vital role in PSCC 
pathogenesis.[120] A more recent study of 38 fresh frozen penile cancers 
revealed hypermethylated differentially methylated regions associated with 
tumour suppressor genes including CDO1, AR1 and WT1. A 4 gene epi-
signature which predicted lymph node metastasis was also identified.[121] 
 
Cyclooxegenase-2 (COX-2) and prostaglandin E2 (PGE2) are both proven to 
be inflammatory mediators of carcinogenesis. COX catalyzes the synthesis of 
PGH2, which is converted, in turn, by microsomal prostaglandin E synthase 
(mPGES-1) to PGE2. Golinjanin et al. have confirmed increased COX-2 and 
mPGES-1 expression in dysplasia, CIS, invasive PSCC and lymph node 
metastases. These molecular markers were overexpressed in PSCCs. [122] 
 
The SCC antigen is a 43kDa glycoprotein, which has been investigated in the 
diagnosis and management of various SCCs. Information on its role in penile 
cancer is limited, but there has been some correlation with disease 
progression, tumour burden and lymph node metastases. Specificity has been 
demonstrated up to 100%, but sensitivity of only 57%.[100]  
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1.5. Molecular Genetics in Other Squamous Cell 
Carcinomas 
Translational research has been defined by The National Institutes of Health 
(NIH) as: “the process of applying ideas, insights, and discoveries generated 
through basic scientific inquiry to the treatment or prevention of human 
disease.” In the case of penile squamous cell carcinoma we can use 
knowledge from other SCCs to facilitate this. 
Many other squamous cell carcinomas also have a variable association with 
HPV. These include cervical cancer, vulval cancer, oropharyngeal cancer 
amongst others. 
 
1.5.1. Cervical Squamous Cell Carcinoma (CSCC) 
Cervical cancer is one of the most common cancers worldwide affecting 
womens health. Annually, approximately 530000 women worldwide are 
identified with cervical cancer and 275000 women die from the disease, 
according to the WHO[123]. Cervical screening programmes have reduced 
the incidence and death rate by 70 - 80% [123, 124]. HPV infection has been 
identified as the principal causative agent in cervical cancer and many HPV 
genotypes have been identified with strong oncogenic potential. These 
include HPV 16, 18, 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82, and 
are attributable to 95% of cervical cancer [123] HPV 16 and 18 are considered 
to be the most high risk. 
However, other genetic changes are thought to contribute to the oncogenesis 
of CSCC. Some of these associations have been summarised in the table 
below (Table 1.5 ). 
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DNA	
aberration	
Clinical	correlation		 Candidate	genes/molecular	correlation		 Reference	
1q	gain	 Occurs	in	advanced	stages	of	tumour	progression	 	 [125]	
2q	loss	 	 ?tumour	suppressor	gene	 [125]	
2q	deletion	 No	clinical	correlation	 Mapping	to	several	genes	including	CFLAR,	CASP10	and	PPP1R7	 [126]	
3p	loss		 Frequent,	but	unrelated	 	 [127]	
	 ?tumour	suppressor	gene	 [125]	
	 microsatellite	markers	D3S1609,	D3S1537,	D3S1619,	and	D3S2405.	TbR-II	and	FHIT	involved	in	cervical	carcinogenesis	
[128]	
3q	gains	 In	a	subset	of	advanced	tumours		 	 [127]	
Gain	is	an	early	event	that	occurs	at	the	transition	from	preinvasive	to	invasive	disease	
Possible	molecular	marker	for	cervical	cancer	detection	 [125]	
	 Positive	correlation	between	an	increased	copy	number	of	PIK3CA	 [129]	
No	clinical	correlation	 Candidate	oncogenes	PIK3CA,	elF-5A2,	CCNL1	 [126]	
4p	gain	 Frequent,	but	unrelated	 	 [127]	
Table 1.5. DNA Aberrations in Cervical squamous cell carcinoma. 
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1.5.2. Vulvar Squamous Cell Carcinoma (VSCC) 
VSCC is a rare cancer with incidence ranging from 0.4 to 20 per 100,000 
according to age. [131] Both HPV related and HPV unrelated tumour types 
exist, with the former occurring mainly in younger women. In older women the 
disease is often associated with chronic inflammation. 
Data regarding the molecular pathways involved in VSCC is less prevalent 
than CSCC. However, studies have revealed some significant genetic 
aberrations. Recurrent copy number gains at 1p and 20, as well as deletions 
4q	loss	 Frequent,	but	unrelated	 	 [127]	
5p	gain	 Occurs	in	advanced	stages	of	tumour	progression	 	 [125]	
8p	loss	 	 ?tumour	suppressor	gene	 [125]	
9p	deletion		 Association	with	the	presence	of	regional	lymph	node	metastases		 	 [127]	
11p	deletion	 	 	 [130]	
11q	deletion	 	 Harbours	U90916	mRNA	of	unknown	function,	ZNF202,	LOH11CR2A,	HSC71,	protein	kinase	C	substrate	RC3	(neurogranin)	PPP2RIB	gene	mutations	identified	
[130]	
13q	loss		 Frequent,	but	unrelated	 	 [127]	
	 ?tumour	suppressor	gene		 [125]	
	 57	
at 2p, 3p and 10 have been observed in VSCCs. [132] TP53 overexpression 
and mutations have been associated with HPV unrelated VSCCs. [133] 
Further studies have demonstrated low level of p16 protein and high level of 
p21 protein were associated with a shorter disease-related survival. [134] High 
stage tumours and lymph node metastases have also been linked to EGFR 
(7p12) copy number increases. [135] 
 
1.5.3. Oesophageal Squamous cell carcinoma (OSCC) 
Oesophageal squamous cell carcinoma is the 6th leading cause of cancer 
related death worldwide [4, 47]. Its incidence is 20 to 30 times higher in China 
than in the USA. [136] It is often aggressive and confers a very poor prognosis. 
 
Type	of	genetic	aberration	 	
Loss	of	heterozygosity	 1p,	3p,	4,	5q,	9,	11q,	13q,	17q,	18q	
Loss	of	tumour	suppressor	gene	function	 P53	mutation	
Mathylation	and/or	loss	of	p16MST1	and/or	p15	 Reduced	Rb	expression	
Gene	amplification	 Cyclin	D1	
HST-1	
EGFR	
INT-2	
Increased	expression	 iNOS	
hTERT	
BMP-6	
COX-2	
c-myc	
β-catenin	
 
Table 1.6. Molecular alterations in OSCC[4]. 
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Other studies have found additional proteins to be upregulated (TPM4, PRX1, 
MnSOD, SCCA1, HSP60, Laminin receptor, Cathepsin D, PKM2, Periplakin, 
careticulin, GRP78, Galectin 7, CD25B, ACTN4, Prx VI) and genes down 
regulated (PLCE1, C20orf54, CHFR, P14, P15, P16, RASSF1A, DAPK, 
RUNX3, UCHL1, ZNF382, UPK1A, FHIT, MLH1, CRBP1, CRABP1)[137] 
Data has also indicated that MMP7, MMP9 and MMP13 may function in the 
early stages of ESCC and that their coexpression predicted poor outcome for 
OSCC patients at an early stage. Similarly, overexpression/ expression of 
Cyclin D1 and p53, as well as reduced expression of E-cadherin, has been 
significantly associated with poor prognosis [138] 
 
1.5.4  Head and Neck Cancer 
Head and neck cancer encompasses squamous cell carcinoma of the oral 
cavity, oropharynx, larynx or hypopharynx and 600, 000 cases arise each year 
worldwide. 5 year survival is poor and ranges from 40-50% [139]. The 
predominant risk factors include the use of tobacco and heavy consumption 
of alcohol. Evidence suggests a synergistic relationship between the two [139, 
140]. Some HNSCCs, mainly oral tongue and oropharyngeal, are caused by 
HPV infection. HPV positive and HPV negative HNSCCs have differing 
clinicopathological and molecular characteristics. HPV negative HNSCC has 
a decreasing incidence, is linked to smoking or excessive alcohol use and 
occurs in those over 60. Prognosis is poor in these patients and TP53 
mutations are frequent. The incidence of HPV positive HNSCC is increasing 
and tend to occur in those under the age of 60. However, prognosis tends to 
be favourable [139, 140].  
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Overall, comparative genomic hybridisation has shown that approximately two 
thirds of oropharyngeal tumours demonstrate chromosome 3q26.3 gains. 
HPV negative HNSCCs harbour a higher number of chromosomal 
amplifications and alterations [141], which is further supported by whole 
exome sequencing data [142]. HPV negative tumours had significantly more 
losses at 3p, 5q, 9p, 15q and 18q and gains or amplifications of 11q13; but 
fewer 16q losses and Xp gains. 16p loss was assocated with better prognosis 
in HPV-related HNSCCs [141]. 
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1.6. PILOT STUDY: P16INK4A AS A SURROGATE 
MARKER FOR HPV INFECTION IN PENILE 
CANCER 
 
1.6.1. Introduction 
At present, HPV DNA is detected by methods such as polymerase chain 
reaction (PCR), but immunohistochemistry (IHC) would be a simpler, cheaper 
method. In clinical practice and in research methodology p16INK4A has been 
used as a surrogate immunohistochemical marker for HPV. We aim to validate 
the accuracy of p16INK4A IHC as a reliable marker of HPV infection in order to 
accurately evaluate the best method for stratifying PSCCs in to HPV related 
and HPV unrelated cases. 
 
1.6.2. Methods and Materials 
237 PSCC samples were examined immunohistochemically for p16INK4A 
protein expression (Figure 10) and 229 PSCC samples were typed for HPV 
by PCR, which was taken as the gold standard.  
 
1.6.2.1. DNA Extraction and PCR 
DNA extraction with a QIAamp DNA Mini kit (51304; Qiagen, Crawley, UK). 
Beta-globin PCR was performed using primers B1 and B19 to confirm the 
adequacy of the extracted DNA. Validated samples were tested for the 
presence of HPV DNA by a broad-spectrum HPV PCR method using short 
PCR fragment (SPF10) primers, which amplify a 65-base pairs (bp) fragment 
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of the L1 open reading frame and HPV genotypes identified by the INNO-LiPA 
line probeassay (Innogenetics NV, Ghent, Belgium; See Dissection and DNA 
Extraction; HPV Analysis). 
1.6.2.2. P16 Immunostaining 
Tissue microarray blocks were prepared using a manual microarrayer. Three 
1 mm tissue cores were taken from each tumour. Four l m sections were cut 
and immunostained using standard heat-induced antigen retrieval methods 
and the ABC kit (PK-6200; Vector Laboratories, Peterborough, UK), according 
to the manufacturer’s instructions. 
 
Primary antibody dilutions for P16 mouse monoclonal antibody (Santa Cruz, 
sc56330, Clone JC8): dilution 1:800. Positive control was positive PSCC. P16 
demonstrated both nuclear and cytoplasmic immunoreactivity. The procedure 
was as follows: 
• Slides dewaxed in xylene 2 × 5 minutes, then placed in 100% ethanol 
1 × 15 minutes 
• Blocked endogenous peroxidase with 3% H202 in methanol solution 
for 10 minutes and washed in running tap water for 1-2 minutes 
• Antigen unmasking solution: slides were placed in a pressure cooker 
in preboiled antigen retrieval solution (Vectastain, H3300, 1.5L of water 
+ 15ml of citrate buffer pH 6.0) and boiled under pressure for 10 
minutes. 
• The pressure cooker was placed under running tap water and pressure 
released. It was allowed to cool to room temperature and the slides 
moved to fresh tap water. 
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• The slides were rinsed with TRIS buffer with 0.1% Tween 20, pH 7.6, 
2 × 2 minutes. 
• Primary antibody: the slides were placed on a staining tray, excess 
liquid tapped off and the primary antibody applied for 60 minutes at 
room temperature. Antibody were diluted in 1% BSA with azide in 
phosphate buffer. 
• The slides were rinsed with Tris buffer with 1% Tween 20, pH 7.6, 2 × 
3 minutes. 
• Secondary antibody: secondary biotynylated universal antibody 
(Vector Lab, Vectastain Universal Elite ABC kit, PK6200) for 30 
minutes, then slides rinsed with TRIS buffer with 0.1% Tween 20, pH 
7.6, 2 × 2 minutes. 
• ABC reagent:complex  avidin + biotynylated horseradish peroxidise ( 
Vector Lab, Vectastain Universal Elite ABC kit, PK6200) for 20 minutes. 
• Chromagen/Substrate solution: DAB solution (BioGenex, HK 153-5KE) 
was applied for 10 minutes. 
• Slides were washed under running tap water fro 2 minutes, 
counterstained in Gill’s number 2 Haematoxylin for 3 minutes, 
differentiated in 1% acid alcohol for 2 seconds and washed under 
running tap water for 5 minutes. 
• Dehydration was then performed with 70% ethanol, 90% ethanol, 2 
minutes each, followed by 2 × 3 minutes in 100% ethanol. 
• Slides were then cleared with xylene 2 × 3 minutes and mounted with 
a xylene based mounting medium (DPX). 
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Sections were scored semi quantitatively by a consultant genitourinary 
pathologist (DB). For nuclear positivity each core was given an estimated 
visual score between 0 and 100%, representing the percentage of 
positively stained neoplastic nuclei. The intensity of staining was measured 
as: 1 (weak), 2 (medium) and 3 (strong). Cytoplasmic expression of p16INK4A 
was determined by intensity of staining alone. Analysis was performed on the 
core with the highest score. A score of >0 was interpreted as positive. 
 
Methodological agreement and correlation between HPV PCR positivity and 
P16 positivity were calculated using the kappa statistic and chi squared, 
respectively. Cohen's kappa coefficient is presently a standard tool for the 
analysis of agreement on a binary outcome between two tests (i.e. the gold 
standard of PCR and the cheaper, faster alternative of p16INK4A). It is more 
robust than just a percentage as it takes in to account the possibility of values 
Figure. 1.11. P16 expression in penile cancer tissue. 
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occurring by chance. Interpretatation of the kappa value is no agreement <0, 
slight agreement = 0-0.2, fair agreement =0.21-0.4, moderate agreement = 
0.41-0.6, substantial agreement =0.61-0.8 and almost perfect agreement = 
0.81-1. 
 
1.6.3. Results 
Of tumours typed for HPV by PCR, 57% (131/229) were HPV positive and 
43% (98/229) HPV negative. 
 Cores with any degree of positive staining for p16INK4A (score 1-3;weak, 
medium and strong) were deemed p16INK4A positive. On comparing HPV PCR 
positive to HPV PCR negative samples, expression of p16INK4A had a 
sensitivity of 66.4% and specificity of 83.6% (kappa= 0.4834). When 
evaluating high-risk HPV versus all low risk and negative HPV, sensitivity was 
68.8% and specificity 83.5% (kappa= 0.4859). HPV16 positive versus HPV16 
negative and all HPV negative samples demonstrated sensitivity of 72.2% and 
specificity of 79.2% (kappa= 0.5176). Each of the aforementioned groups 
demonstrated statistically significant correlation with HPV positivity 
(p<0.0001; Table 1.7). 
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1.6.4. Conclusion 
 p16INK4Aprotein expression using IHC is only a moderate surrogate marker for 
HPV, high risk HPV and HPV16 infections in PSCC. If HPV typing is to 
determine future treatment, up to 25% of cases will be misassigned using 
P16INK4A IHC alone. P16 positivity has also been associated with a better 
prognosis in patients with oropharyngeal tumours. However, based on the 
results of this pilot study, interpretation of molecular data based on p16INK4A 
HPV status would be of limited validity in translation from molecular studies to 
clinical practice. 
 
 
 
 
Comparison Sensitivity Specificity Kappa 
HPV positive vs HPV negative 87/131 
(66.4%) 
82/98 
(83.6%) 
0.4834 
High risk HPV (16+18) vs all low 
risk (not 16+18) and negative 
HPV 
86/125 
(68.8%) 
86/103 
(83.5%) 
0.4859 
HPV 16 positive vs HPV 16 
negative and all negative 
78/108 
(72.2%) 
95/120 
(79.2%) 
0.5176 
Table 1.7. P16 expression sensitivity, specificity and Kappa value (interobserver variability) 
for HPV positive and negative penile cancer tissue samples..  
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1.7 Critical Appraisal of Methods  
 
 
The techniques used in this study included microdissection of penile tissue 
under a stereomicroscope, polymerase chain reaction (PCR) to detect human 
papillomavirus (HPV) DNA, array comparative hybridisation (aCGH) and 
fluorescence in situ hybridisation (FISH). The aCGH was conducted by my 
collaborative colleagues at the Institute of Cancer Research and some of the 
aCGH data analysis was also conducted by collaborative colleagues at 
MSKCC. 
In this critical appraisal I will describe aCGH and discuss the advantages, 
disadvantages, applications and alternative methods. 
 
1.7.1  Polymerase Chain Reaction (PCR) 
PCR is a technique that was discovered in the 1980s by Kary Mullis to amplify 
genes or sections of DNA. PCR is utilises DNA polymerase to synthesize a 
new strand of DNA complementary to a given template strand. DNA 
polymerase can only add a nucleotide onto a preexisting 3'-OH group, so it 
needs a primer to which it can add the first nucleotide. This requirement 
makes it possible to delineate a specific region of template sequence that the 
requires amplification. Taq polymerase enzyme (a heat stale enzyme) adds 
the new DNA bases during thermal cycling (heating and cooling cycles-
90degrees to 50 degrees).  At the end of the PCR reaction, the specific 
sequence will be accumulated in billions of copies (amplicons). These steps 
are repeated 20-40 times, doubling the number of DNA copies each time. The 
quantity and quality of DNA can then be assessed by electrophoresis and 
nanodropping techniques, respectively[143] 
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1.7.1.1 Advantages and Disadvantages of PCR 
One advantage of PCR is that it is very sensitive. So that DNA from just one 
cell can be used for amplification. This allows very small amounts of starting 
material to be used and works well on old or degraded DNA, allowing a 
sufficiently high enough yield of starting material to amplify the DNA of 
interest. The major disadvantage of PCR is also its sensitivity, as minute 
amounts of contaminating DNA (from a different sample) can also be 
amplified. 
 
1.7.2  Comparative Genomic Hybridisation (CGH) and array Comparative 
Genomic Hybridisation (aCGH) 
Traditional CGH used test genome and control genome, which are 
differentially labelled and competitively hybridised to metaphase 
chromosomes[144]. However, resolution was limited to 10-20Mb. This method 
of analysis was used in the first genomic study of 27 fresh frozen penile cancer 
samples in 2001. 
 
DNA microarray hybridisation techniques were developed in the early 1990s. 
Development of cDNA libraries provided large numbers of complementary 
(cDNA) clones and thus facilitated genome wide analysis of gene expression. 
Microarrays use small quantities of DNA/oligonucleotide probes fixed in high 
density to a solid surface in a precise manner. Initially there were two major 
platforms for DNA microarrays: cDNA microarrays on a glass slide and 
Affymetrix GeneChip®. Probes may vary in size from oligonucleotides 
manufactured to represent areas of interest (25–85 base pairs) to genomic 
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clones such as bacterial artificial chromosomes (BAC) of 80,000–200,000 
base pairs. aCGH has better resolution than conventional CGH, as the probes 
cover smaller regions than a metaphase chromosome.  
The basic principles of aCGH are as follows: Fluorescently differentially 
labelled denatured DNA/RNA (test and reference), often in aqueous solution, 
are hybridized to probes on the microarray. Washing and drying steps follow. 
A high-resolution scanner detects signals emitted from the bound fluorescent 
label at each specific spot on the array, determining the ratio from test and 
reference samples. Digital imaging software converts that data in to different 
colours, according to intensity. So, information about the relative copy number 
of sequences in the test genome as compared to the normal genome can be 
acquired with an approximate 0.1Mb resolution [144, 145]. 
In our current study, DNA extracted from microdissected sections was 
subjected to microarray-based comparative genomic hybridisation using a 
32K BAC array platform [146].  
 
 
 
1.7.2.1 Advantages of aCGH 
aCGH is relatively low cost, has an established infrastructure (i.e. quick to get 
data from), with easily available analysis tools and publicly available data sets. 
aCGH has uses in gene expression profiling, protein interaction profiling, 
toxicology, evolutionary biology and physiology [147].  It can detect gains, 
losses, amplifications, deletions, aneuploidies and duplications of any locus 
represented on a microarray. Furthermore, it has low technical variation, good 
ratio response to copy number aberrations (CNAs) and the capacity to detect 
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many non-overlapping CNAs (present in 2-3 or individual platforms). Formalin 
fixed paraffin embedded (FFPE) samples can be used with this method. 
 
1.7.2.2  Disadvantages of aCGH 
BAC array data can suffer from mapping inaccuracies of the clones to the 
human genome. PCR contamination or other steps in the process such as 
labelling or temperature differences can be a source of error with aCGH 
causing ‘background noise’ in the results, which may be normalised/smoothed 
[147, 148]. According to Gunnarsson et al 2008 BAC arrays fail to detect loss 
of heterozygosity (LOH) [149]. 
 
 
1.7.3  High-density oligonucleotide arrays 
High-density oligonucleotide arrays offer a versatile alternative, as the 
oligonucleotides can be specifically made for one target and many different 
oligonucleotide probes specific to a particular gene can be utilised 
simultaneously in order to gain information about gene expression.  
For example, the Affymetrix system involves in situ synthesis of 
oligonucleotide probes on the microarray platform (wafer), using 
semiconductor based photolithography followed by solid phase chemical 
synthesis reactions. These arrays usually have short 25mer oligonucleotides 
and each array can contain up to 900,000 different oligonucleotides. Each 
oligonucleotide is present in millions of copies. So, different oligonucleotide 
probes on the array can represent a single gene and information is gained 
about gene identity and relative expression.  
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The advantages are that it only requires test DNA to be labelled and 
hybridised and oligonucleotides are constructed at specific pre-set locations 
on the microarray (depending on the photomask construct). It has a high 
theoretical resolution, Detects LOH in addition to CNAs and, like aCGH with 
a BAC clone array, can detect many non-overlapping CNAs.  
 
The disadvantages are that it is more expensive than BAC aCGH, and has a 
higher technical variation and lower log(2) ratio response to CNAs. Also, SNPs 
not evenly distributed over the genome [145, 149, 150]. 
 
The Illumina oligonucleotide microarrays use the Illumina BeadArray™ 
system random array of 3micron silica beads in wells spaced 5.7 microns 
apart, with pre synthesized oligonucleotides constructed to greater than 70-
mer (25 nucleotide address code and 50 nucleotide gene specific sequence). 
Each oligonucleotide is attached to a set of beads and any given bead may 
have hundreds of thousands of copies of a particular oligonucleotide. Beads 
coupling different oligonucleotides are assembled and spread across the 
microarray in wells, where they are immobilised. The beads can only be 
identified when the 25mer address code is decoded. So, unlike the Affymetix 
system, probes are randomly placed [145, 151]. 
The Illumina system has the advantage of detecting LOH (highest detection 
rate compared to 32k BAC and Affymetrix 250K) and CNAs, with a high 
theoretical resolution.   
Disadvantage compared to 32K BAC and Affymetrix 250k is highest technical 
variation and lower log(2)ratio response to CNAs, lowest detection of CNAs 
and SNPs not distributed evenly throughout the genome[149]. 
	 71	
 
aCGH has been shown to be as robust as, and to have comparable resolution 
with, high-density oligonucleotide arrays for genome screening for large 
alterations [149, 152, 153].  
 
 
1.7.4  Next Generation Sequencing 
In the early 1970s Dr Frederick Sangar began research in DNA sequencing, 
with his seminal publication in 1977. From 2005 radical changes occurred in 
the Sangar method of DNA sequencing, culminating in the development of a 
massively parallel DNA pyrosequencing system by 454 Life Sciences (Roche) 
[154]. 
This method involves sequencing by synthesis by first breaking the DNA in to 
300-500bp segments, separated in to single strands, then ligated to different 
oligonucleotides, which act as amplification primers. The single strands 
attached to beads, which are immersed in an emulsion droplet. This droplet is 
comprised of a PCR reaction mixture in oil and following PCR amplification 
each bead can have over 10 million copies of the amplified single stranded 
DNA segment. Each bead is deposited in one well on a slide and surrounded 
by smaller beads harbouring ATP sulfyrase and luciferase before being 
washed with a fixed sequence of dNTP precursors. Light is emitted each time 
a nucleotide is added and this information is recorded. This method of 
sequencing has >300 nucleotide read length per reaction with an output of 
0.45 Gb per run of 7hours [145, 155].  The Illumina Genome Analyser also 
utilises the method of sequencing by synthesis, but with bridging PCR 
amplification. The read lengths have increased as the technology has 
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developed to current 150-bp paired end reads.  
Other methods include sequencing by ligation (Genome health/applied 
Biosystems Solid 3), which involves hybridisation to an array of fluorescently 
labelled oligonucleotides, but results in a shorter read length than both 
Illumina and 454 systems.   
 
1.7.4.1  Advantages and disadvantages of Next Generation Sequencing 
So, unlike aCGH, hundreds of thousands of reactions can be read in parallel 
and one is not limited to what’s printed on a microarray. 
Compared to aCGH, NGS allows you to look at the full genome on a fine scale 
structure, counts transcripts rather than looking at hybridisation intensity and 
has better performance.  NGS allows us to examine the same aberrations as 
aCGH but also lends itself to the discovery of balanced chromosomal 
inversions or translocations, point mutations/single base variants and indels. 
However, due to the quantity of data generated and the underdeveloped pool 
of data analysis tools, it can be difficult to analyse and reagent costs still 
remain high [155, 156].  
 
1.7.5  Conclusion 
The disadvantages of all these techniques also include problems of 
contamination with inflammatory cells/ stroma/ normal tissue. This can 
be overcome by doing laser capture microscopy, but this is incredibly 
time-consuming. So, careful microdissection of the required tissue 
needed.  
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The development of NGS has not signalled the ‘death of microarrays’, as once 
predicted[157]. Both aCGH and NGS have their specific advantages and 
disadvantages, and their use very much depends on individual experimental 
necessity. 
 
1.8. AIMS AND OBJECTIVES 
• To determine the spectrum of gene copy number aberrations in a large series 
of PSCCs.  
• To define the correlation of any genetic aberrations with human 
papillomavirus, histopathological subtype, and tumour grade, stage and lymph 
node status. 	
• To identify potential candidate driver genes and to validate them using 
fluorescence in situ hybridization 
• To analyse validated potential driver genes, assessing correlation with human 
papillomavirus, histopathological subtype, and tumour grade, stage and lymph 
node status. 
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CHAPTER 2: METHODS 
2.1. METHODOLOGY FOR PART 1, INCLUDING 
COMPARATIVE GENOMIC HYBRIDISATION 
 
2.1.1. Cases 
We obtained 70 formalin fixed paraffin embedded PSCCs from the Cellular 
Pathology Department of St George’s Hospital. Cases were selected by a 
molecular oncologist and histopathologist to include a range of older and 
newer specimens, some consecutive and non-consecutive cases. Expert 
uropathologists (CC, BT, RR) reviewed cases for grade, stage (including 
lymph node status) and subtype using established methods [65, 158] (Table 
2.1 and Figure 2.1). Patients were entirely anonymised and this study was 
approved by East London and The City Research Ethics Committee Alpha 
(The Orchid Tissue Bank; 09/H0704/4).  
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Figure 2.1. Histological subtypes of penile Squamous cell carcinoma 
demonstrating distinct morphological features. (A) Usual Type (B) 
Verrucous (C) Basaloid. 
B 
C 
A 
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Table 2.1.  Number of cases according to cancer type, HPV status, stage, 
grade and nodal status.  
 
Group for Comparison Subgroup for Comparison Number of Cases 
Cancer Type Basaloid  7 
Usual 50 
Verrucous 7 
HPV status Positive 35 
Negative 29 
Stage Stage 1 4 
Stage 2 8 
Stage 2A 28 
Stage 2B 4 
Stage 3 7 
Stage 3A 8 
Stage 4 5 
Grade Grade 1 6 
Grade 2 17 
Grade 3 41 
Nodal Status Nodal N0 31 
Nodal N1 16 
Nodal N2 13 
Nodal N3 2 
No information  2 
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2.1.2. Dissection and DNA Extraction 
For all cases, regions of PSCC and normal tissue were marked on the 
representative sections by a consultant genitourinary pathologist (DB). Ten to 
fifteen tissue representative sections were cut at 10µm thickness from each 
case and stored at -20C. Slides were dewaxed 2×10 minutes at 45°C and an 
additional 10 minutes at room temperature (xylene dewaxing). Slides were 
allowed to air dry for an additional 10 minutes at room temperature to 
evaporate the xylene.  
The tissue on the slides was microdissected under a stereomicroscope with a 
sterile needle in order to ensure a percentage of tumour cells >90%.  
DNA was extracted from microdissected sections using standard phenol-
chloroform methods and its concentration was measured using PicoGreen® 
assay as per the manufacturer’s instructions (Applied Biosystems, Invitrogen, 
Paisley, UK), as described below. 
 
Tissue was resuspended in 500μl of extraction buffer. The extraction buffer 
comprised 75mM NaCl (3ml of 5M in 200ml), 25mM EDTA pH8.0 (10ml of 
0.5M in 200ml) and 100mM TRIS-HCL pH 8.0 (20ml of 1M in 200ml). 
1% SDS to remove membrane lipids (25μl of 20% in 500μl) and 20mg/ml 
proteinase K (12.5μl in 500μl) was added and mixed immediately. This was 
incubated overnight in a water bath at 50°C. Tissue was checked the next day 
and, if not digested, another 12.5μl of proteinase K was added and further 
incubation at 50°C overnight. This was repeated until there was no visible 
residue remaining. On the last day RNAase was added and further incubation 
for 1hour at 37°C (5μl in 500μl). Proteinase K (12.5μl to 500μl) was added 
again to digest the RNAase and incubated for 3-4 hours at 50°C. 
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The sample and phenol were brought to room temperature. An equal volume 
of phenol was added and the solution thoroughly mixed by inversion for 5 
minutes, before centrifuging at 13,000rpm for 15 minutes. The upper, aqueous 
layer was extracted and transferred to new microcentrifuging tubes. 
Phenol/chloroform 1:1 (250/250) was made just before use and added, mixed 
by inversion for 5 minutes and centrifuged at 13,000rpm for 15 minutes. The 
upper aqueous phase was again extracted and transferred to new micro 
centrifuging tubes. 
500μl of chloroform was added and thoroughly mixed by inversion for 5 
minutes. The solution was centrifuged at 13,000rpm for 15 minutes before 
extracting the upper aqueous phase and transferring to another set of 
microcentrifuging tubes. 
 
For ethanol precipitation, 2.5 volumes of ice cold 100% ethanol was combined 
with 1/10 volume sodium acetate, pH5.2 and stored at -80°C for 30-60 
minutes. 
 
The tubes were centrifuged at the highest speed for 15 minutes at 4°C, which 
allowed the DNA to form pellets. The ethanol was removed. 1ml of cold 70% 
ethanol was added and centrifuged at 13,000rpm for 15 minutes.  
The pellet was dried before dissolving in water and nanodropping to assess 
DNA concentration. 
(This was performed at Barts Cancer Institute). 
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2.1.3. HPV Analysis 
The presence of HPV DNA was detected by PCR method using SPF10 
primers, which amplify a 65-bp fragment of the conserved L1 open reading 
frame and HPV genotypes identified by the INNO-LiPA HPV Genotyping Extra 
Assay (Innogenetics NV Ghent, Belgium) as detailed below. 
2 hoods were utilised, UV treated before and after use, with pens, pipettes, 
beakers water vials, PCR vials and dilution vials. Initially water was added to 
the vials in hood 2. Meanwhile the DNA was placed on ice and ensured that it 
had dissolved. It was opened inside hood 2. 
The PCR mix was prepared in hood 1. For one sample 18.85 Amplification 
mix (kept on ice) and 1.15 enzyme mix (taken out at the last minute and kept 
on ice). 1 extra vial was mixed as a control. The enzyme mix required a short 
spin on the centrifuge before use, as it was viscous. 
 
In hood 2, 5 DNA was extracted from microdissected sections using standard 
phenol-chloroform methods and its concentration was measured using 
PicoGreen® assay as per the manufacturer’s instructions (Applied 
Biosystems, Invitrogen, Paisley, UK). 
 
5μl DNA dilution (or positive control) was added to each amplification/enzyme 
mix, then thoroughly mixed before a short spin and placing on ice. The 
samples were then set for PCR: 
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°C	 Time	95	 5	95	 30	52	 30	72	 30	72	 10	4	 0	(forever)	
 
Examples of the PCR machines used are shown in figure 2.2.  
 
 
To prepare gels for HPV genotyping a 2% solution of agarose was used (2g 
agarose mixed with 100ml TBE). This was microwaved to dissolve all particles 
and stirred at intervals. Ethidium bromide 2-3μl was added before pouring in 
to the tray, setting the gel, removing the comb and transferring to the EP plate. 
2μl of gel loading dye was mixed with 8μl of sample (kept on ice) and added 
to the well. 8μl ladder was also added to the well. The plate was set to 120V 
for 70 minutes. (This was performed at Barts Cancer Institute). 
Figure 2.2. Examples of the PCR machines used in these 
experiments. 
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2.1.4. Microarray Comparative Genomic Hybridisation (aCGH) 
DNA extracted from microdissected sections was subjected to microarray-
based comparative genomic hybridisation using a 32K bacterial artificial 
chromosome (BAC) array platform [146], which has been shown to be as 
robust as, and to have comparable resolution with, high-density 
oligonucleotide arrays [149, 152, 153]. DNA labelling, array hybridisation and 
image acquisition were performed as previously described. Reference and 
tumour DNA samples (300ng) were labelled with Cy3- or Cy5-conjugated 
dCTP, respectively (Amersham Biosciences, Buckinghamshire, UK) using 
random primed BioPrime DNA labelling (Invitrogen Life Technologies) 
according to the manufacturer's protocol, modified to incorporate 1.0mM Cy 
dye, 0.6mM dCTP and 1.2mM dATP, dGTP and dTTP. After labelling at 37 °C 
for 16 hours, non-incorporated reaction constituents were removed by 
MinElute Reaction Cleanup (Qiagen Ltd, Crawley, UK). Labelled reference 
and tumour DNA were co-ethanol precipitated with 100µg human Cot-1 DNA 
(Invitrogen Life Technologies) and re-suspended in 45µl hybridisation buffer 
(50% deionised formamide, 10% w/v dextran sulphate, 2×SSC, 2% SDS, 
20µg yeast tRNA). Labelled DNA was denatured at 70°C for 15 minutes, 
followed by a 30 min incubation at 37°C to allow blocking of repetitive 
sequences by human Cot-1 DNA. Denatured DNA samples were applied to 
the microarray under a coverslip and hybridised at 37 °C for 18 hours. After 
hybridisation, the coverslips were removed by washing slides in 2×SSC/ 1% 
SDS for 15 min at 45 °C. Slides were then washed in 50% deionised 
formamide/2× SSC for 15 min at 45 °C, followed by 2×SSC/ 1% SDS for 30 
minutes at 45°C 
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[159, 160]. After washing, the arrays were dried by centrifugation at 2000rpm 
for 2 minutes. aCGH slides were scanned using an Axon 4000B scanner 
(Axon Instruments, Burlingame, CA, USA) and images were processed using 
Genepix Pro 4.0 image analysis software (Axon Instruments). 
(Performed at The Institute of Cancer Research, London}. 
 
 
2.1.5. Data Analysis and Statistical Methodology 
Cases with >10% of clones missing and clones where data were not available 
in ≥10% of cases were excluded. Analyses were performed using the BACE.R 
R script (R version 2.11.1) was used to pre-process and analyse the aCGH 
data. 
 
After filtering polymorphic BACs, a final dataset of 31,367 clones with 
unambiguous mapping information according to build hg19 of the human 
genome (http://www.ensembl.org) was smoothed using the circular binary 
segmentation (cbs) algorithm. A categorical analysis was applied to the BACs 
after classifying them as representing amplification (>0.4), gain (>0.08 and 
≤0.45), loss (<-0.08), or no change according to their cbs-smoothed Log2 ratio 
values.  
 
Following copy number categorisations for gains, losses or amplifications, 
Fisher’s exact tests were performed to identify statistically significant 
differences (with a false discovery rate-adjusted p-value < 0.05) in 
amplifications and gains/ losses between the different subtypes, grades, 
stages, HPV associations and nodal status. Adjustment for multiple testing 
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was performed with a step-down permutation procedure (maxT), which 
provides a robust control of the family-wise type I error rate (FWER) [161]. 
Unsupervised hierarchical clustering of cbs-smoothed ratios, employing 
Wards clustering algorithm and Euclidean distance metric, was performed. 
 
Subsequent assessment of the robustness of the cluster analysis was done 
by assessing the uncertainty with multiscale bootstrap resampling with the 
pvclust package in R 3.0.1. 
(combined analysis by MSKCC, Institute of Cancer Research and Barts 
Cancer Institute). 
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2.2. METHODOLOGY FOR PART 2, INCLUDING 
FLUORESCENCE IN SITU HYBRIDISATION 
 
2.2.1. TMA Slide Preparation 
egions of PSCC and normal tissue were marked on the representative R
). The plain by a consultant genitourinary pathologist (DB /H&E slidessections
recipient wax block was fixed in to the block holder and screwed into place.  
 
Vertical turrets with the needle of appropriate puncture diameter were pushed 
in to the wax and extracted, producing a cylindrical wax core. 
The donor wax block was placed on a metal block holder under the needles, 
and utilising the marked H&E slide as a template, the needle was pushed 
through the donor block where tumour should be situated and a cylindrical 
core of donor tissue extracted. This was aligned over the predetermined core 
space and inserted to the appropriate depth. The procedure was repeated 
until all cores were transferred. The TMA block was then placed in an 
incubator for 5-10 minutes at 37°C to soften the wax. A plain glass slide was 
used to press the cores in to the block, leaving a smooth surface. 
(Performed at Barts Cancer Institute). 
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2.2.2. Bacterial Culture Preparation and BAC DNA extraction  
To obtain the PI3K gene probe, the RP11245C23 BAC clone was cultured 
and BAC DNA was extracted, using Maxiprep kit (Qiagen®), according to 
standard protocol. Solid agar was removed from storage in the fridge and 
melted in a microwave. 100ml agar was added to a separate conical flask and 
cooled to 60°C. Chloramphenicol 100μl was added to 100ml agar and mixed 
well. The mixture was then poured in to plates near the Bunsen burner and 
the lids left half open. Once the agar was set, lids were closed and plates 
turned upside down and incubated at 37°C.  
The BAC clone was obtained from -80°C storage and, using a blue sterile 
loop, the agar plates were seeded. New loops were used for A,B,C,D. 
 
 
Figure 2.3. Example of 
a PSCC TMA slide 
(with H&E staining). 
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7 hours later the Bunsen burner was set and near the flame, a single colony 
was picked with the blue loop and mixed into 5ml broth medium in a 50ml 
tube. This was clearly labeled, the lid loosened and placed on a shaker 
overnight at 37°C, 225-300rpm. 
 
1.5ml bacterial culture was aliquot in to eppendorf tube. Cells were spun at 
13,000rpm for 5 minutes at room temperature. Supernatant was discarded 
and the cells were resuspended in 150μl P1 solution (Maxiprep, Qiagen). 
150μl of P2 solution (Maxiprep, Qiagen) was added to lyse cells and the tube 
gently shaken to mix. The mixture was sat at room temperature for 5 minutes 
until the liquid became almost translucent. 150μl of P3 solution (Maxiprep, 
Qiagen) was added slowly to each tube, which was gently agitated during 
addition. A thick white precipitate formed and the tubes were placed on ice for 
10 minutes. They were then centrifuged at 13,000rpm for 20 minutes, before 
 
 
A 
B 
C 
D 
Figure 2.4. BAC culture preparation. Formatted: Font: 12 pt
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transferring the supernatant to a fresh tube and spinning again at 13,000rpm 
for 5 minutes. The plasmid DNA was precipitated by alcohol precipitation 
(supernatant transferred to a 2ml tube that contained 1125μl 100%EtOH and 
45μl NaCl) then tubes were placed at -80°C for 30 minutes. Tubes were spun 
again at 13,000rpm for 15 minutes at 4°C. The supernatant was discarded 
and the pellet rinsed in 0.5ml of fresh 80% Ethanol, before spinning at 
13,000rpm for 5 minutes at 4°C. the supernatant was then aspirated off and 
air-drying commenced for 10 minutes at room temperature to allow the ethanol 
to evaporate. The clean DNA pellet was then resuspended in Tris-EDTA buffer 
and stored at -20°C. 1.5μl was nanodropped to assess concentration. 
Control probes RP11348P10 (chromosome 3p) and CTD2006E17 
(chromosome 5) were sourced from an internal BAC DNA library.  
(Performed at Barts Cancer Institute). 
 
 
2.2.3. BAC DNA Amplification and Cleaning 
For BAC DNA amplification we used commercial Illustra™ GenomiPhi™ V2 
DNA Amplification Kit (GE healthcare). BAC DNA was heated to 55°C for 5 
minutes, then spun at 13,000rpm for 10 minutes. Sample buffer was mixed 
with template DNA: PCR tube with 9μl of sample buffer and 1μlof BAC DNA. 
Template DNA was denatured by heating the samples to 95°C for 3 minutes 
(in the PCR cycler), then cooled to 4°C on ice for 5 minutes. A ‘master mix’ 
was prepared for each amplification reaction by adding a further 9μl of 
‘reaction buffer’ and 1μl of polymerase (enzyme mix). Vials were kept on ice.  
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The program on the PCR machine was set as follows: 
30°C for 1.5 hours 
65°C for 10 minutes  
4°C forever 
 
A gel was then run to check the smear (≈10kb, 120V for 30 minutes). Phenol 
chloroform cleaning was then performed. 80μl of 1×TE buffer was added to 
the sample (DNA volume + TE volume = 100μl). Under the fume hood 50μl 
phenol/ 50μl chloroform was added and mixed for 3 minutes, then spun at 
13,000rpm for 2 minutes, 25°C. The top aqueous layer containing the 
extracted DNA was transferred to a fresh tube, 100μl chloroform added, mixed 
for 3 minutes, spun for 2 minutes at 13,000rpm at 25°C. DNA was precipitated 
by transferring the top layer to a fresh tube, placing it on ice, adding 5μl of 4M 
NaCl, adding 250μl 100% ethanol. This was mixed and left at -80°C for 30 
minutes. Further spinning was performed at 4°C for 20 minutes at 13,000rpm. 
The ethanol/salt was removed without disturbing the DNA. The pellet was 
washed with 1 volume of 80% ethanol at room temperature to remove the 
remains of the salt from the DNA. It was then spun at 4°C for 10 minutes at 
13,000rpm. The ethanol was pipetted out and left to air dry. The DNA was 
diluted in 20-30μl of 1×TE buffer and the quantity of the DNA measured using 
the nanodrop spectrophotometer.  
(Performed at Barts Cancer Institute). 
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2.2.4. BAC DNA Labelling (Indirect) 
PI3K gene probe was labeled SpectrumOrange and control probes 
SpectrumGreen, using BioPrime® DNA labeling system (Applied Biosystems, 
Invitrogen). 300ng of cleaned amplified BAC DNA was diluted in 24μl of water 
and 20μl of random primer added. This was placed in the PCR cycler for 5 
minutes at 95°C, then put on ice for 10 minutes.  For biotynylated probes, 5μl 
of kit 10×dNTP kit biotynylated mixture was added (red/orange). For DIG 
labeled probes, 1.75μl of DIG-11-dUTP (pH 7.5, Roche, UK) + 5μl of special 
DIG 10×dNTP [(1mM dATP, dGTP, dCTP, and 0.65mM dTTP (5μl of 100mM 
stock G, A, C, and 3.25μl of T to 500μl H20, Roche UK)]. 1μl Klenow was 
added and the solution placed on the PCR cycler for 3 hours at 37°C and 
placed on ice afterwards. 5μl of stop buffer was added. Microspin G50 
columns were prepared by spinning at 3500rpm for 1 minute, then washing in 
200μl of TE buffer at 3500rpm for 1 minute. The columns were transferred to 
eppendorf tubes, the DNA added to the centre of the column and spun at 
3500rpm for 2 minutes. 1.5ul was nanodropped. 1μl of salmon sperm was 
added (10μg/μl, Herring sperm DNA Sigma, D-7290) and 30μl of COT1 DNA 
(Applied Bioscience, Invitrogen). 4μl of 4M NaCl and 222μl ethanol were 
added, mixed and placed in an -80°C freezer for 30 minutes. Further spinning 
was performed at 13,000rpm for 20 minutes at 4°C. The pellet was rinsed with 
100-200μl of fresh 80% ethanol. Spinning was set at 13,000rpm for a further 
10 minutes at 4°C. The ethanol was pipetted out and the pellet left to air-dry 
for 5-10 minutes. 20μl of water was added before mixing and placing on a hot 
plate at 50°C for 5 minutes. The solution was then stored in a -20°C freezer.   
(Performed at Barts Cancer Institute). 
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2.2.5. Tissue Microarray Slide Preparation and Probe Hybridisation 
TMA slides were dewaxed in xylene, washed in ethanol and water. Next, they 
were boiled in pre-treatment buffer (Spotlight tissue pre-treatment kit, 
Invitrogen) for 15 minutes, washed in distilled water for 2-3 minutes and 
digested with pepsin solution (Digest All-3, Invitrogen) for 5 minutes at 28°C.  
 
After washing in water and air-drying the slides, 1-1.5μl of each probe was 
pipetted in to 10μl, following the manufacturer instructions, coverslip applied 
and sealed with rubber cement. Then hybridization was performed at 37°C for 
24 hours (pre warmed humidity box placed slides were denatured at 98°C for 
10 minutes in an incubator for 24-48 hours at 37°C.  
post-hybridisation washes were then performed: 3 rinses in 2xSSC (saline-
sodium citrate) at 42°C, followed by 2×5 minute washes in 50% formamide/ 
2xSSC at 42°C. Further 2 × 5minute washes in 2xSSC at 42°C and SSCT at 
room temperature for 2 minutes. 
 
Slides were placed in a humidity chamber and covered with 200μl SSCTM 
and a coverslip, then incubated for 15 minutes at 37°C. stock Streptavidin-
CY3 (pink) and anti-DIG-FITC antibody (green). 1μl was removed from the 
surface and diluted in 200μl of SSCTM per slide. Slides were washed in SSCT 
at room temperature for 3 minutes, dried, 1μl of anti-DIG-FITC/ SSCTM 
(green) added, coverslip added and incubated at 37°C for 10 minutes. Slides 
were washed in SSCT at room temperature for 3 minutes, dried, 1μl of 
Streptavidin-Cy3/SSCTM (red) added, coverslip added and incubated at 37°C 
for 10 minutes. Further washes were performed (SSCT room temperature for 
2 minutes, PBS at room temperature for 2×5 minutes) before slides were 
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placed in 70% ethanol 2×20 seconds and air-dried. 23μl of Vectashield 
antifade solution containing DAPI (Vector Laboratories LTD) was added to the 
slide followed by a coverslip. 
(Performed at Barts Cancer Institute). 
 
 
2.2.6. Microscope Procedure 
FISH slides were scanned and analysed using the Applied Imaging Ariol® 
System (Applied Imaging, San Jose, CA, USA). A minimum of 100 cells with 
clear hybridization signals were counted per core.  
On the basis of FISH results in normal penile foreskin, tumours with more red 
FISH signal (PI3CK) in >30% of cells were considered positive for gene copy 
number gain. Amplification was defined as a ratio of ≥3. 
 
Due to typical variation in cutting TMA blocks, some cores were not seen on 
the stained sections or had not enough cancer tissue left in them for proper 
assessment. Therefore, number of patients for each antibody/probe is 
different. 
(Performed at Barts Cancer Institute). 
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CHAPTER 3: Results 
3.1. ARRAY CGH RESULTS 
 
3.1.1. Patients And Study Samples 
Of the 70 PSCC cases, 64 had adequate DNA quality and purity for successful 
array CGH analysis.  
Demographics including HPV status, stage, grade, lymph node status and 
histological classification can be found in Table 3.1. Genome plots were 
generated for each case and showed various patterns of chromosomal 
expression. Some examples are as follows: Case 17 (usual type PSCC), 
exhibited specific gain/amplification in regions 1p, 3q and 5 (3.1A). Case 62 
(verrucous type PSCC) showed gains in 1q, 2, 3q, 5p and 8q, with obvious 
amplification in chromosome 11p (Fig 3.1B). Cases 26 (usual type PSCC) and 
70 (basaloid type PSCC) also showed gain in the 3q region; as well as 8q and 
13p, respectively (Figs 3.1C and 3.1D). 
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Group	for	Comparison	 Subgroup	for	Comparison	 Number	of	Cases	
Cancer	Type	 Basaloid		 7	
	 Usual	 50	
	 Verrucous	 7	
HPV	status	 Positive	 35	
	 Negative	 29	
Stage	 Stage	1	 4	
	 Stage	2	 8	
	 Stage	2A	 28	
	 Stage	2B	 4	
	 Stage	3	 7	
	 Stage	3A	 8	
	 Stage	4	 5	
Grade	 Grade	1	 6	
	 Grade	2	 17	
	 Grade	3	 41	
Nodal	Status	 Nodal	N0	 31	
	 Nodal	N1	 16	
	 Nodal	N2	 13	
	 Nodal	N3	 2	
	 No	information		 2	
Table 3.1.  Demographics of PSCC cases according to histological 
subtype, HPV status, stage, grade and nodal status. 
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Figure 3.1. Microarray-based comparative genomic hybridisation analysis invasive penile squamous cell 
carcinoma components. This is a measure of  copy number variations at a given locus. Genome plots obtained with 
the 32K bacterial artificial chromosome array platform for: (A ) Case 17 (usual type), (B) Case 62(verrucous) , (C) 
Case 26 (usual type) and (D) Case 70 (basaloid). Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 
and loss<-0.08. 
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3.1.2. Array CGH and Candidate Driver Genes 
 PSCCs were shown to harbor many highly recurrent gains, the highest 
frequencies occurring on chromosomes 1p13.3-q44 (88%), 3p12.3-q29 
(86%), 7p22.3-q36.3 (88%), 8p12-q24.3 (84%), 9p24.3-q34.3 (88%) and 
20p13-q13.33 (84%) (Fig 3.2A, Table 3.2). PSCCs also harbored highly 
recurrent losses of 2q33-q37.3 (86%), 3p26.3-q11.1 (83%) and 11q12.2-q25 
(81%) (Fig 3.2A, Table 3.2). The highest frequency recurrent amplifications 
were of 3q27.2-q29 (11%) and 8q21.13-q24.3 (23%) (Fig 3.2B, Table 3.2).  
 
Our analysis of PSCC samples did not identify deletions or high-level loss of 
genetic loci and, despite the highly recurrent changes, there were genetic 
aberrations that were restricted to only a subset of the cases (Table 3.2). 
These loci enclose several genes identified in areas of gain, amplification and 
loss. Gain of 3p12.3-q29 harbour, amongst many other genes, PRKCI, 
PIK3CA, DCUN1D1, LAMP3 and RPL35A. The F-box protein, SKP2 (S-phase 
kinase-associated protein 2) was included in gain of 5p15.33-p11 and 
amplification of 5p15.33-p11 and the oncogene MYC is also highlighted in the 
gained region 8p12-q24.3. Amplification of 3q27.2-q29 encompasses the 
genes PIK3CA, SENP5 (SUMO1/Sentrin Specific Peptidase 5), CLDN1, 
TNK2 (tyrosine kinase, non-receptor, 2) and FBXO45 (F-box protein 45). 
Genes of interest in the amplified region 3q26.1-q27.2 include FNDC3B and 
ACTL6A/BAF53 (actin-like 6A/BRG1 associated factor 53A).  CPT1A, FGF3/4 
and CCND1 are revealed in the amplified region 11p12.-p14.1.  
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Figure 3.2. Samples of invasive penile squamous cell carcinoma. (A) Frequency plot of copy number gains and losses. (B) 
Frequency plot of high level gain or amplification.(C) Hierarchical cluster analysis for all cases comparing stage, HPV status, subtype, 
grade and nodal status (to show whether PSCCs could form a discrete group based on their pattern of gene copy number aberrations). 
The proportion of tumours in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted 
(y axis) for each BAC clone according to its genomic position (x axis). Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 
and loss<-0.08. 
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Chromosome	 Gains	 Losses	 Amplification	
Locus	 Frequency	 Locus	 Frequency	 Locus	 Frequency	
1	 p13.3-q44		 88%	 p36.33-p34.2		p32.3-p32.2	 56%		47%	 q32.2	 6%	
2		 p21-q33.3	 83%	 q33-q37.3	p22.3-p16.3		p24.2-23.2	 86%	55%	40%	 	 	3		 p12.3-q29	 86%	 p26.3-q11.1	q13.13-13.31	 83%	40%	 q27.2-q29	q26.1-q27.2	 11%	8%	4		 q34.2-q35.2	 39%	 p16.3-p11			q28.3-q35.2			q13.3-q28.3			 55%	55%	47%	 	 	
5		 p15.33-p11	 67%	 q35.1-q35.2			q33.3-q35.1	q13.2	 64%	48%	44%	 p15.2-p14.3	p14.3-p11	p15.33-p15.2	
	
9%	8%	6%	
6		 p12.3-q12	 44%	 q16.3-q25.2	p21.1-p12.3			 67%	42%	 	 	
7			 p22.3-q36.3	 88%	 q31.1-q36.3	 64%	 	 	8			 p12-q24.3	 84%	 p23.3-q11.1	 72%	 q21.13-q24.3	 23%	9			 p24.3-q34.3	 88%	 p23-p21.3			q33.3-q34.3	 53%	52%	 	 	10	 	 	 q23.1-26.3	p15.3-p11.1			p21.3-q23.1	 77%	66%	64%	 	 	11		 p12.3-q14.1	 39%	 q12.2-q25			p15.5-p14.3			 81%	64%	 p14.1-p12	 6%	12		 q24.11-q24.33			 42%	 p13.3-p11.21	q24.23-q24.31	
	
61%	39%	 	 	13	 	 	 q12.2-q31.1			q31.1-q34			 55%	47%	 	 	14		 q11.2-q32.33			 66%	 q23.3-q24.3	 45%	 	 	15		 q11.2-q24.3	 47%	 q21.1-q25.3			q25.3-q26.3			 56%	55%	 	 	16		 p11.2-q24.3			 77%	 q22.2-q24.3			q12.1-q21	 64%	39%	 	 	17		 q21.33-q25.3	 53%	 p13.3-p11.1	q25.1-q25.3			q12-q21.33	 69%	55%	48%	 	 	
18	 	 	 q12.1-q23	p11.31-q12.1	 75%	55%	 	 	
19		 p13.11-q13.43	 64%	 p13.3-p12	 58%	 	 	20		 p13-q13.33	 84%	 p13-p11.23	q12-q13.2	 52%	39%	 	 	21		 q11.1-q22.3			 66%	 q21.2-q22.3	 69%	 	 	22	 	 	 q11.1-q13.3	 66%	 	 	23		 q21.31-q28	 44%	 q28	 45%	 	 	
Table 3.2. Penile Cancer Overall Recurrent Copy Number Amplifications, Gains and 
Losses. The frequency of gains, losses and amplifications at each identified chromosomal 
locus is demonstrated. 
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Potential tumour suppressor genes, also found in other squamous cell 
carcinomas, have been discovered in the lost regions 2q33-q37.3 (PLCD4), 
3p26.3-q11.1 (RBMS3, PLCD1, and CACNA2D3) and 11q12.2-q25 (CPT1A, 
CCND1, FGF4/FGF3, and PPP2R1B). 
 
3.1.3. HPV Subgroup-Analysis 
Firstly, we sought to define whether HPV DNA positive and HPV DNA 
negative PSCCs would be underpinned by distinct patterns of gene copy 
number aberrations. Multi-Fisher's exact test adjusted for multiple 
comparisons revealed that HPV-positive and HPV-negative PSCCs have 
similar patterns of copy gains and that higher frequencies were demonstrated 
in 1q, 3q, 5p, 7p and 8q and amplifications in 3q, 5p and 8q for both HPV-
negative and HPV-positive tumours. 
Regions of differential gain included 1q, 2p, 7p and 10q, and regions of 
differential loss on 6p, 11p and q and 17p and q. When an unadjusted p value 
was used, 17p loss was exhibited with an increased frequency in the HPV 
negative group (p<0.05), but other areas of differential gain and loss showed 
no pattern of association with either the HPV positive or negative group. When 
p values were adjusted, regions with a statistically significant higher frequency 
of cases in HPV positive cohort exhibited gain on 1q (151,622,431-
151,793,285; p=0.035). When p values were adjusted, regions with a 
statistically significant higher frequency of cases in HPV negative cohort 
exhibited gain of 2p (60,835,599-61,089,333; p=0.034), 7p (48,668,454-
49,846,998; 0.034), 10q (108,751,067-109,429,862; p=0.047) and loss of 11p 
(46,103,041-47,520,939; p<0.05). No significant differences in the prevalence 
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of specific amplified loci were identified. Hierarchical cluster analysis failed to 
demonstrate a clear difference in clustering of genetic change between HPV-
positive and HPV-negative tumours (Figs 3.2C and 3.3). 
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Figure 3.3. HPV status of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ high level 
gain in HPV positive and HPV negative PSCC samples. The proportion of tumours in which each bacterial artificial chromosome 
(BAC) clone is gained (green bars) or lost (red bars) is plotted (y axis) for each BAC clone according to its genomic position (x axis). 
Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 and loss<-0.08. 
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3.1.4. Further Clinico-Pathological Subgroup-Analysis 
In addition, we conducted further analysis based on other defined clinic-
pathological variables (for details of specific gene loci, see Table 3.3). 
 
 
 
 
 
 
Subgroup	 Chromosome	 Differential	Gain	 Differential	Loss	 Differential	Amplification	
Basaloid	 1q	 153,406,844-153,890,950,		168,360211-168,582,272,		169,081,525-169,575,212		170,011,827-170,919965	(p<0.05)	
	 	
3q	 193,646,036-193,914,131		(p=0.04,	region	close	to	telomere);	 	 	11p	and	11q	 	 26,348,389	-	26,748,623	87,095,202	-	88,351,544		129,739,104	-	129,887,737		130,767,849	-134,	927,	296	(close	to	telomere)	(p<0.05)	
	
13q	 	 88,676,494	-	92,029,220		95,059,210	-	95,931,996		(p=0.03)	 	15q	 	 31,951,325-32,376,877	(p=0.03)		 	16q	 	 57,823,567	-	57,992,604	(p=0.02)	58,540,478	-	59,005,775	(p<0.01)	81,387,855	-	81,836,485	(p=0.03)	 	3q	 	 	 121,495,658	-	121,972,355		167,516,772	-	169,326,472	(p<0.05);	8q	 	 	 125,100,708	-	127,884,025		129,247,390	-	129,501,508	(p<0.05).	
Non	
verrucous	
11p	 	 47,518,955-47,867,829	(p<0.05)	 	17q	 	 46,618,787	-	47,536,003	47,581,243	-	477,729,834		48,652,564	-	49,397,628	 	
Usual	 3p	 	 16,287394	-	16,435,851	16,455,294	-	16,785,131		72,520,499	-	72,993,504	(p<0.05).	 	
Grade	1+2	 2p	 	 18,441,084	-	18,611,588,		36,236,583	-	36,349,058,		71,974,149(p<0.05)	 	5p	and	q	 	 39,312,375	-	39,608,343,		125,596,256	-	125,957,381(p<0.05)	 	
Grade	3	 8q	 	 98,217,510	-	98,381,393,		98,622,574	-	99,325,883	99,650,748(p<0.05)	 	11p	 	 47,518,955	-	47,671(p<0.05)	 	
Stage	3	and	4	 5q		 	 142,012,666	-	142,175,698	(p=0.03),	 	6p		 	 45670490	-	45,851,371		(p<0.01)		 	18p		 	 125,640,882	-	126,607,828	128,096,371	-	128,625,942	(p<0.05).	 		 	 	 	
Node	
negative	
2p	 	 36,920,270	-	37,578,954		38,621,890	-	40,066,256	 	4q	 	 101,026,920	-102,065,074	(p=0.03);	 	9q	 	 91,181,836	-	91,566,892	(p<0.05)	 	10q			 	 114,067,767	-	115,375,350	(p<0.05);	 	15q		 	 50,550,602	-	52,277,893	(p<0.05);	 	20p			 	 8,412,274	-	8,758,526,		8,819,804	-	9,531,260,		17,184,216	-	17,484,732,		17,852,916	-	19,328,441	(p<0.05).	
	
Table 3.3. Clinico-pathological Subgroup Analysis of Differential Copy Number Changes. 
Statistically significant regions of amplification, gain and loss classified according to 
histopathological subtype. 
Deleted: ¶
Deleted: Subgroup ... [1]
Formatted Table
Deleted:   ¶
¶
¶
¶
	 102	
Analysis of histological subtypes uncovered differential gain of regions on 1q 
(p<0.05) and 3q(p=0.04, region close to telomere), differential loss of 11p and 
q (p<0.05, close to telomere), 13q (p=0.03), 15q (p=0.03), 16q (p=0.02), and 
differential amplification of 3q and 8q (p<0.05), when comparing basaloid to 
non-basaloid subtypes (Fig 3.4). In regions of these chromosomes statistically 
significant gain, loss and amplification were shown in more cases in the non-
basaloid group compared to the basaloid group. Comparing verrucous cases 
to non-verrucous differential loss was discovered on 11p and 17q (p<0.05), in 
significantly more cases in the non-verrucous than verrucous cohort. No 
significant differences in the prevalence of specific gained or amplified loci 
were identified. Comparing usual type to non-usual type, differential loss was 
found on 3p (p<0.05) and 17q (unadjusted p<0.05, adjusted p=0.1-0.33). 
Interestingly there were no significant differences in the prevalence of specific 
gained or amplified loci were identified. 
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Figure 3.4. Histological subtype of PSCCs. Fishers Exact plots of differential copy number gains and losses or 
amplifications/ high level gain in Basaloid and non-basaloid PSCC samples. The proportion of tumours in which each bacterial 
artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y axis) for each BAC clone according to 
its genomic position (x axis). Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 and loss<-0.08. 
 
 Formatted: Left:  2.2 cm, Bottom:  4.4 cm, Width:  29.66
cm, Height:  20.99 cm
Moved (insertion) [2]
Formatted: Font: 10 pt
Formatted: Font: 12 pt
	 104	
A supervised analysis of the aCGH results according to histological grade 
revealed differential gains in chromosome 6p and differential losses in 
chromosomes 2p, 5p and q, 8q and 11p. Gains of 6p were more frequently 
found in tumours of a low histological grade (i.e. 1 and 2) than in high-grade 
lesions (i.e. 3), but this was not statistically significant when adjusted p 
values were calculated. Loss of 2p and 5p and q were significantly more 
frequently found in low-grade lesions (p<0.05). Loss of 8q and 11p were 
significantly more frequently found in high-grade tumours (p<0.05). No 
significant differences in the prevalence of specific amplified loci were 
identified (Fig 3.5). 
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Figure 3.5. Histological grade of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ 
high level gain in high grade (3) and low grade (1-2) PSCC samples. The proportion of tumours in which each bacterial artificial 
chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y axis) for each BAC clone according to its 
genomic position (x axis). Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 and loss<-0.08. 
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PSSCs of different stages displayed distinct patterns of differential loss on 5q 
(p=0.03), 6p (p<0.01) and 18p, as well as amplification of 8q (Fig 3.6). These 
aberrations were significantly more frequently found in tumours of high 
histological stage (i.e. 3 and 4) than in low stage lesions (i.e. 1 and 2). No 
significant differences in the prevalence of specific gained loci were identified. 
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Figure 3.6. Clinical Stage of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ 
high level gain in high stage (3-4) and low stage (1-2) PSCC samples. The proportion of tumours in which each bacterial 
artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y axis) for each BAC clone according 
to its genomic position (x axis). Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 and loss<-0.08. 
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Analysis of aCGH data according to nodal status (N0, N1, N2, and N3) yielded 
more frequent gain of 7q and loss of 2pq (p<0.05), 4q (p=0.03), 9q (p<0.05), 
10q (p<0.05), 11q (p<0.05), 15q (p<0.05) and 20p (p<0.05) in node negative 
cases compared to node positive cases (Fig 3.7).  For 7q this was not 
statistically significant when an adjusted p value was calculated (unadjusted 
p =0.001-0.04; adjusted p=0.24-0.6). No significant differences in the 
prevalence of specific amplified loci were identified. 
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Figure 3.7. Lymph node status of PSCCs. Fishers Exact plots of differential copy number gains and losses or amplifications/ 
high level gain in lymph node positive and lymph node negative PSCC samples. The proportion of tumours in which each 
bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (y axis) for each BAC clone 
according to its genomic position (x axis). Amplification is defined as >0.4 on the log scale, gain >0.08≤0.45 and loss<-0.08. 
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Given the diversity of gene copy number aberrations of PSSCs, we performed 
class discovery analysis using hierarchical clustering. There were stable 
clusters, but none showed enrichment for a particular clinico-pathological 
feature (Fig 3.2C). 
 
3.1.5. aCGH Cohort: Contingency Analysis 
There was statistical significance when comparing low stage (1,2) against 
high stage (3,4) PSCCs for gain/amplification/ no gain of the 3q26 region 
(p=0.0198). However, no statistical significance was found when comparing 
histological subtypes or grades. 
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3.2. FISH DATA OVERALL 
 
A cohort of 258 patients were identified from our PSCC TMA tissue bank. 
Each patient was represented by 3 cores on each TMA slide. 20 patients were 
excluded from the analysis due to incomplete staging data sets. FISH analysis 
was conducted as previously described, with some examples demonstrated 
below: 
 
 
 
 
 
 
 
 
 
Normal	cell:	PI3CK	(red),	RP11348P10	(green)	 
Amplification:	11	red,	3	green 
Figure 3.8. FISH capture images showing PI3K (red) and RP11348P10 
(green). Demonstration of normal and amplified cells. Normal cells have 
matching numbers of red and green dots, with at least 2 of each per cell. 
Amplified cells have at least 3 times the number of red dots to green. 
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Figure 3.9. FISH capture images showing PI3K (red) and 
RP11348P10 (green). High red to green ratios indicate gain or 
amplification of PI3K. 
 Multiple fluorescence 
red:green ratio 
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Figure 3.10. FISH capture images 
showing PI3K (red) and 
RP11348P10 (green).  
(A) TMA7, 1903605. (B) TMA19, 
H0242908. (C) TMA20, 713210. (D) 
TMA20, 1652109. 
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Demographics including HPV status, stage, grade, lymph node status and 
histological classification were recorded. Samples were excluded due to 
incomplete data sets. Data sets were stratified by ‘gain, amplification, no gain’ 
and then ‘gain and amplification, no gain’ (Tables 3.4, 3.5, 3.6 and 3.7). 
 
 
 
 
 
 
 
Histopathological Subtype Gain 
(n=) 
Gain (%) Amplification 
(n=) 
Amplication (%) No 
Gain 
(n=) 
No 
Gain 
(%) 
Total 
(n=) 
Basaloid 8  38.1 5  23.8 8  38.1 21 
Verrucous 1  4.3 0 0 22  96 23 
Usual 52  33.5 2  1.3 101  65.2 155 
Warty 0 0 0 0 8  100 8 
Mixed u/b 4  45 0 0 5  55 9 
Mixed u/w 0 0 0 0 1  100 1 
Mixed u/v 2  18.2 1  9.1 8  72.7 11 
Mixed v/w 0 0 0 0 7  100 7 
Mixed u/sarc 1  50 0 0 1  50 2 
Sarcomatoid 1  100 0 0 0 0 1 
       238 
Histological 
Grade 
Gain 
(n=)  
Gain 
(%) 
Amplification 
(n=) 
Amplification 
(%) 
No Gain 
(n=) 
No Gain 
(%) 
Total 
Grade 1 2 4.4 0 0 43 95.6 45 
Grade 2 21 26.3 1 1.3 58 72.5 80 
Grade 3 43 38.0 9 8.0 61 54.0 113 
       238 
Table 3.4. TMA sample breakdown: the number and percentage of cases 
demonstrating Gain, Amplification or No Gain using FISH Analysis, According 
to Histopathological Subtype. Statistical significance in the increased gain/ 
amplification in basaloid and usual subtypes (p=0.0003). 
Table 3.5. TMA sample breakdown: the number and percentage of cases 
demonstrating Gain, Amplification or No Gain using FISH Analysis, 
According to Histological Grade. Statistical significance in the increased 
gain/ amplification in Grade 3 disease (p<0.0001). 
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When comparing all PSCC histopathological subtypes within the cohort, 
statistically significant differences were found between all subtypes (gain and 
amplification vs no gain; p=0.0003); in the basaloid subtype vs others (gain 
and amplification vs no gain; p=0.0056); verrucous subtype vs others (gain 
and amplification vs no gain; p=0.0017) and usual subtype vs others (gain vs 
Clinical Stage 
Gain 
(n=) 
Gain 
(%) 
Amplification 
(n=) 
 Amplification 
(%) 
No 
Gain 
(n=) 
 No 
Gain 
(%) 
Total 
Stage 1 16 19.0 2 2.4 66 78.6 84 
Stage 2 35 32.7 3 2.8 69 64.5 107 
Stage 3 12 31.6 5 13.2 21 55.3 38 
Stage 4 4 66.7 0 0 2 33.3 6 
       235 
HPV 
Status 
Gain 
(n=) 
Gain 
(%) 
Amplification 
(n=) 
 Amplification 
(%) 
No gain 
(n=) 
No gain 
(%) 
Total 
HPV 
positive 
10 25.6 0 0 29 74.4 39 
HPV 
negative 
7 22.6 1 3.2 23 74.2 31 
Table 3.7. Number of Cases Demonstrating Gain, Amplification or No 
Gain using FISH Analysis, According to available HPV status: the 
aCGH subgroup cohort is analysed. 
Table 3.6. TMA sample breakdown: the number and percentage of cases 
demonstrating Gain, Amplification or No Gain using FISH Analysis, 
According to Clinical Stage. Statistical significance in the increased gain/ 
amplification in high stage disease (p=0.01). 
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amplification vs no gain p=0.0098). When comparing gain vs amplification vs 
no gain, there was no statistical significance between all subtypes, in the 
basaloid group and in the verrucous group. Statistical significance was also 
not demonstrated when comparing gain and amplification vs no gain in the 
usual PSCC cohort. 
	 117	
 Figure 3.11.  FISH on PSCC samples. A graph comparing histopathological subtypes: PI3CKA gain and amplification 
vs no gain. (p=0.003) 
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Figure 3.12.  FISH on PSCC samples. A graph comparing basaloid with other histopathological subtypes: PI3CKA gain 
and amplification vs no gain. (p=0.0056)) 
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Figure 3.13.  FISH on PSCC samples. A graph comparing verrucous with other histopathological subtypes: PI3CKA 
gain and amplification vs no gain. (p=0.0017) 
 
Deleted: ¶
¶
Deleted: ¶
¶
¶
¶
Deleted: 
Formatted: Font: 12 pt
Formatted: Font: 12 pt
	 120	
 
 
Figure 3.14.  FISH on PSCC samples. A graph comparing usual with other histopathological subtypes: PI3CKA 
gain vs amplification vs no gain. (p=0.0098) 
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Statistical significance was demonstrated between all histological grades 
(gain vs amplification vs no gain; p<0.0001); all clinical stages (gain and 
amplification vs no gain; p=0.0125); stage 1 vs other stages (gain vs 
amplification vs no gain; p=0.0214); stage 3 vs other stages (gain vs 
amplification vs no gain; p=0.0084) and low stage vs high stage (gain vs 
amplification vs no gain; p=0.0091). No statistical significance was shown 
when comparing all stages, stage 2 or stage 4 (gain vs amplification vs no 
gain). 
There was no statistically significant difference when comparing HPV positive 
to negative samples           
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Figure 3.15.  FISH on PSCC samples. A graph comparing histological grades: PI3CKA gain vs 
amplification vs no gain. 
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Figure 3.16.  FISH on PSCC samples. A graph comparing clinical stages: PI3CKA gain and amplification vs no 
gain.(p=0.0125) 
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Figure 3.17.  FISH on PSCC samples. A graph comparing clinical stage 1 with stages 2,3 and 4: PI3CKA gain vs amplification 
vs no gain.(p=0.0125) 
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Figure 3.18.  FISH on PSCC samples. A graph comparing clinical stage 3 with stages 1,2 and 4: PI3CKA gain vs amplification 
vs no gain.(p=0.0084) 
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Figure 3.19.  FISH on PSCC samples. A graph comparing low clinical stage 1 and 2 with high clinical stage 3 and 4: PI3CKA 
gain vs amplification vs no gain.(p=0.0091) 
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CHAPTER 4: DISCUSSION 
 
4.1. INTERPRETATION OF HPV STATUS 
 
Data about HPV positive and negative pathways is emerging that may guide 
future treatment. p16INK4A immunohistochemistry (IHC) is a much cheaper 
way to assess HPV status than polymerase chain reaction (PCR) or in-situ 
hybridisation (ISH) and it is widely available.  
Wittekindt et al. examined 34 tonsillar SCCs in 2005 and concluded that 
p16INK4A IHC is fully equivalent to HPV DNA detection [162]. Later studies and 
ours have found that p16 is not a surrogate marker for the replacement of HPV 
PCR [163]. However, it has been suggested in other SCCs that PCR and IHC, 
in combination, may be of greater diagnostic validity [163]. A paper by Seiwert 
et al. goes further to suggest that neither P16 INK4A IHC alone or in conjunction 
with low density DNA-based HPV ISH would be an accurate biomarker for 
diagnostic assessment or management criteria that would affect patient 
outcomes [164]. A systematic review by Grønhøj Larsen et al. demonstrated 
the vast disparity between studies in the diagnosis of HPV, as well as the 
definition of p16 overexpression. A threshold of >70% of cytoplasmic and 
nuclear staining has a greater sensitivity for the presence of HPV [165]. 
 
Based on our data, if HPV typing is to determine future treatment, up to 25% 
of cases will be misassigned using p16INK4A IHC alone. Furthermore, 
interpretation of molecular data based on p16INK4A HPV status would be of 
limited validity in translation from molecular studies to clinical practice [166]. 
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4.2. COMPARISON OF ARRAY CGH IN PSCC 
 
4.2.1. Genome Wide Copy Number Aberrations  
Many studies to date exploring PSCC molecular genetics have focused on 
single gene studies utilising immunohistochemistry or other methodologies.  
A study by Alves et al. analysed 26 PSCC samples by metaphase spread 
CGH. Although many copy number aberrations were discovered, the most 
common copy number gains were detected at 8q24, 16p11-12, and 20q11-13 
(11 cases); 22q (10 cases); 19q13  (9 cases) and 5p15 (8 cases) [97].  Our 
data has demonstrated copy number gains at 1p13.3-q44 (88%), 2p21-q33.3 
(83%), 3p12.3-q29 (86%), 4q34.2-q35.2 (39%), 5p15.33-p11 (67%), 6p12.3-
q12 (44%), 7p22.3-q36.3 (88%), 8p12-q24.3 (84%), 9p24.3-q34.3 (88%), 
11p12.3-q14.1 (39%), 12q24.11-q24.33 (42%), 14q11.2-q32.33 (66%), 
15q11.2-q24.3 (47%), 16p11.2-q24.3 (77%), 17q21.33-q25.3 (53%), 
19p13.11-q13.43 (64%), 20p13-q13.43 (64%), 21q11.1-q22.3 (66%) and 
23q21.31-q28 (44%). Although some of these copy number gains are in 
agreement, results cannot be directly comparable due to sample size and 
methodology. The Alves study analysed only 26 samples and used 
metaphase spread CGH, whereas this study analysed 70 samples utilising 
array CGH, which has a much higher resolution. 
 
However, a more recent analysis of 46 PSCC samples, using array CGH and 
HPV genotyping has shown recurrent copy number gains on 3q (3q12.3-
q13.13, 29%; 3q13.13-q13.31, 34%; 3q13.31-q25.31, 42% and 3q25.31-q29, 
42%), 5p (5p13.3, 26% and 5p15.33, 26%), 8q (8q11.1-q11.23, 34%; 8q12.1, 
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26%; 8q12.1-q21.13, 34%; 8q21.2-q24.3, 66% and 8q22.3, 61%), 9p (9p12-
p11.2, 26% and 9q33.3-q34.11, 29%), 20p (20p12.1, 26%) and 21p (21p11.1, 
26%).  These highly recurrent gains are in keeping with those found in our 
study on chromosomes 3, 5, 8, 9, 20 and 21. 
 
This study did not show evidence of deletions, whereas Alves et al. discovered 
regions of recurrent deletions on chromosomes 4, 13 and X chromosome. 
 
Data in this study demonstrated several highly recurrent losses at 1p36.33-
p34.2 (56%), 1p32.3-p32.2 (47%), 2q33-q37.3 (86%), 2p22.3-p16.3 (55%), 
2p24.2-p23.2 (40%), 3p26.3-q11.1 (83%), 3q13.13-13.31 (40%), 4p16.3-p11 
(55%), 4q28.3-q35.2 (55%), 4q13.3-q28.3 (47%), 5q35.1-q35.2 (64%), 
5q33.3-q35.1 (48%), 5q13.2 (44%), 6q16.3-q25.2 (67%), 6p21.1-p12.3 (42%), 
7q31.1-q36.3 (64%), 8p23.3-q11.1 (72%), 9p23-p21.3 (53%), 9q33.3-q34.3 
(52%), 10q23.1-q26.3 (77%), 10p15.3-p11.1 (66%), 10p21.3-q23.1 (64%), 
11q12.2-q25 (81%), 11p15.5-p14.3 (64%), 12p13.3-p11.21 (61%), 12q24.23-
q24.31 (39%), 13q12.2-q31.1 (55%), 13q31.1-q34 (47%), 14q23.3-q24.3 
(45%), 15q21.1-q25.3 (56%), 15q25.3-q26.3 (55%), 16q22.2-q24.3 (64%), 
16q12.1-q21 (39%), 17p13.3-p11.1 (69%), 17q25.1-q25.3 (55%), 17q12-
q21.33 (48%), 18q12.1-q23 (75%), 18p11.31-q12.1 (55%), 19p13.3-p12 
(58%), 20p13.3-p12 (52%), 20q12-q13.2(39%) 21q21.2-q22.3 (69%), 
22q11.1-q13.3 (66%) and 23q28 (45%). This is in keeping with losses found 
in other data at 3p (3p26.3-p25.1, 26%; 3p24.3-p22.2, 42%; 3p22.2, 26%; 
3p22.2-p21.32, 34%; 3p21.1-p14.3, 26%; 3p14.1, 32%; 3p13-p11.1, 34%), 8p 
(8p23.3-p11.21, 50%), 9p (9p21.3, 26%) and 21p (21p11.1, 26%). 
	 130	
Amplifications were noted in our study on 1q, 3q, 5p, 8q and 11p, but none 
such were documented by Alves et al. or Busso-Lopes et al. 
The percentage frequency of copy number gains and losses was higher in this 
study when compared to those in common with Busso-Lopes et al.[167]. 
 
4.2.2. Copy Number Aberrations and HPV Status 
Our HPV positive cohort exhibited significant gain on 1q (151,622,431-
151,793,285; p=0.035), but this does not correlate with other data, which 
found significant regions of gain at 8p12, 9p13.3, 16p13.3 and 19q13.32 in 
HPV positive tumours. Furthermore, there were no areas of significant loss 
found in our study in correlation with HPV positive tumours. This is 
contradictory to other data [167]. Our HPV negative cohort exhibited 
significant gain of 2p (60,835,599-61,089,333; p=0.034), 7p (48,668,454-
49,846,998; 0.034), 10q (108,751,067-109,429,862; p=0.047) and loss of 11p 
(46,103,041-47,520,939; p<0.05). However, such an association has not 
been found in other studies. 
 
It is known that HPV alters cell physiology inactivating RB and p53 pathways 
[48, 111] and our genomic data shows copy number loss at 13q12.11-q34 
(80% of HPV positive cases) and 17p13.3-p11.1 (63% of HPV positive cases), 
harboring RB1 and TP53 genes, respectively. However, these changes did 
not differ from the HPV negative cohort with statistical significance. It is 
possible that TP53 and RB1 may be mutated in the cases without HPV 
infection. Further investigation, such as mutational analysis, will be required 
to elucidate this [168].  
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The TP53 pathway may also be inactivated by amplification or overexpression 
of an ubiquitin ligase, MDM2 (murine double minute 2). TP53 is usually kept 
at low levels by MDM2 in normal cells. MDM2 and TP53 form an auto-
regulatory negative-feedback loop, in which TP53 induces the expression of 
MDM2, which then facilitates the breakdown of TP53 in the nucleus and 
cytoplasm, inhibits its transcriptional activity and assists its nuclear export 
[168, 169]. Differential gain or differential amplification of this gene was not 
demonstrated at 12q15 in the HPV cohorts or in the overall data. However, 
Alves et al. had confirmed amplification on 12q, but only in 4.3% of PSCC 
cases, which does encompass the MDM2 gene [97]. pRB1 pathway 
inactivation could also be caused by gains/ amplification of CCNE1, CCND1, 
CDK2 and CDK4, but our data did not show differential copy number change 
at the corresponding loci between the HPV positive and HPV negative 
cohorts[168]. However, gain of the regions encompassing CCNE1 (19p13.11-
q13.43; 71% cases) and CCND1 (11q12.2-q14.1; 46% cases) were found in 
the HPV positive group, and both gain and amplification of the region 
incorporating CCND1 (11q13.3-q13.4; 20% and 3% cases, respectively) were 
found in the HPV negative group [168]. 
Using IHC, FISH and PCR methods, EGFR, HER3 and HER4 (not HER2) 
association with PSCC has been proven. HER3 expression was also found 
more commonly in HPV+ve cases and positively correlated with cytoplasmic 
Akt1 expression.[104, 105] pEGFR has been expressed more in HPV-ve than 
HPV+ve PSCCs [104]. 
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4.2.3. Copy Number Aberrations and Clinopathological Status 
In addition to HPV status, other studies have compared genomic aberrations 
to clinical stage, pathological stage, lymph node metastases and survival[98, 
167]. However, given that high grade and basaloid tumours have been 
associated with aggressive disease and poor prognosis, we also analysed 
histological grade and histopathological subtype. Interestingly, significant 
areas of differential gain were found in basaloid tumours at 1q (p<0.05) and 
3q (p=0.04); amplification at 3q (p<0.05) and 8q (p<0.05); loss at 11pq 
(p<0.05), 13q (p=0.03), 15q (p=0.03), 16q (p<0.05). This suggests that 
regions highlighted on 3q and 8q may harbour candidate driver genes.  
For Grade 3 tumours, statistically significant differential loss was found at 8q 
(p<0.05) and 11p (p<0.05), may correspond to tumour suppressor genes. 
 
With regards to changes identified in high clinical stage, as compared to low 
clinical stage, we found differential loss on 5q (p=0.03), 6p (p<0.01) and 18p, 
as well as amplification on 8q.  However, this has not been supported by other 
study, which only found statistically significant loss at various loci on 3p to be 
associated with high stage (3p26.3-p25.1, p=0.013; 3p24.3-p22.2, p=0.013; 
3p22.2, p=0.013; 3p22.2-p21.32, p=0.03; 3p21.1-p14.3, p=0.001; 3p14.1, 
p=0.022; 3p13-p11.1, p=0.004). 
 
Busso-Lopes did not find statistically significant genomic aberrations 
associated with lymph node status, whereas this study found significant loss 
in node negative cases at 2pq (36,920,270-37,578,954; 38,621,890-
40,066,256; p<0.05), 4q (101,026,920-102,065,074; p=0.03), 9q 
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(91,181,836-91,566,892 ; p<0.05), 10q (114,067,767-115,375,350 ; p<0.05), 
11q (p<0.05), 15q (50,550,602-52,277,893 ; p<0.05) and 20p (8,412,274-
8,758,526; 8,819,804-9,531,260; 17,184,216-17,484,732; 17,852,916-
19,328,441 p<0.05) [167] 
 
pEGFR expression has also been strongly related to increase risk of 
recurrence and shorter overall survival.[106] Cancer specific survival and 
disease free survival were shown to be significantly lower in those cases with 
loss of 3p21.1-p14.3 (p=0.006 and p=0.023, respectively) and gains of 
3q25.31-q29 (p=0.017 and p=0.042, respectively)[167]. Alves et al. reported 
genetic aberrations associated with shorter survival, but failed to clarify 
whether this is overall, disease free or disease specific. Our data did not 
include survival information for comparison. 
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4.2.4. Potential Candidate driver Genes and genes of Interest 
Our current data has revealed patterns of copy number gains, losses and 
amplifications in a PSCC cohort that correspond to potential genes of interest.  
 
3p copy number gain in this study harbours PRKCI, PIK3CA, DCUN1D1, 
LAMP3, RPL35A. 5p gain correlates to the SKP2 gene and 8p with the MYC 
gene. Amplification of 3q in our study correlates with genes such as PIK3CA, 
SENP5, CLDN1, TNK2, FBXO45, FNDC3B, ACTL6A/BAF53; and 11p to 
CPT1A, FGF3/4 and CCND1 [168].  
 
To understand the significance of some of these genes, it is key to appreciate 
their role within the cell cycle and involvement in signalling pathways. Gain of 
3p12.3-q29 in this study codes for the p110α catalytic subunit of PI3-kinase. 
The other component of this heterodimer is an adaptor/regulatory subunit 
(p85) [170]. PI3CKA, as part of the PI3-kinase/AKT signalling pathway, plays 
a key role in the regulation of cell growth and apoptosis [170].  PRKCI, a 
member of the protein kinase C (PKC) family of serine/threonine protein 
kinases is also located in this region. It is calcium-independent and 
phospholipid-dependent [171], and is involved in a wide variety of cellular 
processes, including transformed growth, invasion, survival and chemo 
resistance of tumour cells [172].  
 
Within the gained 5p15.33-p11 lies SKP2. It comprises the substrate 
recognition unit of the SCFSKP2 ubiquitin ligase complex and has been involved 
in the ubiquitin driven breakdown of cyclin dependent kinase inhibitor p27 (a 
dosage dependent tumour suppressor protein), which is a key regulator of G1 
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progression. SKP2 overexpression leads to cell cycle progression, although it 
is known to facilitate the throughput of both positive and negative regulators 
of cell cycle progression[173] 
 
On Chromosome 8p the MYC gene, encodes for a transcription factor that 
plays a role in cellular processes such as cell growth and proliferation, cell 
cycle progression, differentiation, apoptosis, transcription and cell motility 
[167]. 
 
SENP5 is a SUMO (small ubiquitin-like modifier) specific protease. The 
addition of SUMO proteins is responsible for the reversible post-translational 
modification of proteins. SUMOS are conjugated to cellular regulators, which 
changes the localization, activity and stability of the substrates [174].  CLDN1  
(Claudin 1) is a member of a family of principal proteins found at epithelial and 
endothelial cell interphases, important for tight junction formation and function 
[175]. TNK2 is a ubiquitously expressed non-receptor tyrosine-protein and 
serine/threonine-protein kinase that is implicated in cell spreading and 
migration, cell survival, cell growth and proliferation. TNK2 forms a robust 
complex with all isoforms of AKT and directly regulates AKT's plasma 
membrane recruitment, thereby bypassing the PI3-kinase pathway [176].  
FNDC3B is contained in the amplified region 3q26.1-q27.2. It induces the 
epithelial-to-mesenchymal transition (EMT) and activates PI3-kinase/Akt, RB1 
and TGFβ signalling pathways, amongst others [177]. 
 
This is supported by data showing high level genetic gain in PSCCs in MYC 
(11/60) and CCND1 (8/60) [as well as SOX2 (8/60), ATP11B (5/60), EGFR 
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(6/60) and TERT (4/60)] [178].  MYC gene gains or amplification, and 
increased gene and protein expression have previously been document in 
PSCCs[179] and more recently have been amplified in both HPV positive and 
negative cases, with no particular correlation [167]. LAMP3 gains have also 
been confirmed by array CGH and gene overexpression by transcript 
evaluation [167]. 
 
Some of the potential candidate driver genes identified in our study have been 
investigated in a recent analysis of 20 patients with PSCC. This group has 
described clinically relevant genomic aberrations, including some mutations. 
In concordance with our data, they discovered clinically relevant genomic 
aberrations in PIK3CA (25%) and CCND1 (20%). However, further genetic 
changes were also described in CDKN2A (40%), NOTCH1 (25%), EGFR 
amplification (20%), BRCA2 insertions/deletions, RICTOR amplifications 
(10%) and FBXW7 point mutations (10%)[98]. This study did not find 
alterations in the RAS family members in those patients with EGFR 
amplification, unlike a previous study by Andersson et al. that identified KRAS 
gene mutations. This group also discovered HRAS gene (7%) and KRAS gene 
mutations (3%) in larger, more advanced tumours [107].  
Furthermore, Andersson et al. found aberrations in PI3KCA in 29% of cases, 
which corresponds to changes found in our study and others [98, 178]. 
We also discovered copy number loss and corresponding potential genes of 
interest at 2pq (PLCD4), 3p (RBMS3, PLCD1, CACNA2D3) and 11q (CPT1A, 
CCND1, FGF3/FGF4, PPP2R1B). However, this has in part been contradicted 
by data showing amplification of FGF3 and FGF4 [98].  
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The discrepancies between our study and others may be attributed to 
methodology as well as cohort. For example, the study by Ali et al. focused 
only on high stage tumours (85% stage IV, 15% stage III), which we have 
demonstrated to have a statistically significant different genomic profile to low 
grade tumours. We utilised aCGH, but next generation sequencing and 
mutational analysis were used by others [98, 107, 178]. It is possible that 
some genetic aberrations in our study may actually harbour underlying genetic 
mutations, as described elsewhere. 
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4.2.5. Genetic Aberrations in Other Squamous Cell Carcinomas and 
Clinical Correlation 
 
4.2.5.1. Cervical Squamous Cell Carcinoma (CSCC) 
It is well known that HPV is a causative factor for cervical squamous cell 
carcinoma (CSCC). Many of the observed genetic changes seen in cervical 
cancer are shared with the finding in PSCC in our study. Namely, recurrent 
copy number gains 1pq, 2pq, 3q, 5p, 6p and q, 7p, 8p and q, 9p and q, 10p, 
11p and q, 12p and q, 13q, 15q, 18q, 19q, 20pq and 22q [124, 126, 180, 181]. 
1q, 3q and 5p gain have all been associated with advanced stages of CSCC 
tumour [125, 127]. 
 
Interestingly, amplifications on 3q were also found in CSCCs and commonly 
in HPV16 positive tumours and the PI3CKA gene locus (as well as hTR, ETS1, 
ETV5 and OPA1) [180]. 8q amplification, (seen in our PSCC cohort and in 
CSCCs), was commonly found in HPV 18 positive tumours and associated 
with genes c-MYC, eIF3 and PSCA [180]. Although, the presence of these 
amplification were the same as in our PSCC cohort, no such association with 
HPV status was exhibited. 
 
4.2.5.2. Vulvar Squamous Cell Carcinoma (VSCC) 
3q and 12q gains were more common in HPV positive tumours and 8q more 
common in HPV negative tumours[182]. Further copy number gain was 
revealed by Purdie in an exclusively HPV positive cohort in 1p, 1q, 8p, 8q, 9p, 
9q, 19, 20p, 20q, 22q, Xp and Xq [132]. Our cohort of PSCCs also found 
differential gain at a similar frequency in 1q in the HPV positive subgroup[168]. 
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Recurrent deletions have been described in VSCCs at 2p, 3p and 
chromosome 10, but no deletions were discovered in our PSCC cohort[132]. 
Unlike our PSCC data set, high stage tumours and lymph node metastases in 
VSCCs have also been linked to EGFR (7p12) copy number increases [135]. 
Many markers have been implicated in malignant transorfmation of lichen 
sclerosis to squamous cell carcinoma. MCM3, cyclin D1, Ki-67, p53 and γ-
H2AX proteins have been upregulated in lichen sclerosis and SCC of the vulva 
and penis.[183] 
 
Similar to penile cancer, most vulval tumours are SCCs of varying subtypes 
(keratinizing, basaloid, warty). Two different types of VSCC have been 
postulated and identified. One HPV related and one HPV unrelated, derived 
from independent precursors, differing in p53 mutation, microsatellite 
instability and allelic imbalances.[184, 185] Integration of high risk type HPV 
DNA in to the host genome is proven to be an early part of the pathway for 
monoclonal expansion of dyplastic cells in uterine cervical cancer[186] and it 
was first demonstrated in both VSCC and VIN in 2004.[187] Together with the 
identification of some clinical, pathological and genetic similarities between 
penile and vulvar/cervical cancer, these studies suggest that detailed HPV 
subtyping as well as more detailed genetic analysis, such as next generation 
sequencing, will be key to unlocking the pathogenetic drivers of progression 
in PSCCs. 
 
Furthermore, the bivalent HPV vaccine (HPV16/18) reported a 75% reduction 
in HPV16/18 associated vulvar/vaginal precursor lesions, comparing 
vaccinated women to controls[188, 189] and the quadrivalent vaccine 
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(6/11/16/18) was efficacious in >95% against HPV 16/18 vulvar intraepithelial 
neoplasia Grades, 1,2 and 3.[190] This indicates that HPV subtyping in 
PSCCs is likely to play a vital role in targeted disease prevention as well as 
management. 
 
4.2.5.3. Oesophageal Squamous Cell Carcinoma (OSCC) 
Based on aCGH studies, recurrent copy number gains have been identified in 
OSCCs, including 2p, 3q, 3q, 5p, 7pq, 8q, 9q, 10q, 11q, 12p, 14q, 16p, 17p, 
19pq, 20pq, 22 [191-194]. Recurrent amplifications have been demonstrated 
on 2q, 3q, 5p, 7p and q, 8q, 11q, 12q, 18q, 19q, 20q [191, 192, 194-196]. 
Some of these have commonality with results in our study[168]. These 
aberrations have highlighted similar potential candidate driver genes, such as 
CLDN1, PI3CKA on 3q [192]; MYC on 8q[194]; CCND1, FGF3 and FGF4 on 
11q[191] 
 
Chromosomal amplifications in OSCC at 2q12–14, 3q24–26, and 7q21–31 
were associated with lymph node metastasis[193], whereas we discovered 
differential losses on 2pq, 4q, 9q, 10q, 11q and 20p associated with node 
negative disease[168]. Amplification at 7p13–21 was related to distant 
metastasis and, therefore amplification at these regions correlated with worse 
survival[193]. However, in contrast with our data set, these endpoint 
parameters of distant metastases and survival were not analysed.  
Meta analyses and systematic reviews of HPV infection in OSCC 
demonstrates 11.7% -38.9% overall HPV positive OSCC cases. [197-204]  
However, on examination of these data, it was concluded that HPV is not a 
prominent carcinogen in OSCC.[205] Other studies have claimed that the 
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controversial aetiological role of HPV in OSCC is a consequence of poorly 
designed, low power studies and concludes that HPV increases the risk of 
OSCC 3-fold.[200] Therefore, the genetic similarities between PSCC and 
OSCC may represent changes in a non-HPV dependent pathway in PSCC 
pathogenesis. 
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4.3. PI3CKA FISH, CLINICOPATHOLOGICAL 
CORRELATION AND CLINICAL SIGNIFICANCE 
 
The prevalence of PI3CKA overexpression, gain and mutations in PSCCs has 
already been described, as has its significance in other squamous cell 
carcinomas.  
 
Fluorescence in situ hybridisation yielded statistically significant results with 
regard to histopathological subtype, histological grade and clinical stage, but 
not HPV status. There was a statistically significant high frequency of PI3CKA 
gain/amplification in the basaloid tumour PSCC subgroup (61.9%) compared 
to verrucous (4.3%) and usual subtypes (34.4%)(p<0.001). 
Statistical significance was demonstrated between all grades, with grade 3 
tumours exhibiting the highest percentage of PI3CKA gain (38%) and 
amplification (8%) (p<0.0001).  
 
 
The difference in PI3CKA expression (gain/amplification vs no gain) between 
all clinical stages was found to be statistically significant (p=0.0125). 
Moreover, gain and amplification in low stage (stage1+2; 26.7% and 2.6%, 
respectively) compared to high stage PSCCs (3+4; 36.4% and 11.4%, 
respectively) was statistically significant (p=0.0091). 
 
	 143	
The high frequency of PI3CKA gain/amplifications demonstrated in these 
subgroups suggest that patients with basaloid, high grade, high stage PSCCs 
would benefit from chemotherapeutic agents that manipulate the 
PI3CK/AKT/mTOR pathway. 
 
The PI3CK/AKT/mTOR pathway is complex and, as previously described, 
consists of many feedback loops. This lends itself to targeting of many 
different components of the PI3CK pathway. Pharmaceutical agents currently 
include ‘pan PI3CK’ inhibitors, which inhibit all 4 isoforms of class I PI3CK (α, 
β, γ, δ); isoform specific inhibitors of PI3CK isoforms; AKT inhibitors; ATP-
competitive inhibitors of mTOR only and ATP-competitive inhibitors of class I 
PI3CK and mTOR [206].  
 
 
Many agents are currently available and/or in various stages of clinical trials. 
Some examples of interest include Buparlisib (BKM120; Novartis), pan class 
PI3K currently in phase 2 trials for head and neck SCCs and tumours with 
PI3CKA activating mutations; BYL719 (Novartis), PI3K p110α currently in  
phase 2 trials for advanced solid tumours with PI3CA alteration, OSCCs and 
head and neck cancers [206]. 
However, it is worth considering that PI3CKA subunit P110α specific inhibitors 
may be of less benefit in those tumours with changes downstream of PI3K in 
their genomic profile, but upstream from mTOR. 
Further clinic trials are warranted, specifically in PSCCs, and perhaps 
targeting those with basaloid subtype, high grade and high stage tumours. 
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4.4. EXPERIMENTAL LIMITATIONS  
 
An important issue to address in this study and in order for adequate 
comparison to other studies, is that of tumour heterogeneity.  This describes 
the varying differences between tumours of the same type in different patients, 
and between cancer cells within a tumour. It is an important concept in 
diagnostics, treatment response and resistance, cancer progression and 
relapse, as well as clinical trial design.[207-209]  Interpatient tumour 
heterogeneity occurs as no two patients with the same subtype of tumour 
behave the same clinically, in the presence or absence of treatment. [208] 
This can be related to host factors such as vascular permeability to drugs or 
cells or drug half-life determined by germline variants.[210]   
Intratumour heterogeneity is well known and refers to the presence of 
different, but distinct cellular populations with specific phenotypic 
features.[211, 212] It utilizes Darwin’s theory of evolution, whereby beneficial 
mutations proliferate promoting the ‘survival of the fittest’ cells. Clonal 
expansion then occurs with various subclones having preferential features for 
invasion, proliferation or migration. [213-215] This is evidenced by many 
cytogenetic studies involving solid tumours, where tumour cells rarely display 
the same karyotype.  
Intermetastatic heterogeneity refers to heterogeneity among metastases 
when metastases at different secondary sites arise from different cellular 
population within a primary tumour.[208, 210] 
Heterogeneity among the cells of an individual metastasis is called 
Intrametastatic heterogeneity.  Given that each metastases originates from a 
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single cell with initial mutations, the metastases will also undergo cell division 
and thus acquire further mutations.[208, 210] 
Many studies have explored tumour heterogeneity, specifically intratumour, in 
other squamous cell carcinomas, such as oropharyngeal[216], skin[217], 
oesophageal[218] and head and neck[219], as well as non squamous cell 
carcinomas such as colon and breast[217]. Evidence has shown that a single 
biopsy is not representative of the mutational landscape of some 
tumours.[216, 218] 
 
Given this information, it is reasonable to assume that any results obtained 
from our study would be affected by interpatient and intratumour 
heterogeneity, proving to be a rate limiting step in our analysis.  
 
In relation to the negative controls in the experiment, tissue was taken from 
adjacent penile tissue deemed not to harbour SCC. The advantage of this is 
the use of penile tissue and its associated genetic profile, compared to other 
experimental studies that have used cervical tissue (all HPV-related) or other 
SCC tissue with varying association to HPV. The obvious disadvantage is that 
tissue adjacent to PSCC may have also been exposed to carcinogens such 
as HPV, therefore potentially altering it’s molecular genetic signature. This 
may present certain limitations in the interpretation of results as compared to 
‘negative controls’. One potential method to overcome this limitation would be 
to run controls from penile tissue that has never been exposed to any potential 
carcinogen for PSCC. 
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Future work would need to include array CGH and/or Next generation 
sequencing of multiple samples of the same tumour and comparisons 
between primary tumour and metastases. Metastases from local and distant 
sources would need to be analysed in order to account for intertumour 
heterogeneity. Furthermore, clones from premalignant tumours have been 
shown to share genetic and kinetic features with those of malignant tumours, 
so any future analysis of PSCCs should also include PeIN.[209] 
 
Tumour subtypes also have implications on the interpretation of results. As 
suggested by our data, basaloid PSCCs may benefit from specific targeted 
therapies. However, mixed forms of PSCCs exist, comprising approximately 
10-20% of PSCCs. [220, 221] 
Therefore, interpretation of molecular data is likely to underreport clinical 
and/or prognostic associations due to coexisting subtypes. 
 
4.5. CONCLUSION 
There remains a general paucity of studies in PSCC compared to other 
squamous cell carcinomas. A few studies have begun to investigate 
methylation[222] and microRNA expression profiles[223]  in PSCCs, but fewer 
detailing cell culture lines. Nonetheless, the library of PSCC genetic data is 
expanding and our current study lays the foundation for clinical trials involving 
PI3K/AKT/mTOR chemotherapeutic agents in high-risk PSCC patients. 
 
 
 
CHAPTER 5: FUTURE WORK: Possible Future 
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Design Of Experiments And Targeted 
Therapies. 
 
 
Suggestions for future experiments would include: 
 
1. aCGH using multiple sites from the primary tumour, inguinal and/or 
pelvic lymph nodes in the same patient. Benefit: Potential information 
about tumour metastases. Flaw: No accounting for varying types of 
heterogeneity 
2. NGS using multiple sites from the primary tumour, inguinal and/or 
pelvic lymph nodes in the same patient. Benefit: Information 
interpatient and intratumour heterogeneity. Flaw: No information 
about function 
3. Utilisation of PSCC cell lines to analyse tumourigenicity in HPV 
positive and negative samples 
Ideally, the second suggested experiment would include PeIN samples, to 
provide information regarding pathogenesis and progression; HPV DNA PCR 
and subtyping; FISH to further validate potential driver genes and functional 
analysis. 
Therapies targeted to specific pathways such as PI3CK/AKT/mTOR, as 
described in chapter 14, could be further refined if future experiments are able 
to provide crucial information about tumour heterogeneity and progression. 
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CHAPTER 7: SUPPLEMENTARY FILES: CGH DATA 
 
 
 
chrom	 start	 end	 start.MB	 end.MB	 start.probe	 end.probe	 probes	 length	MB	 maxM	 max.overlap	 cases	1	 11754	 1496725	 0.01	 1.5	 RP11-34P13	 RP11-197P23	 5	 1.484971	 0.554943782	 6	 6,	17,	29,	37,	46,	52,	70	1	 2277295	 32451741	 2.28	 32.45	 CTD-2554A16	 RP11-757P15	 335	 30.174446	 0.633859268	 16	 4,	7,	9,	10,	14,	16,	17,	18,	19,	21,	22,	23,	26,	31,	33,	34,	35,	36,	38,	46,	50,	55,	57,	59,	62,	63,	65,	68,	70	1	 32545135	 109341580	 32.55	 109.34	 RP11-601F01	 RP11-719H07	 811	 76.796445	 1.365253026	 10	 2,	6,	7,	9,	14,	15,	16,	17,	18,	19,	20,	21,	22,	23,	24,	25,	26,	31,	32,	34,	35,	36,	37,	40,	42,	43,	46,	49,	50,	55,	57,	58,	63,	65,	68,	69,	70	1	 110628929	 248876423	 110.63	 248.88	 RP11-19H01	 RP11-378I20	 1202	 138.247494	 0.854935927	 42	 1,	2,	4,	6,	7,	9,	10,	13,	14,	15,	16,	18,	19,	20,	21,	22,	23,	24,	25,	26,	28,	29,	31,	32,	34,	35,	36,	37,	38,	40,	41,	42,	43,	44,	46,	47,	48,	49,	50,	52,	53,	54,	55,	57,	58,	59,	60,	61,	62,	63,	65,	66,	67,	68,	69,	70	2	 52662	 9488711	 0.05	 9.49	 CTD-2379H09	 RP11-119K02	 101	 9.436049	 0.451055025	 9	 6,	18,	19,	25,	33,	44,	46,	50,	58,	59,	62,	65,	68	2	 10224532	 11376387	 10.22	 11.38	 RP11-648N08	 RP11-345J13	 13	 1.151855	 0.601788225	 7	 4,	18,	19,	26,	33,	44,	50	2	 11833674	 21147289	 11.83	 21.15	 RP11-5H04	 RP11-452B12	 90	 9.313615	 0.646614458	 19	 2,	6,	15,	16,	18,	19,	22,	26,	33,	34,	36,	37,	40,	44,	46,	48,	49,	50,	59,	62,	65,	67,	68	2	 21292813	 23312949	 21.29	 23.31	 RP11-33C24	 RP11-709L24	 20	 2.020136	 0.376970078	 4	 6,	33,	34,	58	2	 28620933	 30536431	 28.62	 30.54	 RP11-651P03	 RP11-517F01	 19	 1.915498	 0.371011469	 8	 2,	6,	18,	33,	38,	43,	44,	50,	51	2	 31021572	 32212295	 31.02	 32.21	 CTD-2270C11	 RP11-172A22	 13	 1.190723	 0.402270948	 5	 2,	6,	20,	33,	44	2	 33853418	 36548413	 33.85	 36.55	 RP11-702B22	 RP11-351D19	 34	 2.694995	 0.330761965	 4	 48,	50,	65,	68	2	 44605689	 45454646	 44.61	 45.45	 RP11-764D02	 RP11-117H06	 7	 0.848957	 0.390396322	 3	 44,	59,	62	2	 47626896	 206032624	 47.63	 206.03	 RP11-436K12	 RP11-458C09	 1630	 158.405728	 1.191018971	 25	 1,	2,	6,	7,	9,	10,	13,	14,	15,	16,	17,	18,	19,	21,	22,	25,	26,	28,	29,	31,	32,	33,	34,	35,	36,	37,	38,	40,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	58,	59,	61,	62,	63,	65,	66,	67,	68,	69,	70	2	 206803496	 216984568	 206.8	 216.98	 RP11-572M02	 RP11-504L12	 113	 10.181072	 0.495153811	 6	 6,	13,	15,	31,	40,	44,	59,	66,	67	2	 219707003	 220010127	 219.71	 220.01	 RP11-792H10	 RP11-663D11	 4	 0.303124	 0.423047034	 3	 44,	50,	67	2	 220536177	 221976286	 220.54	 221.98	 RP11-660N10	 RP11-16O23	 17	 1.440109	 0.383709244	 5	 43,	44,	46,	50,	67	2	 222786046	 223481998	 222.79	 223.48	 RP11-71J24	 RP11-16P06	 9	 0.695952	 0.286755133	 3	 6,	44,	67	2	 224540998	 226010532	 224.54	 226.01	 RP11-728A07	 RP11-723I23	 11	 1.469534	 0.27690089	 3	 44,	49,	67	2	 227972362	 230221103	 227.97	 230.22	 RP11-793C01	 RP11-811M10	 26	 2.248741	 0.38741239	 5	 24,	44,	50,	65,	67	
Table S1. Gains in 3 or more cases. Gain threshold =0.08 
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2	 231087013	 231795985	 231.09	 231.8	 RP11-23P08	 RP11-166K19	 7	 0.708972	 0.345550322	 6	 32,	37,	44,	49,	65,	67	2	 232748842	 235918176	 232.75	 235.92	 RP11-763N15	 RP11-689L02	 38	 3.169334	 0.410339734	 7	 4,	34,	37,	44,	47,	50,	57,	67	2	 240418400	 241943846	 240.42	 241.94	 RP11-251L10	 RP11-637O03	 17	 1.525446	 0.469889354	 7	 10,	11,	15,	26,	28,	38,	57	3	 72141	 2062977	 0.07	 2.06	 RP11-385A18	 RP11-806C02	 18	 1.990836	 0.410772638	 4	 23,	36,	51,	52	3	 7716915	 11193163	 7.72	 11.19	 RP11-25C11	 RP11-412L15	 33	 3.476248	 0.502643683	 9	 4,	6,	14,	17,	18,	23,	33,	36,	63	3	 12790928	 14077909	 12.79	 14.08	 RP11-548H07	 RP11-271E02	 12	 1.286981	 0.590348764	 3	 17,	23,	63	3	 17669683	 19208255	 17.67	 19.21	 RP11-152E15	 RP11-254E06	 20	 1.538572	 0.381481777	 7	 22,	23,	32,	34,	46,	52,	53	3	 19491897	 20570209	 19.49	 20.57	 RP11-641E06	 RP11-636F24	 11	 1.078312	 0.460311067	 3	 16,	23,	52	3	 26034359	 27282507	 26.03	 27.28	 RP11-806P23	 RP11-261I16	 12	 1.248148	 0.373786153	 4	 23,	47,	55,	65	3	 34287566	 35344372	 34.29	 35.34	 RP11-644C19	 RP11-802J21	 20	 1.056806	 0.458726305	 4	 6,	9,	21,	23,	51	3	 38009522	 38386586	 38.01	 38.39	 RP11-91E04	 RP11-206M15	 5	 0.377064	 0.241035769	 3	 23,	33,	51	3	 44847712	 45267301	 44.85	 45.27	 RP11-195F22	 RP11-67G04	 5	 0.419589	 0.349456769	 3	 23,	40,	46	3	 45915755	 46627083	 45.92	 46.63	 RP11-275I06	 RP11-494P19	 10	 0.711328	 0.414689869	 8	 2,	22,	23,	34,	35,	36,	37,	46	3	 58696014	 60304452	 58.7	 60.3	 RP11-693O21	 RP11-182G24	 21	 1.608438	 0.434400707	 10	 2,	9,	15,	16,	17,	22,	34,	37,	44,	46	3	 62359778	 63629740	 62.36	 63.63	 RP11-126N04	 RP11-672O06	 13	 1.269962	 0.39112393	 3	 17,	36,	37	3	 67867627	 68525394	 67.87	 68.53	 RP11-449J05	 RP11-692D04	 5	 0.657767	 0.269851678	 3	 36,	37,	46	3	 75559251	 197791562	 75.56	 197.79	 CTD-2026G06	 RP11-721B03	 1379	 122.232311	 1.41948688	 42	 1,	2,	3,	4,	6,	7,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	23,	26,	28,	29,	31,	32,	33,	34,	35,	36,	37,	38,	40,	41,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	58,	59,	60,	61,	62,	65,	66,	67,	68,	69,	70	4	 24423	 4385074	 0.02	 4.39	 RP11-116N15	 RP11-658B07	 60	 4.360651	 0.859017292	 7	 1,	6,	7,	10,	17,	28,	34,	54,	58,	65	4	 5251484	 6559485	 5.25	 6.56	 RP11-544B05	 RP11-340L10	 16	 1.308001	 0.435110771	 5	 10,	17,	20,	33,	60	4	 7959698	 12396606	 7.96	 12.4	 CTD-2104N03	 RP11-784O01	 45	 4.436908	 0.56234862	 8	 10,	14,	17,	20,	21,	34,	43,	53,	58,	59,	65	4	 18057368	 20511722	 18.06	 20.51	 RP11-468A23	 RP11-12E05	 24	 2.454354	 0.425507452	 4	 10,	25,	34,	54	4	 30516721	 31354108	 30.52	 31.35	 RP11-351I04	 RP11-59M16	 7	 0.837387	 0.37142611	 3	 32,	54,	65	4	 31901143	 32614803	 31.9	 32.61	 RP11-483M09	 RP11-261I15	 6	 0.71366	 0.411970616	 3	 24,	32,	65	4	 33916168	 34338702	 33.92	 34.34	 RP11-306G17	 RP11-436B03	 4	 0.422534	 0.307853342	 3	 32,	38,	65	4	 35644789	 37693218	 35.64	 37.69	 RP11-328G14	 RP11-453M22	 19	 2.048429	 0.553077834	 6	 32,	37,	46,	53,	54,	65	
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4	 48625294	 52835102	 48.63	 52.84	 RP11-413C15	 RP11-365H22	 13	 4.209808	 0.550341594	 11	 15,	29,	34,	37,	43,	44,	46,	47,	50,	57,	65,	68	4	 55527232	 57549699	 55.53	 57.55	 RP11-452H23	 RP11-261M03	 21	 2.022467	 0.334158961	 4	 19,	26,	57,	66	4	 59534034	 77976594	 59.53	 77.98	 RP11-506N02	 RP11-54L18	 184	 18.44256	 1.737337004	 11	 2,	19,	20,	32,	34,	37,	44,	47,	48,	50,	55,	57,	65	4	 78049078	 79485603	 78.05	 79.49	 RP11-184F15	 RP11-13P22	 18	 1.436525	 0.378003162	 5	 19,	34,	50,	55,	65	4	 84538784	 85472450	 84.54	 85.47	 RP11-72G08	 RP11-678H22	 9	 0.933666	 0.455953889	 3	 19,	50,	65	4	 91347616	 95152800	 91.35	 95.15	 RP11-324B17	 RP11-198E18	 30	 3.805184	 0.405669482	 3	 19,	50,	65	4	 96109849	 99725022	 96.11	 99.73	 RP11-643B21	 RP11-234D09	 28	 3.615173	 0.514867007	 5	 19,	37,	50,	54,	65	4	 103388343	 106274623	 103.39	 106.27	 RP11-347O08	 RP11-542F11	 23	 2.88628	 0.512335738	 3	 19,	46,	54	4	 112097391	 113347139	 112.1	 113.35	 RP11-326N15	 RP11-313K06	 10	 1.249748	 0.455338502	 3	 19,	46,	51	4	 113833766	 119492918	 113.83	 119.49	 RP11-224E18	 RP11-586D05	 63	 5.659152	 0.508204967	 5	 19,	28,	32,	50,	51,	54	4	 129877825	 139478479	 129.88	 139.48	 RP11-699E02	 RP11-639P04	 103	 9.600654	 0.708735612	 5	 19,	28,	32,	44,	46,	50,	63,	65	4	 144508534	 146080268	 144.51	 146.08	 RP11-481K16	 RP11-566J16	 17	 1.571734	 0.352168921	 5	 19,	28,	37,	47,	65	4	 152192970	 154032207	 152.19	 154.03	 RP11-263D05	 RP11-761L20	 15	 1.839237	 0.562599268	 3	 19,	28,	40	4	 160224378	 161676865	 160.22	 161.68	 RP11-138A23	 RP11-48F23	 13	 1.452487	 0.906784745	 4	 19,	28,	60,	65	4	 167311243	 169417106	 167.31	 169.42	 RP13-580K08	 RP11-963C20	 21	 2.105863	 0.386885226	 4	 15,	19,	28,	65	4	 170039933	 174184389	 170.04	 174.18	 RP11-805F24	 RP11-702P04	 45	 4.144456	 0.41062841	 6	 18,	19,	28,	41,	50,	54	4	 175184907	 176977397	 175.18	 176.98	 RP11-784F12	 RP11-598O12	 16	 1.79249	 0.469640791	 3	 19,	28,	46	4	 177343346	 190899780	 177.34	 190.9	 RP11-489J24	 CTD-2011O21	 151	 13.556434	 0.564144335	 19	 1,	6,	9,	10,	14,	17,	18,	19,	21,	23,	26,	28,	29,	34,	37,	40,	43,	44,	46,	47,	50,	54,	59,	65,	68	5	 18263	 52234095	 0.02	 52.23	 RP11-811I15	 RP11-272D02	 660	 52.215832	 1.651707198	 29	 1,	2,	4,	5,	6,	7,	10,	11,	14,	15,	16,	17,	18,	20,	22,	23,	26,	28,	29,	31,	32,	33,	34,	35,	36,	37,	41,	44,	46,	48,	49,	50,	52,	54,	57,	59,	60,	62,	63,	65,	67,	68,	69	5	 52210528	 53082549	 52.21	 53.08	 RP11-207D08	 RP11-343F04	 19	 0.872021	 0.412947075	 5	 1,	17,	48,	54,	57	5	 53395898	 58555555	 53.4	 58.56	 RP11-139J03	 RP11-275J10	 102	 5.159657	 0.580722949	 10	 6,	17,	19,	32,	33,	40,	43,	46,	49,	51,	57,	62	5	 58649195	 59251501	 58.65	 59.25	 RP11-214O08	 RP11-306M13	 10	 0.602306	 0.394500523	 3	 17,	49,	50	5	 65595893	 66696908	 65.6	 66.7	 RP11-803O15	 RP11-148G17	 19	 1.101015	 0.570376323	 10	 13,	17,	19,	20,	31,	32,	40,	42,	46,	49,	68	5	 68181690	 70966110	 68.18	 70.97	 RP11-141O11	 RP11-350A19	 28	 2.78442	 0.597491406	 6	 6,	17,	29,	31,	37,	58,	63	5	 72817005	 73086396	 72.82	 73.09	 RP11-122F20	 RP11-184M18	 6	 0.269391	 0.31070073	 4	 17,	19,	40,	49	5	 73245608	 73800564	 73.25	 73.8	 RP11-421A01	 RP11-641I13	 5	 0.554956	 0.343847275	 3	 17,	40,	49	
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5	 74972137	 76434304	 74.97	 76.43	 RP13-505D04	 RP11-372H22	 28	 1.462167	 0.416584522	 5	 17,	23,	50,	65,	68	5	 83193176	 87674639	 83.19	 87.67	 RP11-619G11	 RP11-512I16	 86	 4.481463	 0.562525554	 11	 17,	19,	24,	32,	34,	35,	37,	44,	46,	50,	51,	54	5	 88410786	 88783007	 88.41	 88.78	 RP11-788M06	 CTD-2015A14	 5	 0.372221	 0.371654662	 3	 11,	17,	61	5	 94787436	 96386835	 94.79	 96.39	 RP11-719P17	 RP11-331L16	 24	 1.599399	 0.481950734	 5	 1,	17,	31,	40,	49,	51	5	 113795468	 114587256	 113.8	 114.59	 RP11-449M19	 RP11-68A11	 8	 0.791788	 0.343735367	 3	 17,	50,	65	5	 117285836	 120964814	 117.29	 120.96	 RP11-567A12	 RP11-724I05	 70	 3.678978	 0.433476945	 5	 17,	24,	32,	41,	53,	54	5	 128342206	 128898432	 128.34	 128.9	 RP11-336L14	 RP11-700I23	 8	 0.556226	 0.399968534	 3	 17,	25,	46	5	 130022544	 130898042	 130.02	 130.9	 RP11-417D12	 RP11-336A21	 9	 0.875498	 0.338091677	 3	 17,	37,	46	5	 133893943	 134538897	 133.89	 134.54	 RP11-620I22	 RP11-107M07	 8	 0.644954	 0.443832232	 4	 15,	17,	19,	48	5	 134666055	 136219229	 134.67	 136.22	 RP11-310B08	 RP11-310L19	 31	 1.553174	 0.604561584	 5	 17,	19,	46,	48,	65	5	 139834199	 140827682	 139.83	 140.83	 RP11-727B23	 RP11-323J18	 10	 0.993483	 0.377206398	 8	 17,	37,	42,	50,	55,	65,	66,	68	5	 143196607	 146491433	 143.2	 146.49	 RP11-560F05	 RP11-577D13	 36	 3.294826	 0.58399206	 5	 17,	44,	48,	62,	65,	67	5	 147087466	 149175583	 147.09	 149.18	 RP11-708P10	 RP11-807F06	 32	 2.088117	 0.534541616	 10	 16,	17,	19,	32,	40,	43,	46,	49,	52,	53,	62	5	 150641463	 153142831	 150.64	 153.14	 RP11-248D18	 RP11-450M19	 24	 2.501368	 0.50190423	 5	 17,	47,	48,	65,	68	5	 154545933	 155124799	 154.55	 155.12	 CTD-2015M16	 RP11-318B23	 6	 0.578866	 0.369728431	 3	 17,	46,	58	5	 156237953	 157239274	 156.24	 157.24	 RP11-26C16	 RP11-631N12	 9	 1.001321	 0.474315532	 6	 17,	36,	37,	46,	51,	58	5	 159791217	 168120027	 159.79	 168.12	 RP11-135K08	 RP11-775P19	 90	 8.32881	 0.651333293	 13	 2,	13,	15,	17,	19,	29,	32,	38,	40,	42,	44,	46,	50,	65,	67,	68	5	 168977856	 169884900	 168.98	 169.88	 RP11-486H05	 RP11-637B03	 12	 0.907044	 0.449077082	 6	 17,	34,	35,	37,	46,	50	5	 170212814	 170921033	 170.21	 170.92	 RP11-453D13	 RP11-117L06	 7	 0.708219	 0.331295885	 4	 15,	17,	34,	50	5	 172827341	 174397365	 172.83	 174.4	 RP11-286M20	 RP11-488I22	 21	 1.570024	 0.515418615	 5	 13,	17,	43,	61,	62	5	 175143915	 175547728	 175.14	 175.55	 RP11-690D05	 RP11-690I08	 11	 0.403813	 0.508074556	 6	 2,	4,	17,	37,	46,	61	5	 175865339	 176330703	 175.87	 176.33	 RP11-340I16	 RP11-1G22	 4	 0.465364	 0.622523863	 3	 2,	4,	17	6	 129242	 2831467	 0.13	 2.83	 RP13-486F12	 RP11-650H15	 25	 2.702225	 0.460522748	 8	 1,	7,	20,	21,	35,	37,	46,	50,	57,	65	6	 3192012	 10606643	 3.19	 10.61	 RP11-440D24	 RP11-467C21	 92	 7.414631	 0.467736309	 8	 7,	16,	19,	21,	32,	34,	46,	50,	57,	67,	68	6	 11928871	 12404898	 11.93	 12.4	 RP11-101G19	 RP11-338L10	 8	 0.476027	 1.87970878	 3	 46,	51,	66	6	 12770661	 15357755	 12.77	 15.36	 RP11-805G18	 RP11-277N23	 37	 2.587094	 1.915055575	 4	 4,	16,	51,	66	
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6	 15655693	 16066941	 15.66	 16.07	 RP11-730C10	 RP11-810G03	 5	 0.411248	 2.092017873	 3	 41,	51,	66	6	 18297551	 21545576	 18.3	 21.55	 RP11-573J17	 RP11-120L02	 43	 3.248025	 1.491874605	 4	 17,	21,	23,	66	6	 25988413	 26519964	 25.99	 26.52	 RP11-186F18	 RP11-624L06	 5	 0.531551	 0.467510577	 5	 23,	31,	32,	46,	49	6	 26528215	 29719543	 26.53	 29.72	 RP11-457M11	 RP11-133I23	 35	 3.191328	 0.374649777	 5	 21,	23,	43,	46,	50,	66	6	 30865617	 31311968	 30.87	 31.31	 CTD-2007P10	 RP11-6O07	 5	 0.446351	 0.355577698	 3	 21,	23,	50	6	 37252124	 38206310	 37.25	 38.21	 RP11-564K19	 CTD-2010F16	 11	 0.954186	 0.443645134	 3	 2,	21,	23	6	 38847000	 39407310	 38.85	 39.41	 RP11-95M22	 RP11-599H12	 5	 0.56031	 0.400862025	 3	 18,	21,	23	6	 39821087	 41283162	 39.82	 41.28	 RP11-61I13	 RP11-793E22	 18	 1.462075	 0.412750318	 7	 16,	18,	21,	23,	26,	33,	51,	66	6	 41539454	 42967609	 41.54	 42.97	 RP11-645B11	 RP11-730K19	 15	 1.428155	 0.451253211	 5	 19,	22,	23,	49,	51	6	 44278961	 45886382	 44.28	 45.89	 RP11-152M23	 RP11-135M04	 19	 1.607421	 1.736577295	 12	 21,	22,	23,	37,	44,	46,	48,	49,	51,	59,	62,	67	6	 46723898	 68815841	 46.72	 68.82	 RP11-111B22	 RP11-542F09	 224	 22.091943	 1.39894036	 16	 4,	7,	14,	16,	18,	19,	21,	23,	24,	28,	29,	32,	42,	43,	46,	47,	48,	49,	50,	51,	53,	54,	59,	63,	65,	66,	68,	70	6	 76247960	 78716157	 76.25	 78.72	 RP11-122P04	 RP11-182H01	 26	 2.468197	 0.461161013	 6	 2,	21,	36,	37,	59,	65	6	 97927350	 98424277	 97.93	 98.42	 RP11-63N01	 RP11-769B08	 6	 0.496927	 0.522340007	 3	 32,	35,	46	6	 100457032	 101429476	 100.46	 101.43	 RP11-691K21	 RP11-654I23	 10	 0.972444	 0.370918414	 3	 15,	46,	53	6	 104862808	 107636989	 104.86	 107.64	 RP11-301J19	 RP11-453G21	 37	 2.774181	 0.578341825	 19	 1,	2,	5,	11,	14,	15,	22,	32,	34,	35,	36,	37,	42,	43,	44,	46,	49,	51,	61,	67	6	 114352412	 116242021	 114.35	 116.24	 RP11-112L15	 RP11-754P12	 20	 1.889609	 0.377274383	 3	 46,	50,	65	6	 117122121	 118176692	 117.12	 118.18	 RP11-34F18	 RP11-20C12	 11	 1.054571	 0.479793949	 7	 13,	21,	22,	44,	46,	50,	58	6	 121675907	 122015392	 121.68	 122.02	 RP11-207F16	 RP11-695L09	 3	 0.339485	 0.288066194	 3	 14,	31,	46	6	 122796430	 123415218	 122.8	 123.42	 RP11-555J17	 RP11-618I07	 4	 0.618788	 0.380655424	 3	 31,	46,	65	6	 128034100	 129147955	 128.03	 129.15	 RP11-126M23	 RP11-241J05	 13	 1.113855	 0.379531193	 7	 15,	31,	44,	46,	49,	50,	51	6	 134384176	 135751640	 134.38	 135.75	 RP11-807A14	 RP11-170P19	 12	 1.367464	 0.973394657	 6	 22,	34,	44,	46,	49,	57	6	 136621876	 139960511	 136.62	 139.96	 RP11-422G24	 RP11-649D20	 31	 3.338635	 0.465564826	 9	 22,	34,	36,	44,	46,	49,	51,	54,	57,	65	6	 141944507	 143665469	 141.94	 143.67	 RP11-762O13	 RP11-195D03	 16	 1.720962	 0.438740432	 4	 42,	46,	51,	57,	67	6	 152977043	 154593824	 152.98	 154.59	 RP11-107B11	 RP13-525D09	 24	 1.616781	 0.409448608	 5	 22,	46,	48,	65,	66	6	 158416653	 159567966	 158.42	 159.57	 RP11-170L24	 RP11-361B12	 12	 1.151313	 0.396534784	 5	 2,	7,	37,	46,	57	6	 160756540	 161376798	 160.76	 161.38	 RP11-583B08	 RP11-99A24	 8	 0.620258	 0.417784838	 9	 7,	16,	17,	46,	48,	50,	57,	59,	65	
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6	 163327102	 168874650	 163.33	 168.87	 RP11-621H02	 RP11-212J04	 61	 5.547548	 0.692730906	 4	 2,	7,	16,	46,	57,	68	6	 170333649	 171008924	 170.33	 171.01	 RP11-375F20	 RP11-113J06	 8	 0.675275	 0.480051634	 7	 2,	7,	17,	32,	36,	43,	57	7	 10239	 159124355	 0.01	 159.12	 CTD-2245C05	 CTD-2319F20	 1723	 159.114116	 2.22513479	 35	 1,	2,	3,	4,	5,	6,	7,	9,	10,	13,	14,	15,	16,	17,	18,	19,	20,	21,	24,	25,	26,	28,	29,	31,	32,	33,	34,	35,	37,	38,	40,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	58,	59,	60,	61,	62,	63,	65,	66,	67,	68,	70	8	 47943	 13106804	 0.05	 13.11	 RP11-130K11	 RP11-620F02	 136	 13.058861	 0.665458581	 9	 5,	6,	7,	9,	13,	15,	17,	18,	24,	29,	34,	35,	41,	43,	57,	60,	63,	68,	69	8	 18716135	 21822843	 18.72	 21.82	 RP11-533K07	 RP11-809O05	 27	 3.106708	 0.501427564	 4	 7,	13,	18,	32,	60	8	 23212697	 25059184	 23.21	 25.06	 RP11-791G08	 RP11-813A12	 16	 1.846487	 0.356606106	 4	 7,	13,	32,	60	8	 26806820	 27320758	 26.81	 27.32	 CTD-2525M09	 RP11-615F09	 3	 0.513938	 0.413685077	 3	 7,	13,	63	8	 29137731	 29891266	 29.14	 29.89	 RP11-755K01	 RP11-624F05	 7	 0.753535	 0.488284989	 4	 7,	13,	32,	46	8	 30697749	 146236289	 30.7	 146.24	 RP11-43L20	 CTD-2300I18	 1118	 115.53854	 3.993353515	 44	 1,	2,	4,	6,	7,	9,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	24,	25,	26,	27,	28,	29,	32,	33,	34,	35,	36,	37,	38,	40,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	54,	55,	57,	58,	59,	60,	61,	62,	63,	65,	66,	67,	68,	70	9	 34994	 141064884	 0.03	 141.06	 RP11-143M01	 RP11-35I18	 1218	 141.02989	 2.068997592	 27	 1,	2,	3,	4,	6,	7,	10,	11,	14,	15,	16,	17,	18,	19,	20,	21,	22,	23,	25,	26,	27,	28,	29,	31,	32,	33,	34,	35,	36,	37,	38,	40,	41,	42,	43,	44,	46,	47,	49,	50,	51,	52,	53,	54,	55,	58,	59,	60,	61,	62,	63,	65,	66,	67,	68,	69	10	 61001	 3088580	 0.06	 3.09	 RP11-631M21	 RP11-725K04	 29	 3.027579	 0.48554182	 9	 1,	4,	13,	17,	18,	34,	50,	57,	58,	68	10	 3494567	 5901314	 3.49	 5.9	 RP11-1I08	 RP11-731K06	 18	 2.406747	 0.393521328	 6	 15,	17,	40,	51,	53,	57	10	 6275766	 7028973	 6.28	 7.03	 RP11-712A03	 RP11-794B04	 6	 0.753207	 0.266994036	 6	 2,	17,	32,	46,	50,	51,	68	10	 8005458	 10173964	 8.01	 10.17	 RP11-554F11	 RP11-106B19	 20	 2.168506	 0.380288549	 8	 2,	13,	15,	32,	46,	50,	53,	57,	58,	68	10	 23548567	 24238211	 23.55	 24.24	 RP11-792P23	 RP11-48B07	 7	 0.689644	 0.31434998	 3	 50,	57,	68	10	 24308793	 26091560	 24.31	 26.09	 RP11-361I03	 RP11-307B23	 18	 1.782767	 0.400637432	 4	 15,	23,	57,	68	10	 34107288	 44916388	 34.11	 44.92	 RP11-452D04	 RP11-256K07	 82	 10.8091	 0.76735961	 13	 4,	7,	18,	21,	29,	35,	46,	47,	48,	50,	51,	57,	59,	65,	67,	68	10	 45557371	 52577659	 45.56	 52.58	 RP11-722B22	 RP11-564C04	 73	 7.020288	 0.496128966	 7	 1,	5,	7,	9,	17,	18,	29,	32,	34,	35,	41,	42,	48,	51,	54,	58,	59,	68	10	 65607081	 67729565	 65.61	 67.73	 RP11-33K18	 RP11-68A21	 30	 2.122484	 0.439270673	 3	 47,	48,	68	10	 82176524	 88179055	 82.18	 88.18	 RP11-137H02	 RP11-396M20	 60	 6.002531	 0.491472025	 6	 4,	18,	34,	47,	58,	65,	67,	68	10	 89602439	 91281166	 89.6	 91.28	 RP11-302L04	 RP11-168O10	 14	 1.678727	 0.502404128	 3	 49,	51,	53	10	 91492409	 92135173	 91.49	 92.14	 RP11-621C07	 RP11-155M14	 7	 0.642764	 0.357569713	 4	 47,	49,	53,	60	10	 106261774	 111600434	 106.26	 111.6	 RP11-389J06	 RP11-781K03	 48	 5.33866	 0.571199093	 9	 6,	9,	33,	34,	43,	46,	47,	61,	65,	68	10	 131746738	 135503747	 131.75	 135.5	 RP11-343L20	 RP11-1065F16	 46	 3.757009	 0.475334044	 13	 1,	2,	4,	7,	9,	13,	16,	18,	34,	43,	46,	55,	62,	65,	66,	68	11	 61992	 2984217	 0.06	 2.98	 RP11-505K21	 RP11-494F04	 26	 2.922225	 0.403611605	 6	 4,	7,	13,	17,	53,	54	
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11	 4291607	 6023702	 4.29	 6.02	 RP11-497E22	 RP11-236F24	 16	 1.732095	 0.391488602	 4	 35,	37,	50,	59	11	 12944351	 13698246	 12.94	 13.7	 RP11-756C18	 RP11-398N06	 6	 0.753895	 0.421913394	 4	 40,	44,	59,	66	11	 14459900	 15107078	 14.46	 15.11	 RP11-140L24	 RP11-39F19	 5	 0.647178	 0.386144856	 3	 46,	59,	66	11	 17338325	 19328882	 17.34	 19.33	 RP11-778E21	 RP11-118A14	 28	 1.990557	 0.457106749	 5	 4,	7,	18,	34,	59,	66	11	 20193789	 23568183	 20.19	 23.57	 RP11-281P10	 RP11-766K09	 39	 3.374394	 0.494882677	 3	 52,	66,	68	11	 23510130	 26248652	 23.51	 26.25	 RP11-713P14	 RP13-489D21	 32	 2.738522	 0.470125887	 4	 32,	36,	52,	68	11	 26223924	 27479986	 26.22	 27.48	 RP11-344L23	 RP11-426P16	 16	 1.256062	 0.340510175	 4	 29,	32,	51,	52,	66	11	 27601920	 29463648	 27.6	 29.46	 RP11-587D21	 RP11-186B03	 18	 1.861728	 0.405867786	 4	 29,	44,	52,	59	11	 29875329	 43984276	 29.88	 43.98	 RP11-610H21	 RP11-613D13	 178	 14.108947	 1.320791521	 12	 10,	18,	19,	20,	29,	31,	32,	34,	42,	46,	49,	50,	51,	52,	59,	61,	62,	65,	70	11	 44088185	 44652852	 44.09	 44.65	 RP11-367A11	 RP11-331J09	 5	 0.564667	 0.532207246	 3	 20,	42,	62	11	 45164617	 45598144	 45.16	 45.6	 RP11-10C06	 RP11-767K07	 4	 0.433527	 0.326281754	 4	 29,	42,	57,	65	11	 47992004	 61966826	 47.99	 61.97	 RP11-576I08	 RP11-135C04	 126	 13.974822	 0.434981499	 13	 13,	14,	22,	29,	32,	42,	43,	46,	50,	51,	52,	54,	55,	57,	59,	65,	66,	68,	70	11	 62361224	 77958238	 62.36	 77.96	 RP11-831H09	 RP11-757N22	 159	 15.597014	 0.665584667	 15	 2,	4,	7,	10,	13,	15,	16,	17,	18,	20,	21,	22,	26,	35,	43,	47,	48,	49,	50,	51,	54,	59,	60,	65,	67	11	 78234684	 85329115	 78.23	 85.33	 RP11-15N10	 RP11-29E15	 63	 7.094431	 0.548710051	 11	 2,	4,	7,	9,	26,	29,	43,	46,	48,	49,	50,	52,	65	11	 87163121	 94945815	 87.16	 94.95	 RP11-794H24	 RP11-814O09	 71	 7.782694	 0.475235111	 7	 29,	35,	46,	48,	49,	50,	59,	65	11	 95912006	 100415119	 95.91	 100.42	 RP11-775D16	 RP11-770L06	 67	 4.503113	 1.953602727	 4	 24,	41,	48,	51,	62,	65	11	 102220512	 103036596	 102.22	 103.04	 RP11-315O06	 RP11-556M24	 7	 0.816084	 0.72954447	 3	 4,	15,	48	11	 104619135	 105419323	 104.62	 105.42	 RP11-6A04	 RP11-113K16	 6	 0.800188	 0.69069457	 4	 4,	19,	36,	48	11	 114374412	 114920770	 114.37	 114.92	 RP11-56P08	 RP11-271A21	 7	 0.546358	 0.347939648	 3	 44,	59,	65	11	 117686824	 118283049	 117.69	 118.28	 RP11-16M20	 RP11-30E01	 6	 0.596225	 0.346077019	 5	 19,	22,	34,	51,	59	11	 118313325	 118688380	 118.31	 118.69	 RP11-606K01	 RP11-770K18	 3	 0.375055	 0.272050466	 3	 19,	51,	57	11	 119325390	 119956724	 119.33	 119.96	 RP11-305N23	 RP11-81I13	 7	 0.631334	 0.367976066	 3	 7,	17,	19	11	 127593564	 128155432	 127.59	 128.16	 RP11-334A15	 RP11-702B10	 4	 0.561868	 0.333445316	 4	 15,	42,	50,	53	11	 128746377	 130183754	 128.75	 130.18	 RP11-78O20	 RP11-567O18	 15	 1.437377	 0.537378394	 13	 2,	7,	14,	15,	19,	22,	29,	32,	44,	46,	50,	53,	63	11	 130890216	 134927296	 130.89	 134.93	 RP11-385B05	 CTD-2220K02	 54	 4.03708	 0.401992363	 8	 7,	9,	13,	19,	29,	34,	50,	59,	65	12	 147333	 5802366	 0.15	 5.8	 RP13-492B24	 RP11-935C02	 55	 5.655033	 0.593234079	 12	 1,	2,	4,	6,	7,	11,	13,	17,	19,	26,	28,	33,	34,	36,	51,	57	
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12	 7919642	 15002281	 7.92	 15	 RP11-815D16	 RP11-646J15	 65	 7.082639	 0.456712177	 13	 1,	11,	28,	32,	35,	36,	37,	42,	46,	49,	50,	51,	54,	58,	69	12	 16127352	 29680177	 16.13	 29.68	 RP11-660E21	 RP11-432N15	 144	 13.552825	 1.98118114	 7	 11,	20,	32,	36,	43,	47,	49,	51,	65,	68,	70	12	 32891528	 40994033	 32.89	 40.99	 RP11-8P13	 RP11-751O12	 50	 8.102505	 0.511615887	 13	 16,	28,	32,	37,	42,	43,	46,	47,	49,	50,	65,	66,	68,	70	12	 44729840	 45358854	 44.73	 45.36	 RP11-621G16	 RP11-37N21	 6	 0.629014	 0.459906891	 4	 2,	19,	34,	54	12	 45975170	 48023605	 45.98	 48.02	 RP11-352M15	 RP11-375L15	 23	 2.048435	 0.416938018	 16	 1,	2,	15,	19,	26,	31,	32,	34,	35,	37,	42,	49,	53,	54,	61,	65	12	 52450166	 53385624	 52.45	 53.39	 RP13-495C07	 RP11-358P20	 13	 0.935458	 0.539376159	 19	 2,	5,	7,	13,	15,	16,	17,	19,	21,	22,	32,	40,	44,	46,	49,	50,	61,	67,	68	12	 55580707	 56007952	 55.58	 56.01	 CTD-2155J10	 RP11-222A15	 7	 0.427245	 0.323812011	 3	 16,	32,	54	12	 58333587	 100191880	 58.33	 100.19	 RP11-549D07	 CTD-2100B23	 480	 41.858293	 1.121666297	 10	 3,	10,	14,	16,	24,	28,	29,	31,	32,	36,	38,	40,	41,	44,	47,	50,	51,	52,	53,	60,	65,	68	12	 102762669	 103119781	 102.76	 103.12	 RP11-609G15	 RP11-94M24	 3	 0.357112	 0.376039687	 3	 32,	38,	62	12	 107166205	 108819369	 107.17	 108.82	 RP11-115E09	 CTD-2360J23	 17	 1.653164	 0.398498175	 7	 4,	14,	16,	18,	21,	34,	38	12	 109632572	 133778461	 109.63	 133.78	 CTD-2375H07	 CTD-2140B24	 289	 24.145889	 0.883021614	 15	 2,	3,	4,	7,	9,	13,	14,	16,	18,	19,	21,	24,	26,	32,	33,	34,	35,	38,	49,	50,	54,	59,	62,	65,	66,	67,	68	13	 19021001	 20046229	 19.02	 20.05	 RP11-77P19	 RP11-304L17	 8	 1.025228	 0.312053755	 4	 10,	19,	38,	52	13	 20410455	 21325807	 20.41	 21.33	 RP11-214F12	 RP11-12J09	 9	 0.915352	 0.358773619	 3	 17,	38,	52	13	 24037554	 35887257	 24.04	 35.89	 RP11-111B21	 RP11-145J06	 119	 11.849703	 0.871299029	 5	 7,	16,	23,	38,	48,	50,	52,	70	13	 41066676	 43932764	 41.07	 43.93	 RP11-777F08	 RP11-90E20	 31	 2.866088	 0.417986575	 5	 29,	37,	38,	44,	52	13	 47392604	 48086401	 47.39	 48.09	 RP11-548H16	 RP11-71H01	 8	 0.693797	 0.431626736	 3	 10,	38,	52	13	 48698670	 51430949	 48.7	 51.43	 RP11-551P12	 RP11-556K02	 32	 2.732279	 0.628440023	 5	 7,	38,	52,	53,	58	13	 52396790	 64880535	 52.4	 64.88	 RP11-630I06	 RP11-808L13	 140	 12.483745	 0.942654168	 10	 2,	3,	15,	25,	27,	37,	38,	46,	47,	50,	52,	55,	65	13	 65662610	 115074090	 65.66	 115.07	 RP11-211D10	 RP11-228M06	 503	 49.41148	 0.692224554	 11	 1,	2,	7,	9,	10,	15,	18,	19,	27,	29,	32,	38,	40,	47,	48,	49,	50,	51,	52,	57,	60,	70	14	 19968167	 107246329	 19.97	 107.25	 RP11-262I20	 CTD-2313E03	 824	 87.278162	 0.745263642	 27	 1,	2,	4,	7,	9,	10,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	26,	29,	32,	34,	35,	37,	38,	40,	42,	43,	44,	46,	47,	49,	50,	51,	52,	53,	57,	58,	59,	61,	63,	65,	67,	68	15	 20013225	 35550245	 20.01	 35.55	 RP11-207G06	 RP11-456C02	 206	 15.53702	 0.654869132	 20	 1,	2,	4,	6,	7,	9,	10,	15,	18,	19,	29,	32,	33,	34,	37,	43,	46,	47,	48,	49,	50,	52,	53,	54,	58,	59,	60,	62,	65,	68	15	 44751723	 45602224	 44.75	 45.6	 RP11-474E01	 CTD-2026I02	 6	 0.850501	 0.39782822	 4	 33,	57,	63,	68	15	 45841171	 48434939	 45.84	 48.43	 RP11-583C18	 RP11-469D11	 27	 2.593768	 0.877560477	 3	 15,	57,	68	15	 50450216	 51064599	 50.45	 51.06	 RP11-691I09	 RP11-374G16	 5	 0.614383	 0.363075754	 3	 15,	57,	67	15	 52998847	 54270331	 53	 54.27	 RP11-99H18	 RP11-449M12	 13	 1.271484	 0.446342903	 5	 15,	16,	20,	57,	68	15	 58305690	 61419518	 58.31	 61.42	 CTD-2330J20	 RP11-450F24	 29	 3.113828	 0.448491349	 6	 2,	5,	15,	19,	46,	49,	57	
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15	 67473425	 102490914	 67.47	 102.49	 RP11-259J15	 CTD-2260A14	 355	 35.017489	 0.535732124	 9	 4,	5,	7,	10,	15,	18,	22,	23,	29,	31,	33,	34,	41,	44,	47,	48,	57,	59,	61,	62,	68	16	 61002	 15601794	 0.06	 15.6	 RP11-158D10	 RP11-32D19	 158	 15.540792	 0.494780449	 20	 1,	4,	7,	9,	10,	11,	13,	17,	18,	21,	26,	29,	34,	38,	40,	43,	48,	49,	50,	51,	53,	58,	61,	63,	65,	66,	67,	68,	70	16	 16134061	 19886992	 16.13	 19.89	 CTD-2205B05	 CTD-2380F24	 38	 3.752931	 0.423327117	 5	 20,	21,	29,	38,	48	16	 20230543	 29183623	 20.23	 29.18	 RP11-594K06	 RP11-658P06	 93	 8.95308	 1.115617903	 11	 7,	10,	18,	21,	29,	34,	36,	38,	50,	51,	65,	68	16	 29709174	 90044587	 29.71	 90.04	 RP11-683K05	 RP11-566K11	 642	 60.335413	 0.674227873	 30	 1,	2,	4,	5,	7,	9,	10,	13,	14,	15,	17,	18,	19,	20,	21,	22,	24,	26,	28,	29,	31,	32,	33,	34,	35,	37,	38,	40,	41,	43,	44,	46,	47,	49,	50,	51,	52,	53,	54,	55,	57,	58,	59,	62,	63,	65,	66,	68,	70	17	 5375783	 6360736	 5.38	 6.36	 CTD-2268J24	 RP11-574C18	 7	 0.984953	 0.363483735	 3	 1,	26,	68	17	 13149265	 14953744	 13.15	 14.95	 RP11-352N24	 RP11-621L14	 17	 1.804479	 0.470573595	 7	 32,	34,	43,	46,	58,	59,	61,	68	17	 15669333	 16352789	 15.67	 16.35	 RP11-683B12	 CTD-2270G10	 7	 0.683456	 0.603075716	 3	 43,	62,	68	17	 17096141	 18755715	 17.1	 18.76	 RP11-629P11	 RP11-466H01	 21	 1.659574	 0.64700027	 3	 4,	62,	68	17	 20030183	 26188600	 20.03	 26.19	 CTD-2022C07	 RP11-792K19	 42	 6.158417	 0.626032869	 10	 2,	4,	20,	21,	26,	32,	43,	46,	47,	50,	59,	62,	65,	66,	68	17	 31312257	 32596575	 31.31	 32.6	 RP11-626C08	 RP11-167D10	 15	 1.284318	 0.576437647	 5	 26,	47,	50,	58,	68	17	 32959600	 36342865	 32.96	 36.34	 RP11-141H10	 RP11-678G07	 35	 3.383265	 0.355041369	 8	 21,	26,	32,	47,	49,	50,	54,	58,	59	17	 37812835	 38050128	 37.81	 38.05	 RP11-94L15	 RP11-563O04	 3	 0.237293	 0.964529203	 3	 1,	41,	57	17	 38431459	 39913468	 38.43	 39.91	 RP11-686E05	 RP11-413E21	 16	 1.482009	 0.564096584	 14	 2,	9,	20,	21,	31,	32,	41,	43,	44,	50,	55,	57,	59,	68,	70	17	 44420395	 45764186	 44.42	 45.76	 RP11-57A24	 RP11-104O05	 14	 1.343791	 0.457337918	 4	 28,	47,	49,	61	17	 46343515	 46958617	 46.34	 46.96	 RP11-71G24	 RP13-635N19	 8	 0.615102	 0.348831813	 3	 28,	49,	66	17	 47072911	 47536003	 47.07	 47.54	 RP11-622D16	 RP11-36P02	 4	 0.463092	 0.354538058	 3	 28,	43,	49	17	 48395358	 81020949	 48.4	 81.02	 RP11-510P01	 RP11-196O11	 398	 32.625591	 1.097282425	 19	 2,	4,	7,	9,	10,	13,	15,	16,	18,	20,	21,	23,	26,	28,	29,	32,	33,	37,	40,	41,	43,	44,	46,	47,	49,	50,	57,	58,	59,	62,	63,	65,	66,	68	18	 29338	 21660283	 0.03	 21.66	 RP11-1035E02	 RP11-403A21	 205	 21.630945	 0.781644042	 17	 1,	16,	19,	21,	25,	26,	29,	32,	34,	35,	37,	40,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	57,	59,	65,	67,	68,	69,	70	18	 26883391	 27667351	 26.88	 27.67	 RP11-333K18	 RP11-26F22	 6	 0.78396	 0.389788096	 3	 42,	46,	50	18	 27654624	 29314490	 27.65	 29.31	 RP11-145P12	 RP11-549B18	 16	 1.659866	 0.561071686	 13	 2,	7,	13,	14,	19,	34,	40,	42,	43,	44,	46,	53,	63	18	 31439100	 32036804	 31.44	 32.04	 RP11-731A16	 RP11-504C02	 5	 0.597704	 0.447884389	 3	 36,	57,	70	18	 32882913	 34742934	 32.88	 34.74	 RP11-628B22	 RP11-645D05	 15	 1.860021	 0.378177129	 4	 5,	14,	44,	46	18	 35499959	 39378119	 35.5	 39.38	 RP11-25I24	 RP11-188I24	 37	 3.87816	 0.384164127	 3	 32,	46,	53	18	 43759383	 45508410	 43.76	 45.51	 RP11-434F16	 RP11-637E10	 20	 1.749027	 0.477648884	 7	 4,	13,	17,	44,	61,	65,	66	18	 48095633	 48827444	 48.1	 48.83	 RP11-10I06	 RP11-143A24	 6	 0.731811	 0.329156239	 3	 4,	17,	66	
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18	 52048101	 52767276	 52.05	 52.77	 RP11-22C15	 RP11-814G21	 7	 0.719175	 0.441622407	 4	 19,	32,	34,	66	18	 56878020	 57842452	 56.88	 57.84	 RP11-569D06	 RP11-598G07	 10	 0.964432	 0.359474445	 3	 23,	38,	66	18	 60956643	 61575789	 60.96	 61.58	 RP11-495C15	 CTD-2100L13	 7	 0.619146	 0.625742414	 14	 16,	19,	23,	29,	31,	32,	34,	43,	44,	46,	50,	53,	62,	66	18	 75830754	 77875127	 75.83	 77.88	 RP11-640M23	 RP11-565D23	 26	 2.044373	 0.430270454	 4	 5,	10,	18,	66	19	 124843	 2859481	 0.12	 2.86	 RP11-1149J04	 RP11-627B09	 25	 2.734638	 0.366444679	 5	 4,	14,	15,	23,	66	19	 2903607	 5671131	 2.9	 5.67	 CTD-2344O15	 RP11-621B11	 35	 2.767524	 0.404070144	 5	 4,	14,	33,	38,	57,	66	19	 6249888	 9883726	 6.25	 9.88	 RP11-114A07	 RP11-541L23	 44	 3.633838	 0.62158549	 20	 4,	6,	7,	9,	10,	14,	18,	20,	24,	26,	34,	37,	41,	43,	50,	58,	59,	61,	65,	66,	68	19	 19144831	 59077721	 19.14	 59.08	 RP11-88I12	 CTD-2575K21	 496	 39.93289	 1.191647039	 29	 2,	4,	6,	7,	10,	14,	15,	16,	19,	20,	21,	22,	23,	26,	29,	33,	34,	35,	36,	37,	40,	41,	42,	43,	44,	46,	48,	49,	50,	51,	54,	57,	58,	59,	61,	62,	65,	66,	67,	68,	70	20	 90210	 62964520	 0.09	 62.96	 CTD-2506E02	 RP11-476I15	 679	 62.87431	 0.965012721	 17	 1,	2,	4,	5,	6,	7,	9,	10,	11,	13,	14,	16,	17,	18,	19,	20,	21,	22,	26,	27,	29,	31,	32,	34,	35,	36,	37,	38,	40,	41,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	59,	60,	61,	62,	63,	65,	66,	67,	68,	69,	70	21	 10907345	 48102348	 10.91	 48.1	 RP11-733G18	 RP11-457P07	 386	 37.195003	 1.139911093	 17	 1,	2,	3,	4,	5,	10,	13,	14,	15,	18,	19,	20,	22,	31,	32,	33,	34,	35,	37,	42,	43,	44,	46,	47,	48,	49,	50,	51,	53,	54,	55,	57,	58,	60,	61,	62,	63,	65,	66,	67,	68,	70	22	 16061103	 51186519	 16.06	 51.19	 CTD-2177M20	 RP11-423E19	 361	 35.125416	 1.34742302	 35	 1,	2,	4,	5,	6,	7,	9,	10,	13,	14,	16,	17,	18,	20,	21,	23,	24,	25,	26,	28,	29,	32,	33,	34,	35,	37,	38,	40,	41,	42,	43,	44,	46,	47,	50,	51,	52,	55,	58,	59,	60,	63,	65,	66,	68,	69,	70	23	 629113	 8562898	 0.63	 8.56	 RP13-76L22	 RP11-730C18	 78	 7.933785	 0.541404418	 6	 4,	7,	17,	18,	23,	44,	50,	60,	66,	68,	70	23	 18725026	 19409102	 18.73	 19.41	 RP11-576K21	 RP11-393C11	 5	 0.684076	 0.313330137	 3	 23,	55,	60	23	 26883062	 28621303	 26.88	 28.62	 RP11-712B14	 RP11-183D14	 16	 1.738241	 0.42935711	 4	 4,	7,	16,	23,	44	23	 51344313	 87911436	 51.34	 87.91	 RP11-141O19	 RP11-268L07	 316	 36.567123	 0.860015012	 6	 4,	14,	19,	23,	26,	28,	40,	59,	68,	70	23	 88099830	 88408931	 88.1	 88.41	 RP11-356O04	 RP11-340A20	 3	 0.309101	 0.411721333	 3	 14,	26,	70	23	 88524501	 155186928	 88.52	 155.19	 RP11-946B20	 RP11-1245L19	 680	 66.662427	 0.984469755	 13	 4,	9,	10,	14,	15,	16,	17,	18,	19,	21,	22,	23,	24,	26,	29,	32,	40,	44,	46,	50,	52,	55,	58,	65,	66,	68,	69,	70	24	 2706160	 28818361	 2.71	 28.82	 CTD-2010M16	 RP11-1136L22	 210	 26.112201	 0.703399708	 12	 2,	5,	9,	10,	15,	17,	20,	28,	36,	38,	40,	41,	46,	50,	52,	55,	58,	59,	65,	66,	70	
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 chrom	 start	 end	 start.MB	 end.MB	 start.probe	 end.probe	 probes	 length	MB	 minM	 max.overlap	 cases	1	 11754	 40304501	 0.01	 40.3	 RP11-34P13	 RP11-428O04	 433	 40.292747	 -0.577042667	 25	 2,	5,	10,	11,	16,	18,	22,	25,	26,	29,	31,	32,	33,	34,	35,	36,	37,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	57,	58,	59,	60,	62,	65,	66,	67,	68	1	 41088453	 42130880	 41.09	 42.13	 RP11-644L15	 RP11-595K03	 9	 1.042427	 -0.338089113	 4	 21,	32,	52,	59	1	 47886660	 50886713	 47.89	 50.89	 RP11-165I13	 RP11-183G22	 26	 3.000053	 -0.637251807	 26	 2,	13,	15,	20,	22,	29,	32,	34,	35,	36,	37,	43,	44,	46,	47,	49,	50,	51,	52,	53,	54,	59,	62,	63,	66,	67,	68	1	 52757271	 58605591	 52.76	 58.61	 RP11-155O18	 RP11-684M24	 59	 5.84832	 -0.581023544	 29	 1,	2,	4,	7,	13,	14,	15,	19,	20,	22,	29,	32,	34,	35,	36,	37,	43,	44,	46,	47,	50,	51,	52,	54,	59,	63,	65,	66,	67,	68	1	 59127541	 62384029	 59.13	 62.38	 RP11-454N17	 RP11-138I13	 31	 3.256488	 -0.459433139	 11	 2,	14,	29,	34,	35,	37,	44,	50,	59,	65,	66,	67,	68	1	 64000689	 67074441	 64	 67.07	 RP11-384L12	 RP11-10D05	 27	 3.073752	 -0.606244428	 10	 2,	13,	15,	17,	26,	33,	34,	55,	57,	63,	66,	68	1	 67747278	 68820030	 67.75	 68.82	 RP11-102M16	 CTD-2220K05	 14	 1.072752	 -0.329665592	 8	 2,	26,	35,	36,	37,	43,	46,	63	1	 77667437	 78190107	 77.67	 78.19	 RP11-162L20	 RP11-607F18	 4	 0.52267	 -0.264578409	 3	 17,	36,	63	1	 81792341	 86526273	 81.79	 86.53	 RP11-159J16	 RP11-145E10	 47	 4.733932	 -0.344187626	 9	 2,	7,	17,	20,	34,	35,	46,	57,	65	1	 87045913	 88491973	 87.05	 88.49	 RP11-769G03	 RP11-105O04	 17	 1.44606	 -0.341753338	 5	 2,	15,	17,	57,	65	1	 88612382	 88875742	 88.61	 88.88	 RP11-410N03	 RP11-673G07	 3	 0.26336	 -0.203933284	 3	 17,	42,	57	1	 91388101	 92512834	 91.39	 92.51	 RP11-699D18	 RP11-762F06	 7	 1.124733	 -0.463687469	 12	 2,	15,	16,	17,	20,	21,	35,	37,	48,	57,	58,	65	1	 93862966	 97462576	 93.86	 97.46	 RP11-698E17	 RP11-643B10	 36	 3.59961	 -0.501349027	 10	 16,	17,	19,	34,	36,	37,	44,	46,	57,	58,	59	1	 97734363	 98611676	 97.73	 98.61	 CTD-2010F23	 RP11-630H20	 6	 0.877313	 -0.26222285	 4	 17,	43,	46,	57	1	 100337015	 101874916	 100.34	 101.87	 RP11-563H05	 RP11-97K09	 22	 1.537901	 -0.352819718	 4	 3,	17,	44,	57,	65	1	 103484087	 104498060	 103.48	 104.5	 RP11-299H17	 RP11-712C22	 8	 1.013973	 -0.418761755	 3	 17,	19,	38	1	 104819835	 106610652	 104.82	 106.61	 RP13-500L03	 RP11-361I06	 22	 1.790817	 -0.35908447	 3	 17,	19,	38	1	 107415517	 112723725	 107.42	 112.72	 RP11-601C04	 RP11-23P09	 50	 5.308208	 -0.481921208	 15	 1,	16,	17,	19,	20,	21,	29,	34,	37,	43,	44,	46,	57,	58,	59	1	 114244079	 149062561	 114.24	 149.06	 RP11-541A20	 RP11-264O15	 130	 34.818482	 -0.601484369	 19	 1,	2,	3,	4,	5,	7,	10,	13,	14,	15,	17,	18,	19,	20,	21,	29,	37,	38,	40,	48,	49,	50,	54,	57,	58,	61,	63,	65,	70	1	 149702537	 152131750	 149.7	 152.13	 RP11-437M17	 RP11-212D05	 25	 2.429213	 -0.324622185	 9	 6,	16,	29,	43,	46,	47,	61,	62,	68	1	 153406844	 156851480	 153.41	 156.85	 RP11-68O15	 RP11-711O18	 36	 3.444636	 -0.505500346	 12	 6,	16,	22,	29,	34,	37,	42,	44,	46,	47,	59,	61	1	 159963081	 160335378	 159.96	 160.34	 RP11-226L15	 RP11-735D24	 4	 0.372297	 -0.38308337	 5	 2,	16,	34,	37,	50	1	 161037190	 161375796	 161.04	 161.38	 RP11-749M10	 RP11-696E14	 3	 0.338606	 -0.352500715	 5	 9,	16,	21,	26,	34	
Table S2. Losses in 3 or more cases. Loss threshold = -0.08 
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1	 161718790	 163226305	 161.72	 163.23	 RP11-706D17	 RP11-267N12	 16	 1.507515	 -0.388013372	 6	 2,	9,	34,	43,	50,	61	1	 169572743	 171390841	 169.57	 171.39	 RP11-739J03	 RP11-562K10	 22	 1.818098	 -0.487242902	 18	 2,	10,	13,	14,	15,	18,	20,	29,	34,	37,	43,	44,	46,	50,	59,	61,	65,	67	1	 182452396	 184860006	 182.45	 184.86	 RP11-183H04	 RP11-703I24	 24	 2.40761	 -0.430818577	 16	 2,	6,	9,	13,	15,	18,	20,	29,	34,	37,	43,	44,	47,	50,	59,	67,	68	1	 200950047	 206769473	 200.95	 206.77	 RP11-119D06	 CTD-2003B03	 50	 5.819426	 -0.525140862	 20	 2,	6,	13,	15,	16,	20,	29,	32,	33,	34,	35,	37,	43,	44,	46,	47,	48,	50,	53,	59,	61,	67,	68	1	 207866179	 208668170	 207.87	 208.67	 RP11-512L01	 RP11-390D15	 9	 0.801991	 -0.407184398	 25	 2,	6,	13,	14,	16,	19,	20,	21,	28,	29,	34,	35,	37,	41,	42,	44,	46,	47,	50,	53,	59,	60,	61,	65,	67	1	 218499082	 219782534	 218.5	 219.78	 RP11-680C18	 RP11-638I01	 14	 1.283452	 -0.340660723	 7	 13,	14,	20,	34,	37,	50,	63	1	 225927823	 233201265	 225.93	 233.2	 RP11-139K15	 RP11-474C10	 72	 7.273442	 -0.468389999	 6	 16,	18,	29,	35,	37,	44,	47,	52,	53,	58,	63	1	 234526171	 235478470	 234.53	 235.48	 RP11-347H11	 RP11-37J02	 10	 0.952299	 -0.476409889	 17	 2,	6,	13,	18,	20,	26,	28,	29,	33,	34,	37,	44,	47,	48,	59,	67,	68	1	 241205353	 241524135	 241.21	 241.52	 RP11-124K15	 RP11-81A24	 3	 0.318782	 -0.258990562	 3	 13,	22,	35	2	 52662	 3409303	 0.05	 3.41	 CTD-2379H09	 RP11-763G15	 37	 3.356641	 -0.359472965	 11	 14,	16,	21,	36,	37,	40,	44,	49,	52,	53,	61,	67	2	 3386311	 4370913	 3.39	 4.37	 RP13-620F11	 RP11-607M20	 13	 0.984602	 -0.502707328	 4	 40,	49,	52,	53	2	 5174307	 13486333	 5.17	 13.49	 RP13-868N24	 CTD-2127D13	 80	 8.312026	 -0.443404529	 9	 7,	29,	31,	32,	34,	37,	40,	44,	47,	52,	53,	57,	58,	61,	67	2	 15682340	 16567680	 15.68	 16.57	 RP11-422A06	 RP11-62M03	 9	 0.88534	 -0.333046895	 3	 7,	31,	53	2	 18028135	 29375856	 18.03	 29.38	 CTD-2123N14	 RP11-131B07	 115	 11.347721	 -0.422193732	 21	 2,	7,	14,	18,	20,	21,	26,	29,	33,	34,	37,	46,	47,	48,	50,	52,	53,	55,	57,	58,	59,	61,	65,	66,	67,	68	2	 30192749	 31047442	 30.19	 31.05	 RP11-549I08	 CTD-2024L07	 8	 0.854693	 -0.34898989	 10	 2,	7,	20,	21,	29,	34,	37,	43,	50,	67	2	 32325617	 33960357	 32.33	 33.96	 RP11-78E13	 RP11-752B01	 17	 1.63474	 -0.346005811	 10	 2,	7,	16,	20,	21,	37,	46,	50,	65,	67	2	 35865068	 51515121	 35.87	 51.52	 RP11-119B15	 RP11-354L14	 166	 15.650053	 -0.611758996	 26	 2,	4,	7,	13,	14,	16,	17,	18,	20,	21,	22,	24,	26,	28,	29,	31,	32,	33,	34,	35,	36,	37,	44,	46,	48,	50,	52,	57,	58,	59,	61,	65,	66,	67,	68	2	 54087079	 56618241	 54.09	 56.62	 RP11-716H07	 RP11-745D12	 23	 2.531162	 -0.376701691	 5	 7,	17,	26,	58,	65	2	 63829452	 65403071	 63.83	 65.4	 RP11-240J03	 RP11-765O07	 17	 1.573619	 -0.360989468	 9	 17,	20,	21,	26,	29,	33,	55,	58,	65	2	 66554091	 70147528	 66.55	 70.15	 RP11-121M07	 RP11-388C11	 41	 3.593437	 -0.312175921	 5	 17,	22,	34,	37,	50,	67	2	 71605897	 72153371	 71.61	 72.15	 RP11-795D20	 RP11-24G22	 4	 0.547474	 -0.448733322	 8	 2,	17,	20,	21,	22,	32,	47,	53	2	 84912879	 88109724	 84.91	 88.11	 RP11-241M13	 RP11-517A04	 46	 3.196845	 -0.44391495	 15	 13,	16,	17,	18,	19,	21,	23,	29,	32,	33,	37,	40,	41,	43,	46,	47,	48,	55,	61,	65,	66	2	 91900277	 92325171	 91.9	 92.33	 CTD-2057P20	 CTD-2053H07	 8	 0.424894	 -0.342366793	 3	 5,	38,	49	2	 95327172	 95478047	 95.33	 95.48	 RP11-134N21	 RP11-641L06	 5	 0.150875	 -0.433780439	 3	 5,	38,	57	2	 100037583	 101963775	 100.04	 101.96	 RP11-622B21	 RP11-735I05	 14	 1.926192	 -0.278777888	 5	 16,	17,	34,	46,	68	2	 101989133	 103044035	 101.99	 103.04	 CTD-2055H10	 RP11-315O22	 10	 1.054902	 -0.496702805	 11	 13,	16,	17,	18,	29,	33,	40,	50,	55,	58,	65,	66	
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2	 104544974	 114425678	 104.54	 114.43	 RP11-792O24	 RP11-395L14	 96	 9.880704	 -0.45568963	 12	 5,	16,	17,	28,	32,	34,	36,	37,	40,	46,	47,	48,	57,	69	2	 121052413	 122097634	 121.05	 122.1	 RP11-1368G03	 RP11-795C01	 9	 1.045221	 -0.336046414	 8	 29,	32,	34,	36,	37,	42,	46,	48	2	 125259157	 126107022	 125.26	 126.11	 RP11-666M02	 RP11-465G21	 6	 0.847865	 -0.416474042	 3	 15,	26,	27	2	 127373726	 131146431	 127.37	 131.15	 RP11-48K07	 RP11-637N07	 38	 3.772705	 -0.30151319	 7	 16,	29,	32,	40,	42,	46,	51,	54	2	 132369895	 132994118	 132.37	 132.99	 RP11-611E16	 RP11-790H07	 8	 0.624223	 -0.28584957	 3	 17,	38,	40,	54	2	 133170796	 138612903	 133.17	 138.61	 RP11-1L22	 RP11-164L11	 54	 5.442107	 -0.501991779	 5	 3,	14,	17,	27,	29,	40,	54	2	 139114287	 148892579	 139.11	 148.89	 RP11-453M11	 RP11-626B14	 106	 9.778292	 -0.409212791	 19	 2,	7,	10,	13,	14,	16,	17,	18,	19,	20,	23,	24,	25,	29,	33,	37,	40,	46,	50,	54,	57,	65	2	 150458652	 166701980	 150.46	 166.7	 RP11-329H24	 RP11-603P03	 178	 16.243328	 -0.572458023	 8	 7,	11,	14,	16,	17,	26,	27,	33,	34,	35,	37,	50,	51,	54,	57,	66	2	 168204936	 168604205	 168.2	 168.6	 RP11-460N09	 RP11-799J14	 3	 0.399269	 -0.319708408	 3	 7,	20,	43	2	 173503229	 173933000	 173.5	 173.93	 RP11-184N02	 RP11-605G05	 3	 0.429771	 -0.322262373	 3	 2,	7,	54	2	 174423570	 181589238	 174.42	 181.59	 RP11-114P04	 RP11-742J19	 73	 7.165668	 -0.399907683	 10	 2,	7,	16,	17,	21,	23,	34,	35,	36,	48,	54,	57,	61,	65	2	 182738598	 184040459	 182.74	 184.04	 RP11-656I01	 RP11-443A24	 14	 1.301861	 -0.334909542	 7	 2,	7,	17,	43,	46,	50,	68	2	 185978613	 187233061	 185.98	 187.23	 RP11-263B22	 RP11-639N24	 12	 1.254448	 -0.304855285	 3	 7,	17,	35,	38	2	 188183556	 193025193	 188.18	 193.03	 RP11-483I19	 RP11-776K15	 50	 4.841637	 -0.432756387	 15	 2,	7,	13,	15,	16,	17,	18,	20,	21,	26,	34,	37,	43,	44,	46,	50,	58	2	 197788345	 243070770	 197.79	 243.07	 RP11-654I17	 RP11-1159G17	 507	 45.282425	 -0.854521284	 50	 1,	2,	4,	5,	6,	7,	9,	10,	11,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	23,	24,	25,	28,	29,	31,	32,	33,	34,	35,	36,	37,	40,	43,	44,	46,	47,	48,	49,	50,	52,	53,	54,	55,	57,	58,	59,	61,	62,	63,	65,	66,	67,	68,	69,	70	3	 72141	 90235200	 0.07	 90.24	 RP11-385A18	 CTD-2234G15	 947	 90.163059	 -0.695720032	 43	 1,	2,	4,	6,	7,	9,	10,	11,	13,	15,	16,	17,	18,	19,	20,	21,	22,	24,	26,	28,	29,	31,	32,	33,	34,	35,	36,	37,	38,	40,	41,	42,	43,	44,	46,	47,	48,	49,	50,	51,	53,	54,	55,	57,	58,	59,	61,	62,	63,	65,	66,	67,	68	3	 98376733	 102372630	 98.38	 102.37	 RP11-569H14	 RP11-495I11	 33	 3.995897	 -0.489181987	 24	 2,	6,	7,	13,	15,	19,	20,	22,	26,	29,	34,	35,	37,	41,	43,	44,	46,	50,	55,	58,	59,	61,	63,	67	3	 106741158	 107999767	 106.74	 108	 RP11-749B06	 RP11-590C16	 25	 1.258609	 -0.332823117	 4	 7,	13,	46,	59,	61	3	 111180266	 113506732	 111.18	 113.51	 RP11-489M05	 RP11-404I06	 37	 2.326466	 -0.447783751	 25	 1,	2,	7,	10,	13,	15,	17,	19,	22,	26,	29,	33,	34,	35,	37,	43,	44,	46,	47,	48,	50,	55,	58,	59,	61,	67	3	 113693367	 115811913	 113.69	 115.81	 RP11-681B14	 RP11-122J16	 23	 2.118546	 -0.408915614	 18	 1,	2,	7,	13,	18,	19,	20,	22,	26,	29,	33,	37,	46,	48,	61,	63,	65,	67	3	 122423432	 125250402	 122.42	 125.25	 RP11-276F11	 RP11-9M09	 27	 2.82697	 -0.6436394	 21	 2,	7,	15,	18,	19,	20,	28,	29,	33,	34,	35,	36,	37,	43,	44,	46,	48,	50,	53,	59,	61,	67	3	 125337486	 125798505	 125.34	 125.8	 RP11-766E07	 RP11-645I20	 7	 0.461019	 -0.250014924	 3	 19,	46,	49,	53	3	 127266343	 127750493	 127.27	 127.75	 RP11-109F07	 RP11-43P06	 9	 0.48415	 -0.354002998	 5	 37,	44,	46,	53,	61	3	 133341626	 134358544	 133.34	 134.36	 RP11-119I11	 RP11-230A11	 13	 1.016918	 -0.372259591	 7	 1,	15,	34,	37,	46,	48,	65	3	 139534090	 140585785	 139.53	 140.59	 RP11-313L21	 RP11-691G17	 13	 1.051695	 -0.35861052	 4	 19,	37,	44,	46	
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3	 140864281	 141432574	 140.86	 141.43	 RP11-149C06	 RP11-340E06	 10	 0.568293	 -0.413582436	 12	 6,	7,	13,	20,	29,	33,	37,	44,	48,	55,	59,	61	3	 148122650	 150114363	 148.12	 150.11	 RP11-621A01	 RP11-206C23	 34	 1.991713	 -0.439691042	 10	 7,	13,	20,	29,	34,	37,	44,	46,	59,	67	3	 151568533	 152431024	 151.57	 152.43	 RP11-118L18	 RP11-240G05	 10	 0.862491	 -0.465102016	 16	 2,	4,	6,	7,	13,	18,	20,	29,	33,	37,	44,	46,	50,	58,	59,	67	3	 155622372	 156421445	 155.62	 156.42	 RP11-706C11	 RP11-409C07	 7	 0.799073	 -0.340519916	 5	 21,	44,	46,	50,	67	3	 156923932	 157781414	 156.92	 157.78	 RP11-728C10	 RP11-796I01	 14	 0.857482	 -0.284900706	 3	 2,	44,	46	3	 177107658	 178137706	 177.11	 178.14	 RP11-649N02	 RP11-636E13	 7	 1.030048	 -0.294354753	 7	 1,	2,	7,	13,	44,	48,	50	3	 183147982	 184697591	 183.15	 184.7	 RP11-580E11	 RP11-673H19	 17	 1.549609	 -0.288343318	 9	 6,	13,	29,	35,	37,	44,	55,	59,	61,	62	3	 186448928	 188948716	 186.45	 188.95	 RP11-358N22	 RP11-501F24	 24	 2.499788	 -0.467716829	 6	 2,	6,	13,	29,	33,	44,	67	3	 193765675	 195494556	 193.77	 195.49	 RP11-612F19	 CTD-2348G10	 16	 1.728881	 -0.433646207	 7	 6,	19,	20,	29,	37,	44,	48,	59	4	 24423	 48773614	 0.02	 48.77	 RP11-116N15	 RP11-413C15	 536	 48.749191	 -0.966757906	 27	 2,	7,	14,	15,	16,	17,	19,	20,	21,	22,	29,	31,	32,	33,	34,	35,	36,	37,	38,	42,	44,	46,	47,	48,	49,	50,	53,	57,	58,	62,	65,	66,	67,	68,	70	4	 52682898	 59221227	 52.68	 59.22	 RP11-98B06	 RP11-622J01	 65	 6.538329	 -0.362073629	 5	 7,	17,	31,	38,	49,	68	4	 61437024	 62639962	 61.44	 62.64	 RP11-703E08	 RP11-815J05	 10	 1.202938	 -0.393745055	 3	 17,	38,	50	4	 68461278	 70824582	 68.46	 70.82	 RP11-714L24	 RP11-736K12	 23	 2.363304	 -0.409900183	 3	 17,	18,	38	4	 71837004	 135515180	 71.84	 135.52	 RP13-800C07	 CTD-2145F16	 594	 63.678176	 -0.605033011	 19	 2,	4,	7,	13,	15,	16,	17,	18,	20,	21,	28,	29,	32,	34,	37,	38,	43,	44,	46,	47,	48,	49,	50,	58,	59,	60,	65,	66,	67,	68	4	 136182077	 190899780	 136.18	 190.9	 RP11-102H15	 CTD-2011O21	 559	 54.717703	 -0.650086698	 27	 2,	6,	7,	9,	13,	14,	16,	17,	18,	20,	21,	22,	23,	29,	33,	34,	37,	38,	41,	43,	44,	46,	47,	49,	50,	58,	59,	61,	63,	65,	66,	67,	68,	70	5	 18263	 300202	 0.02	 0.3	 RP11-811I15	 CTD-2083E04	 5	 0.281939	 -0.269392286	 3	 7,	21,	32	5	 577391	 1449060	 0.58	 1.45	 RP11-753F19	 RP11-600M08	 8	 0.871669	 -0.390763444	 4	 21,	22,	32,	48	5	 10375665	 10790047	 10.38	 10.79	 RP11-736C06	 RP11-114H22	 6	 0.414382	 -0.403630693	 4	 6,	21,	37,	46	5	 14039229	 14678859	 14.04	 14.68	 RP11-683D22	 RP11-480P13	 8	 0.63963	 -0.347794654	 3	 21,	37,	50	5	 15310678	 15896886	 15.31	 15.9	 RP11-275B07	 RP11-262M24	 5	 0.586208	 -0.314186885	 5	 14,	21,	34,	37,	50	5	 21115348	 21569048	 21.12	 21.57	 RP11-627F13	 RP11-524H13	 4	 0.4537	 -0.285589984	 4	 7,	14,	28,	33	5	 21515070	 22521689	 21.52	 22.52	 RP11-350C05	 RP11-301A11	 10	 1.006619	 -0.312716049	 3	 7,	14,	21	5	 24571911	 24868676	 24.57	 24.87	 RP11-263K18	 RP11-797K20	 7	 0.296765	 -0.343257592	 4	 21,	37,	46,	51	5	 33063457	 33472261	 33.06	 33.47	 RP11-760C03	 RP11-369K20	 4	 0.408804	 -0.307507129	 3	 21,	37,	50	5	 33702512	 33967001	 33.7	 33.97	 RP11-94E06	 RP11-609A15	 4	 0.264489	 -0.247763688	 3	 21,	25,	37	5	 34366947	 34827296	 34.37	 34.83	 RP11-3M07	 CTD-2185N19	 5	 0.460349	 -0.310720378	 5	 16,	21,	25,	37,	50	
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5	 36083698	 36429829	 36.08	 36.43	 RP11-694C10	 RP11-131E15	 5	 0.346131	 -0.324023201	 3	 21,	43,	50	5	 38165093	 39065652	 38.17	 39.07	 RP11-709L16	 RP11-530D21	 17	 0.900559	 -0.449469454	 18	 13,	19,	20,	21,	22,	34,	35,	37,	43,	44,	46,	47,	49,	50,	51,	53,	59,	68	5	 39261297	 39692670	 39.26	 39.69	 RP11-79P22	 RP11-64M11	 10	 0.431373	 -0.377689523	 5	 13,	21,	37,	46,	50	5	 50023007	 50256774	 50.02	 50.26	 CTD-2380H16	 RP11-317O24	 4	 0.233767	 -0.239918773	 3	 7,	18,	50	5	 50570414	 50861195	 50.57	 50.86	 RP11-83A10	 RP11-709K18	 3	 0.290781	 -0.34138889	 3	 7,	44,	50	5	 52022652	 52330508	 52.02	 52.33	 RP11-596K13	 RP11-280C20	 6	 0.307856	 -0.445355199	 10	 7,	20,	21,	37,	44,	46,	48,	50,	59,	68	5	 52974912	 59893531	 52.97	 59.89	 RP11-772H18	 RP11-681M22	 136	 6.918619	 -0.421852042	 10	 7,	16,	18,	21,	22,	26,	32,	33,	35,	37,	44,	50,	51,	55,	58,	59,	62,	67	5	 60582320	 61171529	 60.58	 61.17	 RP11-631M06	 RP11-168H21	 8	 0.589209	 -0.42792369	 4	 7,	47,	65,	67	5	 63672721	 64742331	 63.67	 64.74	 RP11-350J03	 RP11-702C06	 22	 1.06961	 -0.374137912	 6	 7,	20,	33,	37,	43,	50	5	 65905288	 68472549	 65.91	 68.47	 RP11-2D09	 RP11-532N17	 45	 2.567261	 -0.391282368	 17	 7,	13,	14,	18,	20,	26,	33,	43,	44,	47,	50,	51,	58,	63,	65,	66,	67,	68	5	 68550505	 72491095	 68.55	 72.49	 RP11-600P06	 RP11-404A02	 40	 3.94059	 -0.475368105	 28	 2,	7,	13,	14,	16,	18,	19,	20,	21,	22,	26,	29,	33,	34,	35,	37,	43,	44,	46,	47,	50,	52,	59,	63,	65,	66,	67,	68	5	 76252214	 78371060	 76.25	 78.37	 RP11-372H22	 RP11-317M13	 23	 2.118846	 -0.453140751	 10	 7,	13,	14,	16,	21,	34,	41,	46,	52,	63	5	 80284278	 82997523	 80.28	 83	 RP11-80K05	 RP11-572A21	 40	 2.713245	 -0.41310169	 13	 2,	7,	16,	19,	20,	21,	33,	34,	44,	46,	59,	63,	65,	68	5	 87842051	 89521989	 87.84	 89.52	 RP11-619J08	 RP11-401N06	 26	 1.679938	 -0.424878095	 9	 2,	7,	13,	14,	15,	16,	20,	33,	34,	50,	59,	66	5	 90054874	 90769517	 90.05	 90.77	 RP11-143O04	 RP11-68F17	 12	 0.714643	 -0.335805192	 4	 7,	34,	58,	59	5	 94687895	 95826190	 94.69	 95.83	 RP11-127H18	 RP11-217L10	 14	 1.138295	 -0.316149391	 3	 7,	34,	50	5	 95860195	 96296204	 95.86	 96.3	 RP11-740A10	 RP11-691I18	 7	 0.436009	 -0.408408428	 4	 7,	26,	34,	61	5	 114461554	 118065766	 114.46	 118.07	 RP11-123L06	 RP11-335P11	 39	 3.604212	 -0.416374977	 10	 2,	7,	14,	20,	34,	36,	42,	44,	49,	50,	62	5	 121591126	 124331547	 121.59	 124.33	 RP11-59I01	 RP11-690H21	 41	 2.740421	 -0.322211125	 8	 2,	7,	14,	19,	34,	35,	37,	44,	50	5	 125596256	 125957381	 125.6	 125.96	 RP11-691J05	 RP11-44G23	 4	 0.361125	 -0.303857418	 5	 7,	37,	50,	61,	68	5	 126672722	 127667302	 126.67	 127.67	 RP11-231A11	 RP11-354D06	 26	 0.99458	 -0.417655734	 11	 2,	7,	14,	34,	37,	43,	44,	50,	58,	63,	67,	68	5	 129195848	 129722099	 129.2	 129.72	 RP11-470A15	 RP11-446I11	 6	 0.526251	 -0.344074045	 4	 7,	20,	44,	46	5	 133309859	 133787261	 133.31	 133.79	 RP11-586J15	 RP11-766F10	 8	 0.477402	 -0.261548544	 3	 7,	36,	68	5	 133734373	 133951403	 133.73	 133.95	 RP11-397H14	 RP11-64B11	 3	 0.21703	 -0.258289635	 3	 7,	59,	68	5	 135995592	 143329836	 136	 143.33	 RP11-455C12	 RP11-372C09	 104	 7.334244	 -0.569209803	 14	 2,	4,	7,	16,	18,	19,	21,	26,	29,	32,	33,	34,	36,	37,	43,	44,	46,	47,	51,	65	5	 146377135	 147206190	 146.38	 147.21	 RP11-359H09	 RP11-650P18	 16	 0.829055	 -0.494328045	 21	 2,	6,	7,	15,	16,	20,	21,	29,	34,	37,	44,	46,	47,	48,	50,	59,	61,	62,	65,	67,	68	
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5	 147749816	 156485286	 147.75	 156.49	 RP11-421C16	 RP11-641B02	 92	 8.73547	 -0.554641261	 20	 6,	7,	15,	16,	20,	21,	22,	26,	28,	29,	32,	34,	37,	44,	46,	47,	48,	50,	51,	52,	58,	59,	61,	62,	67	5	 156549869	 170252450	 156.55	 170.25	 RP11-155N22	 RP11-747F02	 153	 13.702581	 -0.523149965	 28	 2,	7,	13,	15,	16,	19,	20,	21,	22,	29,	32,	33,	34,	35,	37,	40,	42,	43,	44,	46,	47,	48,	49,	50,	51,	59,	61,	65,	66,	67,	68	5	 170747922	 173198321	 170.75	 173.2	 RP11-117L06	 RP11-317G04	 33	 2.450399	 -0.755718737	 39	 2,	4,	6,	7,	13,	14,	15,	16,	18,	20,	21,	22,	23,	26,	28,	29,	32,	33,	34,	35,	36,	37,	38,	41,	43,	44,	46,	47,	48,	50,	51,	55,	58,	59,	60,	61,	65,	66,	67,	68,	70	5	 173417502	 174999197	 173.42	 175	 RP11-9C14	 RP11-367A24	 26	 1.581695	 -0.314629175	 5	 7,	32,	37,	51,	62	5	 176736949	 177395511	 176.74	 177.4	 RP11-804I24	 RP11-423H02	 5	 0.658562	 -0.404506157	 3	 7,	32,	43	6	 1360029	 3607637	 1.36	 3.61	 RP11-737K22	 RP11-277I07	 22	 2.247608	 -0.395623354	 11	 6,	18,	21,	26,	29,	37,	43,	44,	47,	59,	61	6	 11057623	 12112799	 11.06	 12.11	 RP11-692B12	 RP11-101G19	 12	 1.055176	 -0.379002741	 11	 16,	20,	21,	25,	29,	44,	46,	55,	59,	61,	66	6	 15712163	 20293889	 15.71	 20.29	 RP11-798J17	 RP11-33L14	 52	 4.581726	 -0.358576871	 11	 1,	2,	16,	25,	34,	37,	41,	44,	46,	50,	51,	67,	68	6	 21682819	 23065077	 21.68	 23.07	 RP11-135G11	 RP11-659N17	 15	 1.382258	 -0.305163891	 3	 41,	46,	50	6	 24713086	 25521326	 24.71	 25.52	 RP11-264F19	 RP11-289G11	 9	 0.80824	 -0.361369477	 6	 4,	29,	33,	41,	61,	67	6	 25768481	 26614149	 25.77	 26.61	 RP11-634L01	 RP11-124D05	 8	 0.845668	 -0.420627418	 8	 4,	21,	26,	33,	55,	59,	61,	70	6	 29855456	 37991988	 29.86	 37.99	 RP11-192H11	 RP11-487A08	 93	 8.136532	 -0.566840272	 21	 6,	9,	13,	16,	21,	26,	29,	32,	33,	34,	37,	42,	44,	47,	50,	52,	55,	58,	59,	60,	61,	62,	67	6	 39117530	 41035270	 39.12	 41.04	 RP11-418F15	 RP11-504I10	 22	 1.91774	 -0.688464168	 7	 2,	32,	34,	44,	51,	52,	54	6	 41249867	 41687906	 41.25	 41.69	 RP11-380E17	 RP11-645B11	 4	 0.438039	 -0.373642954	 5	 22,	32,	34,	47,	67	6	 42373615	 44638034	 42.37	 44.64	 RP11-315O16	 RP11-61H05	 28	 2.264419	 -0.496286865	 14	 16,	21,	22,	28,	29,	32,	34,	37,	44,	47,	58,	59,	61,	67	6	 45616097	 48027679	 45.62	 48.03	 RP11-727H16	 RP11-1L16	 27	 2.411582	 -0.503828497	 26	 2,	4,	13,	14,	16,	18,	20,	21,	22,	28,	29,	34,	35,	37,	40,	43,	44,	46,	47,	48,	49,	50,	59,	62,	63,	67,	68	6	 51858231	 53167191	 51.86	 53.17	 RP11-21M13	 RP11-346A02	 11	 1.30896	 -0.318926549	 6	 4,	17,	20,	28,	46,	68	6	 53641713	 54210665	 53.64	 54.21	 RP11-492D07	 RP11-642N05	 5	 0.568952	 -0.268772684	 3	 4,	28,	46	6	 55048764	 57435033	 55.05	 57.44	 RP11-747H05	 RP11-102G20	 23	 2.386269	 -0.373489326	 14	 2,	4,	13,	18,	20,	21,	28,	34,	37,	44,	46,	50,	61,	63,	67	6	 69851005	 102377574	 69.85	 102.38	 RP11-669E01	 RP11-543M18	 363	 32.526569	 -0.491206471	 18	 2,	5,	7,	18,	19,	20,	21,	23,	26,	29,	35,	37,	40,	43,	46,	51,	52,	53,	54,	58,	59,	61,	65,	66	6	 104322788	 153125515	 104.32	 153.13	 CTD-2023D12	 RP11-107B11	 543	 48.802727	 -0.535228844	 37	 1,	2,	3,	4,	6,	7,	10,	13,	14,	15,	17,	18,	19,	20,	21,	22,	23,	26,	28,	29,	32,	34,	35,	37,	38,	43,	44,	46,	47,	48,	50,	52,	53,	54,	57,	58,	59,	61,	62,	65,	66,	67,	68	6	 154330058	 171008924	 154.33	 171.01	 RP11-514P04	 RP11-113J06	 189	 16.678866	 -0.51222393	 12	 7,	15,	19,	23,	32,	34,	36,	37,	40,	47,	48,	50,	52,	53,	55,	58,	61,	65,	66,	67,	68	7	 10239	 2985552	 0.01	 2.99	 CTD-2245C05	 RP11-319L03	 34	 2.975313	 -0.445277683	 10	 6,	21,	29,	32,	37,	44,	46,	47,	48,	50	7	 3795766	 5068948	 3.8	 5.07	 RP11-501K15	 RP11-152I05	 9	 1.273182	 -0.341628952	 3	 32,	50,	51	7	 11560728	 11940594	 11.56	 11.94	 RP11-374F13	 RP11-188M10	 5	 0.379866	 -0.366454867	 4	 15,	18,	20,	48	7	 15012028	 18759415	 15.01	 18.76	 RP11-801J01	 RP11-669C22	 39	 3.747387	 -0.371922285	 13	 4,	7,	15,	17,	18,	20,	21,	23,	34,	36,	44,	46,	58,	59,	63,	65	
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7	 25163654	 25964014	 25.16	 25.96	 RP11-1151M13	 RP11-99O17	 9	 0.80036	 -0.37630954	 3	 34,	50,	67	7	 27138200	 29161368	 27.14	 29.16	 RP13-266D12	 RP11-306F13	 23	 2.023168	 -0.304513248	 5	 22,	37,	48,	50,	53,	67	7	 30697883	 31207273	 30.7	 31.21	 RP11-446A08	 RP11-666D11	 5	 0.50939	 -0.449239554	 5	 34,	37,	53,	67,	70	7	 33678850	 34189600	 33.68	 34.19	 RP11-414O15	 RP11-628G02	 4	 0.51075	 -0.385018413	 4	 34,	43,	50,	70	7	 35713927	 37857595	 35.71	 37.86	 RP11-49G18	 RP11-113M01	 18	 2.143668	 -0.397568143	 3	 17,	66,	70	7	 43906597	 44689770	 43.91	 44.69	 RP11-800O18	 RP11-264K24	 10	 0.783173	 -0.347616947	 4	 6,	21,	37,	70	7	 46729868	 48149182	 46.73	 48.15	 RP11-651K08	 RP11-454K18	 17	 1.419314	 -0.31658723	 5	 6,	37,	46,	68,	70	7	 50674850	 51294533	 50.67	 51.29	 RP11-360K19	 RP11-801F12	 5	 0.619683	 -0.324440375	 3	 2,	51,	70	7	 54988969	 55519498	 54.99	 55.52	 RP11-781C22	 RP11-788K14	 4	 0.530529	 -0.452486375	 4	 3,	50,	55,	58	7	 57055292	 57557880	 57.06	 57.56	 RP11-511E02	 RP11-415F22	 11	 0.502588	 -0.309470872	 4	 44,	48,	49,	51	7	 64981539	 65285677	 64.98	 65.29	 RP11-124K05	 RP11-479O09	 9	 0.304138	 -0.325169964	 4	 4,	5,	7,	10	7	 66913997	 71183425	 66.91	 71.18	 RP13-839K18	 RP11-332E12	 39	 4.269428	 -0.332383185	 9	 1,	2,	3,	7,	15,	49,	51,	57,	65,	66	7	 72309174	 76303376	 72.31	 76.3	 RP11-1328G23	 RP11-122A05	 55	 3.994202	 -0.380274513	 13	 6,	7,	20,	29,	32,	37,	46,	47,	53,	57,	58,	59,	65,	70	7	 76873748	 80296971	 76.87	 80.3	 RP11-764I16	 RP11-764E04	 38	 3.423223	 -0.355349019	 4	 7,	46,	57,	70	7	 81074962	 82156396	 81.07	 82.16	 RP11-284I24	 RP11-560N24	 11	 1.081434	 -0.322683819	 5	 2,	7,	22,	46,	70	7	 90631840	 96694909	 90.63	 96.69	 RP11-291D21	 RP11-2N22	 52	 6.063069	 -0.379181951	 6	 2,	3,	7,	20,	21,	44,	50,	51,	66,	70	7	 105620341	 108125311	 105.62	 108.13	 RP11-193P05	 RP11-522C18	 30	 2.50497	 -0.518913921	 11	 2,	4,	7,	29,	33,	43,	48,	50,	57,	58,	65,	67,	70	7	 110484565	 112220641	 110.48	 112.22	 RP11-495O08	 RP11-397O20	 15	 1.736076	 -0.386581079	 4	 7,	34,	68,	70	7	 113602818	 159124355	 113.6	 159.12	 RP11-658L17	 CTD-2319F20	 498	 45.521537	 -0.526926206	 23	 2,	4,	6,	7,	13,	15,	16,	17,	18,	19,	20,	21,	22,	25,	28,	29,	32,	33,	34,	35,	36,	37,	43,	44,	46,	47,	48,	49,	50,	51,	53,	54,	57,	58,	59,	61,	65,	66,	67,	68,	70	8	 47943	 46943297	 0.05	 46.94	 RP11-130K11	 CTD-2326I15	 454	 46.895354	 -0.663577159	 31	 1,	2,	4,	6,	14,	16,	17,	19,	20,	21,	22,	23,	26,	27,	29,	32,	34,	35,	36,	37,	38,	40,	41,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	59,	61,	62,	63,	65,	67,	68,	69,	70	8	 48218237	 49834597	 48.22	 49.83	 RP11-198I06	 RP11-782N19	 19	 1.61636	 -0.532706303	 5	 18,	20,	29,	37,	50	8	 68776046	 70767835	 68.78	 70.77	 RP11-54K18	 RP11-347D13	 22	 1.991789	 -0.487531205	 7	 2,	20,	34,	37,	46,	50,	68	8	 87113574	 87313943	 87.11	 87.31	 RP13-736G20	 CTD-2210G22	 3	 0.200369	 -0.247146902	 3	 19,	50,	51	8	 91529095	 92483239	 91.53	 92.48	 RP11-127D04	 RP11-353D05	 15	 0.954144	 -0.330430591	 3	 19,	50,	51	8	 92930254	 94756066	 92.93	 94.76	 RP11-118O08	 RP11-633M24	 16	 1.825812	 -0.395028001	 6	 35,	37,	46,	50,	51,	68	8	 97231822	 100325317	 97.23	 100.33	 RP11-387M09	 RP11-281D17	 23	 3.093495	 -0.464155442	 9	 20,	21,	35,	37,	46,	50,	51,	61,	63,	68	
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8	 121054045	 121761287	 121.05	 121.76	 RP11-192N11	 RP11-448F01	 4	 0.707242	 -0.280584473	 3	 34,	46,	68	8	 131446919	 131736519	 131.45	 131.74	 RP11-615N16	 CTD-2178K13	 3	 0.2896	 -0.272682086	 3	 37,	59,	65	8	 141314573	 141797233	 141.31	 141.8	 RP11-613F12	 CTD-2190C07	 4	 0.48266	 -0.22486971	 3	 20,	37,	46	8	 144413179	 146236289	 144.41	 146.24	 RP11-909N17	 CTD-2300I18	 17	 1.82311	 -0.322867848	 5	 32,	37,	46,	47,	53	9	 34994	 10502170	 0.03	 10.5	 RP11-143M01	 RP11-702P22	 102	 10.467176	 -0.564516914	 10	 18,	19,	25,	27,	29,	38,	40,	46,	50,	57,	59,	62,	66	9	 11971439	 21535271	 11.97	 21.54	 RP11-361B13	 RP11-354P17	 103	 9.563832	 -0.482077338	 31	 2,	6,	13,	16,	18,	20,	21,	22,	23,	29,	33,	34,	35,	37,	38,	41,	43,	44,	46,	47,	48,	50,	52,	53,	57,	58,	59,	61,	62,	63,	65,	66,	67,	68	9	 21653777	 22897577	 21.65	 22.9	 RP11-328C02	 RP11-275H17	 10	 1.2438	 -0.442626767	 4	 37,	38,	52,	55,	66	9	 26491031	 28339527	 26.49	 28.34	 RP11-621I07	 RP11-133E06	 16	 1.848496	 -0.373904024	 5	 29,	38,	58,	65,	66	9	 28810762	 29296469	 28.81	 29.3	 RP11-606L07	 RP11-607P10	 6	 0.485707	 -0.240706951	 3	 23,	38,	66	9	 31821164	 36548166	 31.82	 36.55	 RP11-145C22	 RP11-58A20	 44	 4.727002	 -0.412525457	 23	 1,	2,	6,	13,	16,	19,	21,	29,	32,	37,	38,	43,	44,	46,	47,	57,	58,	59,	61,	62,	65,	66,	67	9	 36625615	 74327597	 36.63	 74.33	 RP11-8N06	 RP11-66I21	 124	 37.701982	 -0.467068336	 10	 2,	4,	5,	13,	15,	23,	26,	29,	38,	44,	46,	47,	50,	52,	54,	57,	58,	66,	68,	70	9	 75166027	 75795575	 75.17	 75.8	 RP11-641G15	 RP11-459G03	 5	 0.629548	 -0.233030121	 4	 34,	44,	57,	66	9	 76709711	 80905745	 76.71	 80.91	 CTD-2009M14	 RP11-336N08	 48	 4.196034	 -0.385240168	 9	 3,	13,	17,	18,	29,	35,	44,	46,	50,	57,	66	9	 83762917	 85310589	 83.76	 85.31	 RP11-66D01	 RP11-267O11	 16	 1.547672	 -0.391356769	 4	 34,	52,	57,	66	9	 88729921	 90066771	 88.73	 90.07	 CTD-2005C06	 RP11-815C20	 13	 1.33685	 -0.283049234	 6	 5,	37,	50,	57,	66,	68	9	 91181836	 92942046	 91.18	 92.94	 RP13-60M05	 RP11-193J18	 18	 1.76021	 -0.466729149	 13	 2,	13,	21,	25,	29,	34,	37,	46,	48,	50,	57,	66,	68	9	 97268148	 99545487	 97.27	 99.55	 RP11-139A17	 RP11-354D18	 24	 2.277339	 -0.593958584	 13	 26,	29,	33,	35,	37,	40,	43,	44,	46,	50,	58,	59,	66,	68	9	 101451036	 102633580	 101.45	 102.63	 RP11-785N18	 RP11-624K13	 11	 1.182544	 -0.561145881	 6	 13,	52,	57,	59,	66,	68	9	 110205341	 114467650	 110.21	 114.47	 RP11-150J11	 RP11-450J06	 51	 4.262309	 -0.377281593	 8	 6,	21,	26,	29,	33,	38,	44,	46,	47,	58,	61,	66	9	 115750385	 119690477	 115.75	 119.69	 RP11-349F12	 RP11-355H18	 38	 3.940092	 -0.521313298	 18	 4,	6,	16,	18,	20,	21,	29,	32,	34,	37,	38,	44,	46,	47,	50,	53,	57,	58,	59,	60,	61,	66	9	 119767340	 122943786	 119.77	 122.94	 CTD-2355J09	 RP11-168F17	 37	 3.176446	 -0.350301509	 3	 38,	40,	66	9	 123054774	 125149063	 123.05	 125.15	 RP11-627D03	 RP11-498E02	 19	 2.094289	 -0.366580777	 7	 21,	29,	37,	40,	44,	57,	61,	66	9	 126188492	 140705814	 126.19	 140.71	 RP11-318N17	 RP11-807E24	 155	 14.517322	 -0.595298888	 25	 6,	13,	15,	16,	17,	18,	19,	21,	22,	28,	29,	32,	33,	34,	35,	36,	37,	40,	43,	44,	46,	47,	48,	50,	52,	53,	55,	58,	59,	61,	65,	66,	68	10	 61001	 38291858	 0.06	 38.29	 RP11-631M21	 CTD-2651O11	 391	 38.230857	 -0.501259202	 27	 1,	2,	4,	5,	7,	10,	13,	14,	16,	18,	19,	20,	21,	23,	26,	27,	29,	31,	32,	33,	34,	35,	37,	38,	42,	43,	44,	46,	47,	48,	50,	54,	55,	58,	59,	61,	62,	63,	65,	66,	67,	68	10	 43498972	 54827526	 43.5	 54.83	 RP11-669H09	 RP11-640D24	 129	 11.328554	 -0.557874331	 31	 1,	2,	5,	10,	13,	14,	15,	16,	17,	18,	19,	20,	21,	23,	26,	29,	31,	32,	34,	36,	37,	38,	40,	41,	43,	44,	46,	49,	50,	52,	53,	62,	63,	65,	67,	68,	70	10	 59641813	 65981757	 59.64	 65.98	 RP11-777I20	 RP11-37M19	 59	 6.339944	 -0.524147431	 19	 2,	4,	10,	13,	14,	16,	18,	20,	26,	29,	32,	34,	36,	37,	38,	43,	44,	46,	50,	55,	59,	65,	67	
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10	 70268698	 82435403	 70.27	 82.44	 RP11-45E10	 RP11-635P19	 132	 12.166705	 -0.656922955	 36	 1,	2,	5,	7,	10,	13,	14,	15,	16,	17,	19,	20,	21,	22,	26,	28,	29,	31,	32,	34,	35,	36,	37,	38,	40,	41,	44,	46,	47,	48,	49,	50,	52,	53,	54,	55,	59,	62,	67,	68,	69	10	 84740995	 135503747	 84.74	 135.5	 RP11-99I12	 RP11-1065F16	 497	 50.762752	 -0.64283438	 27	 2,	4,	5,	6,	7,	9,	10,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	24,	26,	27,	29,	31,	32,	33,	34,	36,	37,	38,	40,	41,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	55,	58,	59,	60,	61,	65,	66,	67,	68	11	 61992	 23146871	 0.06	 23.15	 RP11-505K21	 RP11-379A20	 253	 23.084879	 -0.609157975	 29	 2,	4,	6,	7,	10,	13,	14,	16,	17,	18,	20,	21,	26,	28,	31,	32,	33,	34,	36,	37,	43,	44,	46,	47,	48,	49,	50,	52,	53,	54,	57,	58,	59,	62,	63,	65,	66,	67,	68,	69,	70	11	 25284276	 36913581	 25.28	 36.91	 RP11-121N14	 RP11-639N13	 152	 11.629305	 -0.583872279	 12	 2,	4,	13,	14,	16,	18,	21,	26,	29,	32,	33,	34,	35,	37,	44,	46,	49,	55,	57,	58,	65,	66,	67,	70	11	 39527278	 40544511	 39.53	 40.54	 RP11-666M24	 CTD-2333N07	 12	 1.017233	 -0.393971824	 3	 14,	51,	70	11	 41639872	 42644389	 41.64	 42.64	 RP11-598E10	 RP11-687J20	 11	 1.004517	 -0.277117343	 3	 27,	51,	70	11	 43682815	 48027402	 43.68	 48.03	 RP11-701A18	 RP11-449K10	 50	 4.344587	 -0.568979867	 17	 2,	6,	14,	16,	29,	32,	34,	36,	37,	44,	46,	47,	53,	61,	62,	67,	68,	70	11	 56717658	 57577825	 56.72	 57.58	 CTD-2112J16	 RP11-679G21	 9	 0.860167	 -0.285889841	 5	 14,	21,	32,	37,	65	11	 60665323	 134927296	 60.67	 134.93	 RP11-565O16	 CTD-2220K02	 762	 74.261973	 -0.767174864	 38	 2,	5,	6,	7,	9,	10,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	23,	25,	26,	28,	29,	31,	32,	33,	34,	35,	36,	37,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	58,	59,	60,	61,	63,	65,	66,	67,	68,	69,	70	12	 147333	 31123983	 0.15	 31.12	 RP13-492B24	 RP11-138B05	 324	 30.97665	 -0.570974663	 32	 1,	2,	6,	7,	10,	14,	15,	16,	17,	20,	21,	23,	29,	31,	32,	33,	34,	35,	37,	38,	43,	44,	46,	47,	48,	50,	51,	52,	53,	57,	58,	59,	60,	61,	62,	65,	67,	68,	69	12	 31311941	 32024978	 31.31	 32.02	 RP11-48N06	 RP11-765A12	 6	 0.713037	 -0.254969352	 3	 23,	48,	53	12	 33739612	 34559060	 33.74	 34.56	 RP11-102G23	 RP11-396K20	 8	 0.819448	 -0.287238651	 3	 23,	38,	53	12	 40933167	 41980332	 40.93	 41.98	 RP11-180A23	 RP11-413B19	 13	 1.047165	 -0.371858555	 7	 2,	14,	35,	38,	44,	50,	68	12	 46445013	 47112104	 46.45	 47.11	 RP11-145H24	 RP11-755G20	 6	 0.667091	 -0.342756615	 3	 14,	18,	50	12	 47932695	 50810405	 47.93	 50.81	 RP11-805N11	 CTD-2103G15	 35	 2.87771	 -0.443542974	 9	 14,	16,	29,	34,	44,	47,	48,	53,	59,	68	12	 52051871	 55251462	 52.05	 55.25	 RP11-260F08	 RP11-579D07	 48	 3.199591	 -0.430831329	 18	 7,	9,	14,	20,	21,	22,	26,	29,	35,	38,	44,	46,	47,	48,	50,	58,	59,	61,	67,	68	12	 55839028	 59647181	 55.84	 59.65	 RP11-222A15	 RP11-762C22	 49	 3.808153	 -0.433538848	 11	 7,	17,	18,	21,	29,	37,	38,	44,	47,	50,	58,	59,	61,	63,	68	12	 59840694	 60293103	 59.84	 60.29	 RP13-504M09	 RP11-41H06	 5	 0.452409	 -0.247641431	 3	 17,	38,	65	12	 62936437	 63138871	 62.94	 63.14	 RP11-151H22	 RP11-116C08	 4	 0.202434	 -0.352570513	 3	 17,	29,	65	12	 67973690	 71070281	 67.97	 71.07	 RP11-43N05	 RP11-239F06	 36	 3.096591	 -0.304881414	 7	 17,	29,	34,	44,	47,	50,	58,	68	12	 76829202	 77464388	 76.83	 77.46	 RP11-347C05	 RP11-669B18	 7	 0.635186	 -0.287580323	 3	 17,	50,	65	12	 79655563	 82754360	 79.66	 82.75	 RP11-648H15	 RP11-136P03	 28	 3.098797	 -0.342020421	 7	 15,	17,	37,	44,	46,	50,	65,	67,	68	12	 89228817	 97166879	 89.23	 97.17	 RP11-651M05	 RP11-440E03	 89	 7.938062	 -0.460888697	 21	 1,	2,	4,	10,	13,	15,	17,	18,	20,	25,	28,	29,	33,	34,	37,	44,	48,	50,	59,	61,	63,	65,	66,	67	12	 102622583	 107274997	 102.62	 107.27	 RP11-170O02	 RP11-380E20	 43	 4.652414	 -0.376407094	 22	 1,	2,	10,	13,	17,	18,	20,	21,	26,	27,	29,	34,	36,	37,	41,	44,	50,	57,	58,	59,	61,	65,	66,	67	12	 108671001	 108844800	 108.67	 108.84	 CTD-2360J23	 RP11-558G19	 3	 0.173799	 -0.434531246	 3	 21,	34,	35	
	 178	
12	 109019838	 111047137	 109.02	 111.05	 RP11-689B22	 RP11-705H09	 24	 2.027299	 -0.324629578	 10	 6,	14,	20,	21,	29,	34,	42,	50,	59,	61,	65	12	 114564673	 117428067	 114.56	 117.43	 RP11-540B21	 RP11-709C19	 44	 2.863394	 -0.33874467	 7	 6,	20,	21,	34,	35,	49,	59,	65,	66,	68	12	 118973631	 119792401	 118.97	 119.79	 RP11-121J20	 RP11-410F12	 12	 0.81877	 -0.294579521	 3	 6,	11,	50,	51	12	 120578966	 125583558	 120.58	 125.58	 RP11-144B02	 RP11-751F21	 63	 5.004592	 -0.530572562	 22	 6,	10,	16,	18,	21,	22,	24,	29,	32,	33,	34,	35,	37,	44,	46,	47,	48,	50,	53,	59,	60,	61,	65,	66,	67	12	 130872757	 133778461	 130.87	 133.78	 RP11-803C14	 CTD-2140B24	 27	 2.905704	 -0.370427283	 14	 20,	21,	29,	31,	32,	35,	37,	44,	47,	49,	50,	51,	53,	54,	59	13	 20608536	 28261026	 20.61	 28.26	 RP11-717M17	 RP11-422B07	 74	 7.65249	 -0.524521815	 18	 1,	2,	13,	14,	16,	17,	19,	21,	34,	37,	48,	49,	50,	55,	58,	66,	68,	70	13	 28707025	 82548396	 28.71	 82.55	 RP11-192E10	 RP11-678K11	 576	 53.841371	 -0.562912297	 22	 1,	2,	10,	14,	15,	16,	17,	18,	19,	20,	21,	23,	24,	26,	28,	32,	33,	34,	37,	41,	42,	43,	44,	46,	49,	50,	51,	57,	58,	59,	63,	65,	66,	68,	70	13	 84797715	 86067566	 84.8	 86.07	 RP11-738N24	 RP11-390B15	 14	 1.269851	 -0.31034291	 3	 14,	17,	70	13	 86469131	 115074090	 86.47	 115.07	 RP11-484I24	 RP11-228M06	 289	 28.604959	 -0.52903494	 22	 2,	6,	14,	15,	16,	17,	20,	21,	23,	25,	31,	32,	33,	34,	35,	36,	37,	41,	44,	47,	49,	53,	58,	59,	61,	65,	66,	67,	68,	70	14	 20599413	 21375578	 20.6	 21.38	 RP11-621J03	 RP11-219E07	 9	 0.776165	 -0.277383368	 3	 13,	48,	55	14	 26252698	 31525385	 26.25	 31.53	 RP11-684D03	 RP11-426H12	 44	 5.272687	 -0.364419713	 5	 3,	7,	13,	15,	48	14	 44568797	 45608954	 44.57	 45.61	 RP11-814F16	 RP11-777E01	 7	 1.040157	 -0.406043547	 4	 21,	53,	65,	68	14	 50031538	 57091731	 50.03	 57.09	 CTD-2009G12	 RP11-624J12	 60	 7.060193	 -0.365249496	 8	 18,	29,	32,	46,	50,	58,	59,	65	14	 59231415	 60603492	 59.23	 60.6	 RP11-103C06	 RP11-325E04	 12	 1.372077	 -0.380199021	 4	 11,	46,	50,	57	14	 61681879	 62194424	 61.68	 62.19	 RP11-440E11	 RP11-607N18	 4	 0.512545	 -0.401182409	 4	 17,	29,	33,	57	14	 65067058	 65337745	 65.07	 65.34	 RP11-3I06	 RP11-700L24	 3	 0.270687	 -0.328868068	 3	 35,	57,	59	14	 66586716	 78202458	 66.59	 78.2	 RP11-50H07	 RP11-809C19	 113	 11.615742	 -0.461899715	 22	 4,	6,	13,	16,	17,	18,	20,	26,	29,	32,	33,	35,	37,	38,	44,	46,	48,	50,	53,	55,	57,	58,	59,	61,	63,	65,	66,	67,	68	14	 80624207	 81630568	 80.62	 81.63	 RP11-198A06	 RP11-426D12	 10	 1.006361	 -0.363127209	 3	 15,	57,	61	14	 84144667	 84993742	 84.14	 84.99	 RP11-715L20	 RP11-259M05	 9	 0.849075	 -0.354806367	 4	 2,	15,	29,	57	14	 89839889	 97367766	 89.84	 97.37	 RP11-33N16	 RP11-805E15	 71	 7.527877	 -0.396440136	 5	 32,	47,	50,	57,	59,	61	14	 99683934	 106429899	 99.68	 106.43	 RP11-594K17	 RP11-84H09	 71	 6.745965	 -0.461366895	 4	 21,	32,	47,	48,	57	15	 20013225	 45490634	 20.01	 45.49	 RP11-207G06	 RP11-51I03	 311	 25.477409	 -0.66406105	 16	 2,	5,	13,	14,	19,	20,	21,	24,	26,	31,	32,	34,	37,	46,	47,	48,	49,	50,	51,	54,	59,	63,	65,	70	15	 46152098	 46902823	 46.15	 46.9	 RP11-775E07	 RP11-69G20	 6	 0.750725	 -0.275336627	 3	 2,	21,	54	15	 47348697	 86551516	 47.35	 86.55	 RP11-90J19	 RP11-692H04	 384	 39.202819	 -1.256137386	 20	 2,	4,	5,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	24,	28,	29,	32,	33,	34,	35,	37,	38,	44,	46,	47,	48,	50,	51,	52,	54,	59,	61,	62,	65,	67,	69	15	 88017752	 102138466	 88.02	 102.14	 RP11-648K04	 RP11-299I17	 142	 14.120714	 -0.611494264	 27	 2,	4,	6,	7,	9,	13,	14,	16,	17,	18,	19,	20,	21,	24,	25,	26,	28,	29,	33,	34,	37,	43,	44,	46,	47,	50,	51,	52,	54,	59,	65,	66,	67,	68,	69	16	 61002	 5183350	 0.06	 5.18	 RP11-158D10	 RP11-112I18	 58	 5.122348	 -0.430960011	 8	 6,	31,	32,	36,	37,	44,	46,	47,	48,	57,	58,	59	
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16	 5231140	 7803198	 5.23	 7.8	 RP11-691J20	 RP11-550C08	 19	 2.572058	 -0.269640669	 4	 31,	36,	51,	57	16	 10679747	 11225385	 10.68	 11.23	 RP11-78D17	 RP11-594D10	 7	 0.545638	 -0.270071422	 4	 16,	21,	37,	57	16	 13827052	 14810254	 13.83	 14.81	 RP11-448P21	 RP11-430K09	 9	 0.983202	 -0.334725649	 6	 29,	36,	37,	46,	57,	65	16	 15443914	 16483344	 15.44	 16.48	 RP11-32D19	 RP11-413I10	 10	 1.03943	 -0.398352176	 14	 2,	6,	16,	20,	29,	36,	37,	44,	50,	57,	59,	61,	67,	68	16	 19875364	 20211724	 19.88	 20.21	 RP11-295I06	 RP11-453F10	 3	 0.33636	 -0.38859696	 3	 36,	38,	57	16	 20533720	 21229337	 20.53	 21.23	 RP11-486P18	 RP11-470O13	 6	 0.695617	 -0.291223018	 3	 18,	36,	57	16	 22682655	 23153421	 22.68	 23.15	 RP11-645F13	 RP11-20G06	 4	 0.470766	 -0.360078599	 4	 2,	10,	48,	57	16	 29081444	 29483865	 29.08	 29.48	 RP11-426C22	 RP11-350D02	 6	 0.402421	 -0.382598573	 5	 16,	24,	50,	55,	61	16	 30356845	 31136634	 30.36	 31.14	 RP11-495E09	 RP11-196G11	 11	 0.779789	 -0.371520582	 3	 6,	16,	55	16	 47927832	 59005775	 47.93	 59.01	 RP11-755C24	 RP11-700H13	 157	 11.077943	 -0.496947542	 16	 1,	2,	14,	16,	18,	19,	23,	32,	34,	35,	36,	37,	44,	46,	47,	49,	50,	54,	55,	57,	58,	59,	62,	66,	67	16	 59527567	 61662182	 59.53	 61.66	 RP11-52D13	 RP11-50K14	 25	 2.134615	 -0.300396013	 3	 14,	15,	23	16	 61698675	 70811928	 61.7	 70.81	 RP11-25B22	 RP11-309L08	 93	 9.113253	 -0.429087359	 14	 14,	15,	23,	31,	32,	34,	36,	37,	44,	46,	47,	49,	50,	51,	58,	61,	65	16	 72004076	 90044587	 72	 90.04	 RP11-320C14	 RP11-566K11	 273	 18.040511	 -0.631135038	 31	 1,	2,	6,	7,	9,	11,	14,	15,	16,	18,	19,	20,	22,	23,	29,	31,	32,	33,	34,	35,	36,	37,	42,	43,	44,	46,	47,	48,	50,	53,	54,	55,	57,	58,	59,	61,	62,	63,	65,	67,	68	17	 1002	 22087877	 0	 22.09	 CTD-2348K01	 RP11-29L17	 255	 22.086875	 -0.529939251	 32	 6,	7,	10,	14,	15,	16,	20,	21,	22,	23,	24,	25,	26,	29,	31,	32,	33,	34,	36,	37,	38,	40,	41,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	57,	58,	59,	60,	61,	62,	65,	67,	68,	70	17	 31312257	 34675848	 31.31	 34.68	 RP11-626C08	 RP11-1330O06	 36	 3.363591	 -0.41610982	 7	 4,	7,	13,	36,	44,	47,	48,	51,	52	17	 34963048	 49397628	 34.96	 49.4	 RP11-53P06	 RP11-45O08	 177	 14.43458	 -0.761002543	 21	 2,	6,	7,	9,	16,	18,	20,	21,	29,	31,	32,	33,	34,	35,	37,	38,	43,	44,	46,	47,	48,	50,	52,	54,	58,	59,	61,	62,	65,	67,	68	17	 52779593	 56615270	 52.78	 56.62	 RP11-242B03	 RP11-155E20	 44	 3.835677	 -0.428263786	 13	 2,	13,	14,	20,	22,	34,	35,	36,	37,	47,	48,	51,	53,	62,	63,	67	17	 57190805	 58216622	 57.19	 58.22	 RP11-399O18	 RP11-50F16	 14	 1.025817	 -0.349635554	 5	 17,	47,	48,	50,	55,	62	17	 58912632	 59692242	 58.91	 59.69	 RP11-411N18	 RP11-495C20	 8	 0.77961	 -0.265054638	 4	 17,	47,	48,	50	17	 60489272	 69235709	 60.49	 69.24	 RP11-535B03	 RP11-434F24	 109	 8.746437	 -0.433395505	 20	 4,	11,	13,	14,	16,	17,	18,	20,	21,	23,	29,	32,	33,	35,	36,	37,	44,	47,	48,	53,	55,	58,	59,	65,	67	17	 69624321	 70337377	 69.62	 70.34	 RP11-447B08	 RP11-19L20	 7	 0.713056	 -0.316152974	 3	 23,	29,	48	17	 71054500	 72266342	 71.05	 72.27	 RP11-782N11	 RP11-237E21	 16	 1.211842	 -0.379490086	 5	 6,	23,	37,	48,	52	17	 72467173	 81020949	 72.47	 81.02	 RP11-354A01	 RP11-196O11	 106	 8.553776	 -0.599348644	 29	 2,	6,	9,	13,	14,	16,	19,	20,	21,	22,	23,	29,	31,	32,	34,	35,	36,	37,	44,	46,	47,	48,	49,	50,	51,	52,	53,	59,	60,	61,	62,	65,	66,	67,	68	18	 2425554	 3335553	 2.43	 3.34	 RP11-715F03	 RP11-340E22	 12	 0.909999	 -0.343490898	 8	 13,	15,	17,	25,	29,	33,	62,	70	18	 4880015	 28728276	 4.88	 28.73	 RP11-755J02	 RP11-699G07	 231	 23.848261	 -0.456385803	 15	 2,	4,	7,	11,	14,	15,	17,	19,	21,	22,	26,	28,	29,	31,	34,	35,	36,	37,	38,	41,	44,	46,	47,	48,	49,	51,	52,	53,	58,	59,	62,	65,	67,	68,	70	18	 29194012	 77875127	 29.19	 77.88	 RP11-549B18	 RP11-565D23	 517	 48.681115	 -0.605740214	 32	 1,	2,	4,	5,	7,	13,	14,	15,	16,	17,	18,	19,	20,	21,	22,	25,	26,	28,	29,	31,	32,	33,	34,	35,	37,	40,	41,	42,	43,	44,	46,	47,	48,	49,	50,	51,	52,	53,	54,	55,	57,	58,	59,	63,	65,	67,	68,	70	
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19	 124843	 24210459	 0.12	 24.21	 RP11-1149J04	 RP11-460G17	 300	 24.085616	 -0.666226703	 23	 1,	2,	6,	15,	16,	17,	20,	21,	22,	23,	24,	26,	28,	29,	31,	32,	33,	34,	36,	37,	41,	43,	44,	46,	47,	48,	49,	51,	57,	58,	59,	61,	62,	65,	66,	67,	69	19	 30559376	 32408696	 30.56	 32.41	 RP11-371B05	 RP11-14D17	 24	 1.84932	 -0.303839546	 10	 2,	31,	32,	36,	46,	49,	51,	53,	54,	62	19	 34682164	 36128240	 34.68	 36.13	 RP11-615P05	 RP11-238O11	 15	 1.446076	 -0.341398867	 3	 21,	32,	58	19	 36477813	 36746477	 36.48	 36.75	 RP11-532B13	 RP11-811P14	 3	 0.268664	 -0.268331464	 3	 21,	32,	54	19	 38994054	 39427226	 38.99	 39.43	 RP11-540L19	 CTD-2293F14	 6	 0.433172	 -0.287336985	 3	 32,	37,	44	19	 40665444	 42180899	 40.67	 42.18	 RP11-36B02	 RP11-726N13	 16	 1.515455	 -0.384721054	 10	 6,	9,	23,	29,	32,	34,	37,	44,	65,	67	19	 45041824	 50511045	 45.04	 50.51	 RP11-814C11	 RP11-265B05	 74	 5.469221	 -0.454262125	 9	 6,	21,	29,	32,	37,	44,	47,	55,	58	19	 51992896	 55164372	 51.99	 55.16	 RP11-145E06	 RP13-898P22	 68	 3.171476	 -0.351285938	 6	 29,	31,	32,	35,	49,	53,	57	19	 55402318	 56174777	 55.4	 56.17	 RP11-47A10	 RP11-705C04	 8	 0.772459	 -0.340127558	 5	 6,	29,	31,	32,	37	19	 57953032	 59077721	 57.95	 59.08	 RP11-103I13	 CTD-2575K21	 13	 1.124689	 -0.324238177	 4	 6,	31,	32,	53	20	 90210	 21007293	 0.09	 21.01	 CTD-2506E02	 RP11-782O10	 228	 20.917083	 -0.637554032	 27	 1,	2,	7,	9,	10,	13,	14,	16,	19,	20,	21,	22,	32,	33,	34,	37,	43,	44,	46,	47,	48,	49,	50,	52,	53,	57,	59,	61,	63,	65,	67,	68,	70	20	 22502495	 24020865	 22.5	 24.02	 RP11-473J15	 CTD-2503J14	 15	 1.51837	 -0.379342276	 6	 29,	33,	48,	50,	52,	63	20	 24313953	 24861405	 24.31	 24.86	 RP11-121E13	 CTD-2012L20	 5	 0.547452	 -0.218165886	 3	 32,	50,	52	20	 25137908	 26305513	 25.14	 26.31	 RP11-238O04	 RP11-786O24	 12	 1.167605	 -0.356528672	 6	 17,	18,	23,	32,	33,	50,	51,	52	20	 29834448	 32205633	 29.83	 32.21	 RP11-559K10	 RP11-171G22	 29	 2.371185	 -0.473980173	 8	 11,	23,	29,	31,	32,	36,	48,	51,	65	20	 32133864	 40313113	 32.13	 40.31	 RP11-403C11	 RP11-590L17	 97	 8.179249	 -0.485448049	 17	 2,	13,	20,	21,	29,	32,	33,	35,	37,	46,	47,	48,	49,	59,	60,	61,	62,	65,	66,	67	20	 40323067	 50703420	 40.32	 50.7	 RP11-660L18	 RP11-260O01	 117	 10.380353	 -0.563282044	 18	 6,	16,	20,	21,	29,	32,	33,	34,	35,	37,	43,	44,	46,	47,	48,	49,	50,	51,	55,	57,	59,	60,	61,	65,	67	20	 52859341	 54016258	 52.86	 54.02	 RP11-388O19	 RP11-275L10	 17	 1.156917	 -0.303196412	 3	 2,	48,	49,	63	20	 55643089	 62964520	 55.64	 62.96	 RP11-560A15	 RP11-476I15	 84	 7.321431	 -0.491204243	 9	 6,	11,	14,	21,	31,	32,	34,	36,	37,	44,	47,	48,	49,	59,	65,	70	21	 15406754	 19251063	 15.41	 19.25	 RP11-73I15	 RP11-554K20	 32	 3.844309	 -0.556603985	 18	 2,	13,	17,	18,	20,	29,	34,	37,	38,	43,	44,	47,	49,	50,	60,	65,	66,	67,	68	21	 24835560	 25090202	 24.84	 25.09	 RP11-124K12	 RP11-32G15	 3	 0.254642	 -0.274961229	 3	 38,	49,	54	21	 25023642	 48102348	 25.02	 48.1	 RP11-94B04	 RP11-457P07	 268	 23.078706	 -0.804857944	 38	 1,	2,	6,	7,	9,	13,	14,	16,	17,	18,	19,	20,	21,	22,	28,	29,	31,	32,	33,	34,	35,	37,	38,	41,	43,	44,	46,	47,	48,	49,	50,	52,	53,	55,	58,	59,	61,	62,	63,	65,	66,	67,	68,	70	22	 17364565	 51186519	 17.36	 51.19	 RP11-453H13	 RP11-423E19	 341	 33.821954	 -0.488285936	 21	 1,	2,	4,	5,	6,	7,	15,	16,	18,	19,	20,	21,	22,	23,	28,	29,	31,	32,	34,	35,	36,	37,	41,	43,	44,	46,	47,	48,	49,	50,	51,	53,	54,	57,	58,	59,	60,	61,	63,	65,	67,	68	23	 629113	 3111882	 0.63	 3.11	 RP13-76L22	 RP11-418N20	 23	 2.482769	 -0.377702046	 11	 19,	26,	31,	32,	36,	41,	42,	48,	50,	51,	52,	53,	62,	70	23	 8548893	 12158458	 8.55	 12.16	 RP11-404I03	 RP11-637N21	 30	 3.609565	 -0.392526094	 16	 2,	7,	16,	20,	22,	26,	34,	37,	43,	44,	46,	48,	50,	63,	65,	68	23	 13135347	 13624758	 13.14	 13.62	 RP11-331E19	 RP11-144C10	 4	 0.489411	 -0.356590345	 3	 26,	43,	50	
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23	 15240398	 15620494	 15.24	 15.62	 RP11-359C04	 RP11-264L13	 4	 0.380096	 -0.338779494	 3	 17,	36,	68	23	 17000086	 17999095	 17	 18	 RP11-2K15	 RP11-642C14	 9	 0.999009	 -0.359606413	 4	 36,	46,	50,	68	23	 22210029	 24150794	 22.21	 24.15	 RP11-694E22	 RP11-479I01	 19	 1.940765	 -0.277789082	 4	 43,	50,	55,	68	23	 31004554	 31283109	 31	 31.28	 RP11-451N15	 CTD-2190J10	 3	 0.278555	 -0.262638598	 3	 26,	46,	50	23	 31994936	 33302485	 31.99	 33.3	 RP11-339E16	 RP11-644J09	 10	 1.307549	 -0.232980638	 5	 44,	46,	47,	50,	59	23	 37819364	 40298481	 37.82	 40.3	 RP11-788A22	 RP11-224E10	 22	 2.479117	 -0.383623111	 15	 7,	14,	20,	29,	32,	34,	35,	37,	44,	46,	47,	48,	50,	59,	65	23	 43248625	 44202665	 43.25	 44.2	 RP11-561O22	 RP11-605I23	 9	 0.95404	 -0.512897488	 16	 6,	14,	20,	29,	33,	34,	35,	37,	43,	46,	47,	48,	50,	58,	59,	65	23	 66756955	 68744104	 66.76	 68.74	 CTD-2125G24	 RP11-54P15	 19	 1.987149	 -0.345170645	 5	 29,	32,	37,	46,	65	23	 71054587	 71599957	 71.05	 71.6	 RP11-502I03	 RP11-793L19	 3	 0.54537	 -0.277795459	 3	 29,	34,	46	23	 95529153	 96340058	 95.53	 96.34	 RP11-560B01	 RP11-315I18	 6	 0.810905	 -0.289498224	 3	 46,	48,	68	23	 102481637	 103086955	 102.48	 103.09	 RP11-371C12	 CTD-2210J10	 4	 0.605318	 -0.381880157	 5	 21,	37,	43,	50,	65	23	 107414648	 107685878	 107.41	 107.69	 RP11-448E12	 CTD-2023P22	 4	 0.27123	 -0.353897012	 4	 37,	46,	50,	67	23	 135046218	 135422728	 135.05	 135.42	 RP11-274K13	 RP11-217E15	 3	 0.37651	 -0.369926787	 5	 37,	43,	44,	59,	67	23	 151681530	 155186928	 151.68	 155.19	 CTD-2305K05	 RP11-1245L19	 45	 3.505398	 -0.607203278	 28	 3,	6,	13,	15,	16,	20,	25,	29,	31,	32,	33,	34,	35,	37,	38,	42,	43,	44,	47,	48,	50,	52,	57,	59,	61,	62,	65,	66,	68	24	 2706160	 28818361	 2.71	 28.82	 CTD-2010M16	 RP11-1136L22	 210	 26.112201	 -1.136769482	 22	 9,	11,	13,	14,	16,	19,	21,	26,	31,	32,	33,	34,	38,	41,	42,	48,	49,	50,	51,	53,	54,	58,	62,	65,	67,	69	
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chrom	 start	 end	 start.MB	 end.MB	 start.probe	 end.probe	 probes	 length	MB	 maxM	 max.overlap	 cases	1	 2697923	 5642744	 2.7	 5.64	 CTD-2390G19	 RP11-230F23	 42	 2.944821	 0.633859268	 2	 17,	70	1	 6837676	 8005025	 6.84	 8.01	 RP11-312B08	 RP11-620C09	 11	 1.167349	 0.535131226	 1	 70	1	 29806323	 30764342	 29.81	 30.76	 RP11-810H18	 RP11-201L04	 8	 0.958019	 0.571909715	 1	 70	1	 38431499	 39413615	 38.43	 39.41	 RP11-394F04	 RP11-608G12	 11	 0.982116	 0.514880307	 1	 70	1	 48041990	 48429080	 48.04	 48.43	 RP11-458M05	 RP11-330M19	 7	 0.38709	 0.495858716	 1	 17	1	 56466678	 58966657	 56.47	 58.97	 RP11-769I07	 RP11-18M18	 24	 2.499979	 0.55343011	 1	 70	1	 60159577	 62257986	 60.16	 62.26	 RP11-354P07	 RP11-1K15	 18	 2.098409	 0.9446246	 1	 70	1	 62286560	 65143133	 62.29	 65.14	 RP11-805D13	 RP11-93F23	 28	 2.856573	 0.866813324	 1	 70	1	 119335329	 120628847	 119.34	 120.63	 RP11-765M05	 RP11-723D17	 12	 1.293518	 0.651431857	 1	 26	1	 121181443	 143544525	 121.18	 143.54	 RP11-344P13	 RP11-464H08	 19	 22.363082	 0.603288041	 1	 65	1	 150436727	 150695449	 150.44	 150.7	 RP11-713O15	 CTD-2021N04	 3	 0.258722	 0.626659492	 1	 50	1	 152816054	 153503482	 152.82	 153.5	 RP11-352B17	 RP11-68O15	 6	 0.687428	 0.708639967	 1	 19	1	 156664877	 157581587	 156.66	 157.58	 RP11-711O18	 RP11-722H19	 11	 0.91671	 0.78613662	 1	 58	1	 160323189	 160728550	 160.32	 160.73	 RP11-193E22	 RP11-418C06	 3	 0.405361	 0.559916034	 1	 46	1	 168584993	 168982154	 168.58	 168.98	 RP11-30K06	 RP11-738F02	 6	 0.397161	 0.605634068	 1	 58	1	 176373428	 177893478	 176.37	 177.89	 CTD-2016G18	 RP11-33I15	 15	 1.52005	 0.594476995	 1	 58	1	 198177009	 198529197	 198.18	 198.53	 RP11-135A15	 RP11-4N14	 3	 0.352188	 0.768336999	 1	 14	1	 209199331	 209872702	 209.2	 209.87	 RP11-185G15	 RP11-453H04	 9	 0.673371	 0.760238142	 4	 19,	21,	23,	62	1	 221730826	 222102096	 221.73	 222.1	 RP11-392D11	 RP11-815M08	 3	 0.37127	 0.607166256	 2	 23,	49	1	 246004067	 246486397	 246	 246.49	 RP11-727O20	 RP11-88N11	 6	 0.48233	 0.468498845	 1	 58	2	 17287769	 17850566	 17.29	 17.85	 RP11-427M01	 RP11-325P07	 5	 0.562797	 0.646614458	 1	 44	2	 84684385	 91940831	 84.68	 91.94	 RP11-522L19	 RP11-806H03	 84	 7.256446	 1.153541828	 1	 70	2	 97186358	 98830837	 97.19	 98.83	 RP11-67L23	 RP11-1372P11	 22	 1.644479	 0.96912391	 1	 26	
Table S3. Amplifications in 1 or more cases. Amplification threshold =0.4 
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2	 101270202	 103877430	 101.27	 103.88	 RP11-473B22	 RP11-19F20	 24	 2.607228	 0.758245428	 1	 57	2	 112017323	 112758612	 112.02	 112.76	 RP11-803D05	 RP11-809E17	 6	 0.741289	 0.701651823	 1	 70	2	 118688910	 123761285	 118.69	 123.76	 RP11-98C01	 RP11-640F22	 49	 5.072375	 1.191018971	 1	 16	2	 150240355	 151369943	 150.24	 151.37	 RP11-585A11	 RP11-454F04	 16	 1.129588	 0.764640737	 1	 29	2	 158154541	 158442129	 158.15	 158.44	 RP11-23J04	 RP11-149E11	 3	 0.287588	 0.47941102	 1	 46	2	 199324949	 202104991	 199.32	 202.1	 RP11-818G12	 RP11-15C10	 28	 2.780042	 1.067700194	 2	 48,	62	3	 88255965	 125445425	 88.26	 125.45	 RP11-416P02	 RP11-493H22	 431	 37.18946	 1.41948688	 2	 41,	58,	70	3	 125836820	 128132144	 125.84	 128.13	 RP11-311P09	 CTD-2215L01	 31	 2.295324	 0.809426184	 2	 17,	70	3	 129977543	 150821519	 129.98	 150.82	 RP11-129J11	 RP11-509L02	 264	 20.843976	 0.768656522	 3	 17,	57,	70	3	 151476283	 161982749	 151.48	 161.98	 RP11-457N12	 RP11-141G19	 111	 10.506466	 0.696299758	 1	 70	3	 163605449	 185126175	 163.61	 185.13	 RP11-208P04	 RP13-520P23	 216	 21.520726	 1.367594381	 5	 7,	16,	26,	28,	57,	70	3	 185314210	 197791562	 185.31	 197.79	 RP11-238G24	 RP11-721B03	 130	 12.477352	 0.953389618	 7	 7,	17,	21,	22,	49,	57,	70	4	 3393681	 3639841	 3.39	 3.64	 RP11-565K22	 RP11-181M20	 5	 0.24616	 0.859017292	 1	 54	4	 36161294	 36458025	 36.16	 36.46	 RP11-278E22	 RP11-124M05	 3	 0.296731	 0.553077834	 1	 32	4	 45540503	 47101613	 45.54	 47.1	 RP11-475J10	 RP11-620L01	 13	 1.56111	 0.608040837	 1	 47	4	 74980811	 77976594	 74.98	 77.98	 RP11-640L19	 RP11-54L18	 25	 2.995783	 1.737337004	 2	 19,	57	4	 138841349	 139320065	 138.84	 139.32	 RP11-631O14	 CTD-2026P20	 4	 0.478716	 0.708735612	 1	 19	5	 18263	 12310679	 0.02	 12.31	 RP11-811I15	 RP11-107O20	 148	 12.292416	 1.128539709	 3	 2,	15,	57,	67	5	 12784441	 19618940	 12.78	 19.62	 RP11-65G17	 CTD-2015I02	 100	 6.834499	 0.991616028	 5	 2,	15,	29,	48,	57,	67	5	 22527724	 46114310	 22.53	 46.11	 RP11-340I24	 RP11-52C13	 303	 23.586586	 1.651707198	 3	 2,	15,	29,	31,	57	5	 55756032	 56226130	 55.76	 56.23	 RP11-152O02	 RP11-739G07	 7	 0.470098	 0.569971532	 1	 51	5	 67679409	 68449868	 67.68	 68.45	 CTD-2026C02	 RP11-294J17	 15	 0.770459	 0.564433446	 1	 17	5	 134281428	 135164768	 134.28	 135.16	 RP11-757O10	 RP11-737I17	 11	 0.88334	 0.604561584	 1	 17	5	 171004534	 171377793	 171	 171.38	 CTD-2315O11	 RP11-440F23	 4	 0.373259	 0.555667512	 1	 17	6	 12024633	 16223128	 12.02	 16.22	 RP11-796A14	 RP11-566E16	 61	 4.198495	 2.092017873	 1	 66	6	 18389006	 21545576	 18.39	 21.55	 RP11-773C18	 RP11-120L02	 42	 3.15657	 1.491874605	 1	 66	
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1 Abstract 
 
Penile squamous cell carcinoma is a rare disease, in which somatic genetic aberrations 
have yet to be characterized. We hypothesized that gene copy aberrations might correlate 
with human papillomavirus status and clinico-pathological features. We sought to 
determine the spectrum of gene copy number aberrations in a large series of PSCCs and 
to define their correlations with human papillomavirus, histopathological subtype, and 
tumor grade, stage and lymph node status. Seventy formalin-fixed, paraffin embedded 
penile squamous cell carcinomas were centrally reviewed by expert uropathologists. DNA 
was extracted from micro- dissected samples, subjected to PCR-based human 
papillomavirus assessment and genotyping (INNO-LiPA human papillomavirus Genotyping 
Extra Assay) and microarray-based comparative genomic hybridization using a 32K 
Bacterial Artificial Chromosome array platform. Sixty-four samples yielded interpretable 
results. Recurrent gains were observed in chromosomes 1p13.3-q44 (88%), 3p12.3-q29 
(86%), 5p15.33-p11 (67%) and 8p12-q24.3 (84%). Amplifications of 5p15.33-p11 and 
11p14.1-p12 were found in seven (11%) and four (6%) cases, respectively. Losses were 
observed in chromosomes 2q33-q37.3 (86%), 3p26.3-q11.1 (83%) and 11q12.2-q25 
(81%). Although many losses and gains were similar throughout the cohort, there were 
small significant differences observed at specific loci, between human papillomavirus 
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positive and negative tumors, between tumor types, and tumor grade and nodal status. 
These results demonstrate that despite the diversity of genetic aberrations in penile 
squamous cell carcinomas, there are significant correlations between the clinico-
pathological data and the genetic changes that may play a role in disease natural history 
and progression and highlight potential driver genes, which may feature in molecular 
pathways for existing therapeutic  agents. 
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2 Introduction 
 
Penile squamous cell carcinoma (PSCC) is a rare disease, but can have a profound 
physical and psychological effect on those afflicted. It mainly affects men aged 50–70 
years old [1] and, although rare in developed countries, it is a significant health problem 
in developing countries. In Europe and the USA the incidence is less than 1 per 100,000 
men, but the age-standardized rate may   be as high as 3.7 and 2.8 per 100,000 in parts 
of Brazil and Uganda, respectively [2–4]. Penile carcinoma is difficult to treat after 
metastatic dissemination, given that these tumors are relatively radio and chemo  
resistant. 
Histologically, PSSCs comprise a spectrum of lesions that differ in clinical behavior. The 
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most common morphological subtypes of PSCC are usual type (48–65%), basaloid (4–
10%), warty (7–10%) and verrucous (3–8%) [5]. Basaloid carcinomas are the most 
aggressive PSCC subtype, whereas verrucous carcinomas have a more indolent clinical 
course   [6]. 
In comparison to other squamous cell carcinomas, relatively little is known about the 
molecular features of PSCC [7–11]. Similar to squamous cell carcinomas of the female 
lower genital tract, a subset of PSCCs appears to be driven by HPV. In a recent study 
analyzing 102 cases [9], HPV DNA was detected in up to 56% of these tumors; however, 
frequencies ranging from 14% to   100% have been reported in the literature [12]. The 
prevalence of HPV infection seems to correlate with histological type, with HPV DNA 
reported to be found in up to 76% of basaloid carcinomas and in only 22% of the indolent 
verrucous carcinomas [6]. Esophageal squamous cell carcinomas (OSCCs) also comprise 
HPV-positive and HPV-negative tumor types, with the frequency of HPV DNA detection 
being highly variable in both [6, 9, 13–15], which may reflect the discrepancies in detection 
methodology [16]. In oropharyngeal squamous cell carcinoma (OPSCC) HPV positivity 
confers a good prognosis [17] and better disease free survival  [18] compared to HPV-
negative cases. HPV infection has also been well documented in other squamous cell 
carcinomas such as vulva and cervical. 
There is a paucity of data on the somatic genetic characteristics of PSSCs, possibly due 
to the relative rarity of the disease. In England, PSCC services have been managed in 
supra-specialized centers in the UK. This has given us the opportunity to accrue a 
sufficiently sized cohort to analyze the molecular characteristics of PSCCs. Therefore, we 
sought to investigate the repertoire of somatic DNA copy number aberrations in PSSCs, 
and to determine whether patterns and types of gene copy number aberrations would 
correlate with HPV status and clinico-pathological features, including type, grade, stage 
and HPV   status. 
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3 Materials and Methods 
 
Cases 
 
We retrieved 70 formalin fixed paraffin embedded PSCCs from the Cellular Pathology 
Department of St George’s Hospital. Cases were reviewed by a panel of expert 
uropathologists (CC, BT, RR) for grade, stage (including lymph node status) and subtype 
using established methods [19, 20]. Patients’ data were made entirely anonymous and 
this study was approved by East London and The City Research Ethics Committee Alpha 
(The Orchid Tissue Bank;  09/H0704/4). 
 
Dissection and DNA Extraction 
 
For all cases, regions of PSCC and normal tissue were marked on the representative 
sections by a consultant genitourinary pathologist (DB). Ten to fifteen tissue 
representative sections were cut at 10µm thickness from each case and subjected to 
microdissection under a stereomicroscope as previously described  [21]. 
 
DNA was extracted from microdissected sections using standard phenol-chloroform 
methods and its concentration was measured using PicoGreen® assay as per the 
manufacturer’s instructions (Applied Biosystems, Invitrogen, Paisley,   UK). 
 
HPV Analysis 
 
The presence of HPV DNA was detected by PCR method using SPF10 primers, which 
amplify a 65-bp fragment of the conserved L1 open reading frame and HPV genotypes 
identified by the INNO-LiPA HPV Genotyping Extra Assay (Innogenetics NV Ghent, 
Belgium) as previously described [9]. 
 
Microarray Comparative Genomic Hybridization (aCGH) 
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DNA extracted from microdissected sections was subjected to microarray-based 
comparative genomic hybridization using a 32K bacterial artificial chromosome (BAC) 
array platform (Hernandez et al., 2012) which has been shown to be as robust as, and to 
have comparable resolution with, high-density oligonucleotide arrays [22–24]. DNA 
labeling, array hybridization and image acquisition were performed as previously 
described  [25]. 
After filtering polymorphic BACs, a final dataset was produced with unambiguous mapping 
information according to build hg19 (NCBI build 37) of the human genome  
(http://www.ensemble.org). 
 
Data Analysis 
 
Analyses were performed using the BACE.R R script (R version 2.11.1) was used to pre-
process and analyze the aCGH data as previously described [25, 26]. 
After filtering polymorphic BACs, a final dataset of 31,367 clones with unambiguous 
mapping information according to build hg19 of the human genome 
(http://www.ensembl.org) was smoothed using the circular binary segmentation (cbs) 
algorithm. A categorical analysis was applied to the BACs after classifying them as 
representing amplification (>0.4), gain (>0.08 and ≤0.45), loss (<-0.08),   or no change 
according to their cbs-smoothed Log2 ratio values [7,10,9]. Threshold values were 
determined and validated as previously described [21, 26]. 
Following copy number categorizations for gains, losses or amplifications, Fisher’s exact 
tests were performed to identify  statistically significant differences (with a false discovery 
rate-adjusted p-value < 0.05) in amplifications and gains/ losses between the different 
subtypes, grades, stages, HPV associations and nodal status. Adjustment for multiple 
testing was performed with a step-down permutation procedure (maxT), which provides a 
robust control of the family-wise type I error rate (FWER)   [27]. 
Unsupervised hierarchical clustering of cbs-smoothed ratios, employing Wards clustering 
algorithm and Euclidean distance metric, was performed as previously described [26]. 
Subsequent assessment of the robustness of the cluster analysis was done by assessing 
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the uncertainty with multiscale bootstrap resampling with the pvclust package in R 3.0.1. 
 
4 Results 
 
Patients and Study Samples 
 
Of the 70 PSCC cases, 64 had adequate DNA quality and purity for successful array CGH  
analysis. 
Demographics including HPV status, stage, grade, lymph node status and histological 
classification can be found in Table 1. Genome plots were generated for each case and 
showed various patterns of chromosomal expression. Some examples are as follows: 
Case 17 (usual type PSCC), exhibited specific gain/amplification in regions 1p, 3q and 5 
(Fig 1A). Case 62 (verrucous type PSCC) showed gains in 1q, 2, 3q, 5p and 8q, with 
obvious amplification in chromosome 11p (Fig 1B). Cases 26 (usual type PSCC) and 70 
(basaloid type PSCC) also showed gain in the 3q region; as well as 8q and 13p, 
respectively (Fig 1C and   1D). 
 
Fig 1. Microarray-based comparative genomic hybridisation analysis invasive penile squamous cell 
carcinoma components. 
Genome plots obtained with the 32K bacterial artificial chromosome array platform for: (A) 
Case 17 (usual type), (B) Case 62(verrucous), (C) Case 26 (usual type) and (D) Case 70 
(basaloid).    http://dx.doi.org/10.1371/journal.pone.0146740.g001 
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Table 1. Demographics of PSCC cases. 
http://dx.doi.org/10.1371/journal.pone.0146740.t001 
 
 
Array CGH and Candidate Driver Genes 
 
PSCCs were shown to harbor many highly recurrent gains, the highest frequencies 
occurring on chromosomes 1p13.3-q44 (88%), 3p12.3-q29 (86%), 7p22.3-q36.3 (88%), 
8p12-q24.3 (84%), 9p24.3-q34.3 (88%) and 20p13-q13.33 (84%) (Fig 2A, S1   Table). 
PSCCs also harbored highly recurrent losses of 2q33-q37.3 (86%), 3p26.3-q11.1 (83%) 
and 11q12.2-q25 (81%) (Fig 2A, S1 Table). The highest frequency recurrent amplifications 
were of 3q27.2-q29 (11%) and 8q21.13-q24.3 (23%) (Fig 2B, S1 Table). Our    analysis of 
PSCC samples did not identify deletions or high-level loss of genetic loci and, despite the 
highly recurrent changes,   there were genetic aberrations that were restricted to only a 
subset of the  cases. 
 
 
Fig 2. Samples of invasive penile squamous cell carcinoma. 
(A) Frequency plot of copy number gains and losses. (B) Frequency plot of high level 
gain or amplification. (C) Hierarchical cluster analysis for all cases comparing stage, 
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HPV status, subtype, grade and nodal status. The proportion of tumors in which each 
bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) 
is plotted (y axis) for each BAC clone according to its genomic position (x  axis). 
http://dx.doi.org/10.1371/journal.pone.0146740.g002 
 
 
These loci enclose several genes identified in areas of gain, amplification and loss. Gain 
of 3p12.3-q29 harbor, amongst many other genes, PRKCI, PIK3CA, DCUN1D1, LAMP3 
and RPL35A. The F-box protein, SKP2 (S-phase kinase-associated protein 2) was 
included in gain of 5p15.33-p11 and amplification of 5p15.33-p11 and the oncogene MYC 
is also highlighted in the gained region 8p12-q24.3. Amplification of 3q27.2-q29 
encompasses the CLDN1, TNK2 (tyrosine kinase, non-receptor, 2) and FBXO45 (F-box 
protein 45). Genes of interest in the amplified region 3q26.1- q27.2 include FNDC3B and 
ACTL6A/BAF53 (actin-like 6A/BRG1 associated factor 53A). CPT1A, FGF3/4 and CCND1 
are revealed in the amplified region 11p12.-p14.1. 
Potential tumor suppressor genes, also found in other squamous cell carcinomas, have 
been discovered in the lost regions 2q33- q37.3 (PLCD4), 3p26.3-q11.1 (RBMS3, 
PLCD1, and CACNA2D3) and 11q12.2-q25 (CPT1A, CCND1, FGF4/FGF3, and 
PPP2R1B). 
 
HPV Subgroup-Analysis 
 
Firstly, we sought to define whether HPV DNA positive and HPV DNA negative PSSCs 
would be underpinned by distinct patterns of gene copy number aberrations. Multi-Fisher's 
exact test adjusted for multiple comparisons revealed that HPV-positive and HPV- 
negative PSCCs have similar patterns of copy gains and that higher frequencies were 
demonstrated in 1q, 3q, 5p, 7p and 8q and amplifications in 3q, 5p and 8q for both HPV-
negative and HPV-positive  tumors. 
Regions of differential gain included 1q, 2p, 7p and 10q, and regions of differential loss 
on 6p, 11p and q and 17p and q. When an unadjusted p value was used, 17p loss was 
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exhibited with an increased frequency in the HPV negative group (p<0.05), but other 
areas of differential gain and loss showed no pattern of association with either the HPV 
positive or negative group. When p values were adjusted, regions with a statistically 
significant higher frequency of cases in HPV positive cohort exhibited gain on 1q 
(151,622,431–151,793,285; p = 0.035). When p values were adjusted, regions with a 
statistically significant higher frequency of cases in HPV negative cohort exhibited gain 
of 2p (60,835,599–61,089,333; p = 0.034), 7p (48,668,454–49,846,998; 0.034), 10q 
(108,751,067–109,429,862; p = 0.047) and loss of 11p (46,103,041–47,520,939; 
p<0.05). No significant differences in the prevalence of specific amplified loci were 
identified. Hierarchical cluster analysis failed to demonstrate a clear difference in 
clustering of genetic change between HPV-positive and HPV-negative tumors (Figs 2C 
and  3). 
genes PIK3CA, SENP5 (SUMO1/Sentrin Specific Peptidase   5), 
 
 
 
Fig 3. HPV status of PSCCs. 
Fishers Exact plots of differential copy number gains and losses or amplifications/ high 
level gain in HPV positive and HPV negative PSCC samples. The proportion of tumors 
in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost 
(red bars) is plotted (y axis) for each BAC clone according to its genomic position (x 
axis). http://dx.doi.org/10.1371/journal.pone.0146740.g003 
 
 
 
 
Further Clinico-Pathological Subgroup-Analysis 
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In addition, we conducted further analysis based on other defined clinic-pathological 
variables (for details of specific gene loci, see  S2 Table). Analysis of histological subtypes 
uncovered differential gain of regions on 1q (p<0.05) and 3q(p = 0.04, region close to 
telomere), differential loss of 11p and q (p<0.05, close to telomere), 13q (p = 0.03), 15q (p 
= 0.03), 16q (p = 0.02), and differential amplification of 3q and 8q (p<0.05), when 
comparing basaloid to non-basaloid subtypes (Fig 4). In regions of these chromosomes 
statistically significant gain, loss and amplification were shown in more cases in the non-
basaloid group compared to the basaloid group. Comparing verrucous cases to non-
verrucous differential loss was discovered on 11p and 17q (p<0.05), in significantly more 
cases in the non-verrucous than verrucous cohort. No significant differences in the 
prevalence of specific gained or amplified loci were identified. Comparing usual type to 
non-usual type, differential loss was found on 3p (p<0.05) and 17q (unadjusted p<0.05, 
adjusted p = 0.1–0.33). Interestingly there were no significant differences in the prevalence of 
specific gained or amplified loci were identified. 
 
 
 
Fig 4. Histological subtype of PSCCs. 
Fishers Exact plots of differential copy number gains and losses or amplifications/ high level 
gain in Basaloid and non-   basaloid PSCC samples. The proportion of tumors in which each 
bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted 
(y axis) for each BAC clone according to its genomic position (x axis). 
http://dx.doi.org/10.1371/journal.pone.0146740.g004 
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A supervised analysis of the aCGH results according to histological grade revealed 
differential gains in chromosome 6p and differential losses in chromosomes 2p, 5p and 
q, 8q and 11p. Gains of 6p were more frequently found in tumors of a low histological 
grade (i.e. 1 and 2) than in high-grade lesions (i.e. 3), but this was not statistically 
significant when adjusted p values were  calculated. Loss of 2p and 5p and q were 
significantly more frequently found in low-grade lesions (p<0.05). Loss of 8q and 11p     
were significantly more frequently found in high-grade tumors (p<0.05). No significant 
differences in the prevalence of specific amplified loci were identified (Fig 5). 
 
  
 
Fig 5. Histological grade of PSCCs. 
Fishers Exact plots of differential copy number gains and losses or amplifications/ high 
level gain in high grade (3) and low grade (1–2) PSCC samples. The proportion of 
tumors in which each bacterial artificial chromosome (BAC) clone is gained (green 
bars) or lost (red bars) is plotted (y axis) for each BAC clone according to its genomic 
position (x axis). http://dx.doi.org/10.1371/journal.pone.0146740.g005 
 
 
PSSCs of different stages displayed distinct patterns of differential loss on 5q (p = 0.03), 
6p (p<0.01) and 18p, as well as  amplification of 8q (Fig 6). These aberrations were 
significantly more frequently found in tumors of high histological stage (i.e. 3   and 
4) than in low stage lesions (i.e. 1 and 2). No significant differences in the prevalence of 
specific gained loci were   identified. 
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Fig 6. Clinical Stage of PSCCs. 
Fishers Exact plots of differential copy number gains and losses or amplifications/ high 
level gain in high stage (3–4) and low stage (1–2) PSCC samples. The proportion of 
tumors in which each bacterial artificial chromosome (BAC) clone is gained (green 
bars) or lost (red bars) is plotted (y axis) for each BAC clone according to its genomic 
position (x axis). http://dx.doi.org/10.1371/journal.pone.0146740.g006 
 
 
Analysis of aCGH data according to nodal status (N0, N1, N2, and N3) yielded more 
frequent gain of 7q and loss of 2pq (p<0.05), 4q (p = 0.03), 9q (p<0.05), 10q (p<0.05), 
11q (p<0.05), 15q (p<0.05) and 20p (p<0.05) in node negative cases compared to node 
positive cases (Fig 7). For 7q this was not statistically significant when an adjusted p 
value was calculated (unadjusted p = 0.001– 0.04; adjusted p = 0.24–0.6). No significant 
differences in the prevalence of specific amplified loci were   identified. 
 
 
Fig 7. Lymph node status of PSCCs. 
Fishers Exact plots of differential copy number gains and losses or amplifications/ high 
level gain in lymph node positive and lymph node negative PSCC samples. The 
proportion of tumors in which each bacterial artificial chromosome (BAC) clone is gained 
(green bars) or lost (red bars) is plotted (y axis) for each BAC clone according to its 
genomic position (x axis). http://dx.doi.org/10.1371/journal.pone.0146740.g007 
 
 
Given the diversity of gene copy number aberrations of PSSCs, we performed class 
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discovery analysis using hierarchical clustering. There were stable clusters, but none 
showed enrichment for a particular clinico-pathological feature (Fig   2C). 
 
5 Discussion 
 
We have provided a detailed characterization of the genetic landscape of prostate cancer 
by DNA copy number aberrations found    in HPV-positive and HPV-negative PSCCs, and 
demonstrated that these tumors display similar patterns of genetic aberrations despite the 
distinct pathogenetic mechanisms, with statistically significant changes in only a few small 
loci. It has been documented that HPV changes cell physiology inactivating RB and p53 
pathways [28, 29] and our genomic data shows copy number loss at 13q12.11-q34 (80% 
of HPV positive cases) and 17p13.3-p11.1 (63% of HPV positive cases), harboring RB1 
and TP53 genes, respectively. However, these changes were not statistically significant in 
their difference from the HPV negative cohort. It is possible that TP53 and RB1 may be 
mutated in the cases without HPV infection. Further investigation, such as mutational 
analysis, will be required to elucidate this. 
Another mechanism of TP53 pathway inactivation includes amplification/overexpression 
of an ubiquitin ligase, MDM2 (murine double minute 2). TP53 is usually kept at low levels 
by MDM2 in normal cells. MDM2 and TP53 form an auto-regulatory negative- feedback 
loop, in which TP53 induces the expression of MDM2, which then facilitates the 
breakdown of TP53 in the nucleus and cytoplasm, inhibits its transcriptional activity and 
assists its nuclear export [30]. Our data did not support this, as we failed to find any 
differential gain or differential amplification of this gene at 12q15 in the HPV cohorts, or 
amplification in the overall   data. 
However, an earlier small genomic study confirmed amplification on 12q, but only in 4.3% 
of PSCC cases, which encompasses   the 
MDM2 gene [7]. pRB1 pathway inactivation could also be caused by gains/ amplification 
of CCNE1, CCND1, CDK2 and CDK4, but our data did not show differential copy number 
change at the corresponding loci between the HPV positive and HPV negative cohorts. 
However, gain of the regions encompassing CCNE1 (19p13.11-q13.43; 71% cases) and 
CCND1 (11q12.2-q14.1; 46% cases) were found in the HPV positive group, and both gain 
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and amplification of the region incorporating CCND1 (11q13.3-q13.4; 20% and 3% cases, 
respectively) were found in the HPV negative  group. 
One previous paper has been published on the pattern and repertoire of somatic genetic 
aberrations in PSSCs.[7] Alves et al investigated the chromosomal changes found in 26 
PSCCs using a spread of metaphase chromosomes on a microscope slide as a 
hybridization target, prepared as in fluorescence in situ hybridization. In three cases no 
DNA copy number alterations were   detected, but contamination of the PSCC samples 
with normal tissue could not be excluded. Alves et al. observed the most   common copy 
number gains on 8q24 (48%), 16p11–12(48%), and 20q11–13 (48%); 22q (43%); 19q13 
(39%) and 5p15 (35%). In comparison, our data demonstrated copy number gains in similar 
overlapping regions on chromosomes 8p12-q24.3 (84%), 16p11.2-q24.3 (77%), 20p13-
q13.3 (84%), 22q11.1–13.3 (73%), 19p13.11-q13.43 (64%) and 5p15.33-q11.2 (67%). 
Losses  were 
found by the Alves group on 15q, 16q, 21q and 20p. PSCC cases exhibited loss on p and 
q arms of all other chromosomes, excluding chromosomes 22 and Y, which did not show 
loss. We showed amplifications of 1q32.2 (6%), 3q27.2-q29 (11%), 3q26.1- q27.2 (8%), 
5p15.2-p14.3 (9%), 5p14.3-p11 (8%), 5p15.33-p15.2 (6%), 8q21.13-q24.3 (23%) and 
11p14.1-p12 (6%), none of   which 
corresponded to the single amplified case in the Alves data set (37%). Deletions were 
confirmed by Alves et al. at 13q21–22 (43%) and 4q21–32 (30%), but our study did not 
detect deletions in any cases. The number of gene copy number aberrations was  reported 
to be numerically associated with ‘shorter survival’ in Alves et al., but it was not made clear 
whether this was disease-free, disease-specific or overall survival. Our study did not 
assess survival data for comparison with this. Given the relatively low resolution of the 
methods employed by Alves et al. and lack of information on the HPV status of the tumors 
analyzed in their study,   it is difficult to grasp the overall clinical and biological significance 
of their data. However, a more recent study utilizing aCGH describes copy number 
alterations in PSCCs and supports the hypothesis that PSCCs manifest different 
aetiologies according to viral status.[31] 
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Our current data has highlighted patterns of copy number gains, losses and amplifications 
in a PSCC cohort that bear some similarities to those in other HPV related squamous cell 
carcinomas (Table 2). For example, gains and amplifications on chromosomes 3q, 8q, 
11pq and 5p, and losses on 3p and 4q are shared many squamous cell carcinomas. Gain 
of 3p12.3-q29 in our study harbors PIK3CA, which codes for the p110α subunit of PI3-
kinase, as part of the PI3-kinase/AKT signaling pathway. It plays a key function in the 
regulation of cell growth and apoptosis, and it has been associated with cervical, head 
and neck and upper esophageal squamous cell carcinomas [32]. Also located in this 
region is PRKCI, a member of the protein kinase C (PKC) family of serine/threonine 
protein kinases involved in a wide variety of cellular processes and it has been associated 
with lymph node metastases in OSCC [33]. 
 
Table 2. Copy Number Changes in Squamous Cell Carcinomas. 
http://dx.doi.org/10.1371/journal.pone.0146740.t002 
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Within other gained (5p15.33-p11) and amplified (5p15.33-p11) lies SKP2. It comprises the 
substrate recognition unit of the  SCFSKP2 ubiquitin ligase complex and has been involved 
in the ubiquitin driven breakdown of cyclin dependent kinase inhibitor   p27 
(a dosage dependent tumor suppressor protein), which is an important regulator of G1 
progression. Increased levels of expression have been demonstrated in squamous and 
non squamous cell carcinomas and it has been linked with tumor progression and poor 
prognosis [34–37]. Apart from PIK3CA, amplification of 3q27.2-q29 also encompasses 
SENP5, CLDN1 and TNK2. SENP5 is a SUMO (small ubiquitin-like modifier) specific 
protease. The addition of SUMO proteins is responsible for the reversible post translational 
modification of proteins. SUMOS are conjugated to cellular regulators, which changes the 
localization, activity and stability of the substrates. SENP5 plays an important role in many 
cancer types, including esophageal squamous cell   carcinoma 
[38]. CLDN1 is a member of a family of principal proteins important for tight junction 
formation and function. CLDN1 has been detected at significantly increased levels in 
cervical cancer, compared to normal cervical epithelium, and has been implicated in 
cervical cancer progression. TNK2 is a ubiquitously expressed non-receptor tyrosine-
protein and serine/threonine-protein kinase that is implicated in cell spreading and 
migration, cell survival, cell growth and proliferation. TNK2 forms a robust complex with 
all isoforms of AKT and directly regulates AKT's plasma membrane recruitment, thereby 
bypassing the PI3-kinase pathway. This process is facilitated by a novel phosphorylation 
event in AKT, Tyrosine 176 that is invariant from yeast to mammals. TNK2 gains have 
been found in breast, prostate, lung, pancreas, brain, Ewing’s sarcoma and the 
pharmaceutical agent dasatinib is a known inhibitor [39]. 
FBXO45 binds to TP73, a pro-apoptotic gene, and initiates its proteosome dependent 
degradation [40]. FNDC3B is contained in the amplified region 3q26.1-q27.2, inducing the 
epithelial-to-mesenchymal transition (EMT) and activating several cancer pathways, 
including PI3-kinase/Akt, RB1 and TGFβ signaling [41]. CPT1A is an isoform of carnitine 
palmitoyl transferase 1 that has been demonstrated to interact with BCL2 [42]. Some of 
these potential driver genes exist as part of molecular pathways for which therapeutic 
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agents are either already in use or are in various stages of clinical  trials. 
Focusing on our HPV subgroup, we showed gain of 1q to be more frequent in HPV-positive 
cases and gain of 2p, 7p and 10q, as  well as loss of 11p to be more frequent in HPV-
negative cases. Only a subset of the data on other squamous cell carcinomas includes 
HPV DNA analysis, but not all findings are in concordance with those of PSCC. For 
example, Yangling et al. found gain of 3q and 12q to be more common in HPV-positive 
VSCC cases and gain of 8q more common in HPV-negative [43]. Differences were also 
seen in comparison of HPV cohorts in oropharyngeal squamous cell carcinomas [18, 44], 
which highlighted Xp gain and 16q loss more common in HPV-positive cases, and 3p, 5q, 
9p, 15q and 18q loss more common in HPV-negative cases [18]. In contrast  to these 
studies, a higher frequency of 1q gain in our HPV-positive cohort is in accordance with 
HPV-positive VSCCs [45] and CSCCs [46–48]. Further analysis by Jung et al. also 
demonstrated a distinction between HPV-positive (DNA/RNA positive) and HPV-negative 
(DNA/RNA negative and DNA-positive/RNA-negative) tumors, with clustering of the HPV-
positive group, which was not reflected in our PSCC data. 
Although there is lack of gross correlation between genetic copy number change and HPV 
status, more detailed analysis of PSCCs may reveal more striking differences between 
the HPV groups, as disclosed by next-generation sequencing in patients with head  and 
neck squamous cell carcinoma that showed more mutations in HPV-negative than HPV-
positive tumors [49], as well as recent analysis of esophageal epithelial cell lines in vitro 
suggests that HPV infectivity was independent of inflammation and may play a   less 
significant role than first thought [14]. 
In addition, lymph node metastases were associated with chromosomal amplifications in 
OSCC at 2q12–14, 3q24–26, and 7q21–   31, while distant metastasis correlated to 
amplification at 7p13–21 [50]. This is in contrast to our data that highlighted higher 
frequency of statistically significant losses in lymph node negative PSCCs. As lymph node 
status is a marker of prognosis in PSCC, given further analysis, these genetic aberrations 
may have implications with regard to development of early molecular prognostic 
indicators. The statistically significant, small genetic differences in high stage PSCC also 
highlight potential targets for further  analysis of PSCC progression. 
	 205	
The differences in genomic profile between PSCCs and other HPV related squamous cell 
carcinomas may, in part, be attributed to intrinsic genetic differences, the different methods 
of CGH used or the number of cases  analyzed. 
 
6 Conclusion 
 
It has long been suggested that SCCs in different locations may develop through similar 
molecular pathways and that HPV and non-HPV pathways are responsible in the 
pathogenesis of PSCC. The correlations between the clinico-pathological data and copy 
number aberrations in our study supports this, but with the differences in genetic 
aberrations between PSCCs and other types of squamous cell carcinomas this remains 
unproven. Nonetheless, the correlations demonstrated here could play an important role 
in PSCC natural history and progression and highlight potential driver genes, which may 
feature in molecular pathways for existing therapeutic agents. 
Further analysis of PSCCs would need to be conducted to establish whether or not there 
is a final common pathway of HPV and non-HPV associated PSCCs and this would need 
to include next generation sequencing, cell culture studies, acquisition of paired genetic 
information from metastatic lymph node tissue and correlation with survival  data. 
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